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CHAPTER 1  
 
MARINE ALKALOID NATURAL PRODUCTS 
 
Marine Alkaloid Natural Products and Their Medicinal Properties 
Marine sponges are an important and abundant source of novel secondary 
metabolites. Sponges are marine animals that have adapted to survive in various climates, 
warm and cool waters, shallow and deep waters, and even in relatively desolate 
environments. To thrive in these various environments they have developed defensive 
and communicative mechanisms and have also fostered beneficial symbiotic relationships 
with a variety of bacteria and algae. These circumstances, and the fact that marine 
sponges are easily collected, make them a rich source of a diverse array of natural 
products from steroids to terpenoids, peptides, macrolides, and alkaloids.1  
Marine alkaloids are a large and important class of secondary metabolites. 
Alkaloids are generally defined as naturally occurring compounds containing at least one 
basic nitrogen.2 Commonly marine alkaloids will contain complex and unique core 
structures making them interesting targets for biology and pharmacology, and, for total 
synthesis. This diverse group of alkaloids is often separated into smaller sub-classes 
based on common structural features. One such sub-class of secondary metabolites is the 
3-alkylpyridine3 containing secondary metabolites, and representatives of this class of 
                                                
1 a) Faulkner, D. J. Nat. Prod. Rep. 1984, 1, 551-598. b) Perdicaris, S.; Vlachogianni, T.; Valavanidis, A. 
2 Hedt, F. Plant BioChemistry, Academic Press, 2005, 3rd Ed., 403-412. 
3 The six-membered nitrogen-containing heterocycle common to this family of marine alkaloids can be in 
the pyridine, tetrahydropyridine or piperidine oxidation state. Therefore these secondary metabolites can be 
referred to as both the 3-alkylpyridine and the 3-alkylpiperidine containing secondary metabolites. For the 
remainder of this document they will be referred to as the 3-alkylpyridine family of secondary metabolites. 
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metabolites are described in Figure 1.1. These representatives contain increasing 
molecular complexity with tricyclic, tetracyclic, and pentacyclic core motifs, but since 
these 3-alkylpyridine moieties are relatively rare in nature it is believed that they share a 
common biogenetic origin and therefore most likely originate from the sponge itself as 
opposed to some symbiont.4 
 
 
Figure 1.1. Representative Natural Products of the 3-Alkylpyridine Family. 
 
Many of these representative alkaloids have been reported to possess significant 
biological activity ranging from antimicrobial to antiviral, and several are selectively 
cytotoxic.5 Classically these secondary metabolites are primarily screened against a panel 
of cancer cell lines, however, recently they have also been tested against a more broad 
                                                
4 a) Anderson, R. J.; Van Soest, R. W. M.; Kong, F. Alkaloids: Chemical and Biological Perspectives, 
Pelletier, S. W., Pergamon Press, New York, 1996, 10, 301-355. b) Duval, R.; Poupon, E. Biomimetic 
Organic Synthesis, Poupon, E.; Nay, B. Wiley-VCH Verlag GmbH & Co, KGaA., 2011, 1, 181-238. 
5 Sipkema, D.; Franssen, M. C. R.; Osinga, R.; Tramper, J.; Wijfels, R. H. Mar. Biotechnol. 2005, 7, 142-
162. 
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range of biological targets.6 Manzamine A (1.1) has been found to be a potent anti-
malarial in vivo, presumably due to an enhanced immune response. With a single dose 
(100 mol/kg) 40% of P. berghei-infected mice recovered with no detectable parasitemia.7 
Cyclostellettamine A, another related 3-alkylpyridine alkaloid, was found to selectively 
inhibit several histone deacetylases with modest ability giving IC50 values between 17 
and 80 µM.8 Halicyclamine A (1.4) showed growth inhibition against the tuberculosis 
bacterium Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis 
H37Ra with MICs in the range of 1.0–5.0 µg/mL under both aerobic and hypoxic 
conditions.9 Xestospongin C was found to be a potent inhibitor of the inositol 1,4,5-
triphosphate (IP3) receptors and endoplasmic-reticulum Ca2+ pumps and it inhibits the 
IP3-induced increase in the contraction of muscles.10 New data on the broad range of 
specific biological activities of these 3-alkylpyridine alkaloid secondary metabolites 
makes them a popular target for total synthesis, as the collection from sponges is not 
sustainable for acquiring biologically relevant amounts of the metabolites. 
 
Biosynthesis of 3-Alkylpyridine Natural Products 
Understanding the way that natural products are synthesized in nature informs 
synthetic chemists of how transformations are most likely accomplished by nature and 
can lead to novel methods and strategies for scaffold assembly and ultimately natural 
                                                
6 Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2004, 67, 1216-1238. 
7 a) Ang, K. K. H.; Holmes, M. J.; Higa, T.; Hamann, M. T.; Kara, U. A. K. Antimicrob. Agent. Chemother. 
2000, 44, 1645-1649. b) Fattorusso, E.; Taglialatela-Scafati, O. Mar. Drugs 2009, 7, 130-152. c) Ang, K. 
K. H.; Holmes, M. J.; Kara, U. A. K. Parasitol. Res. 2001, 87, 715-721. 
8 Nakao, Y.; Fusetani, N. J. Nat. Prod. 2007, 70, 689-710. 
9 Arai, M.; Sobou, M.; Vilchéze, C.; Baughn, A.; Hashizume, H.; Pruksakorn, P.; Ishida, S.; Matsumoto, 
M.; Jacobs Jr., W. R.; Kobayashi, M. Bioorg. Med. Chem. 2008, 16, 6732–6736. 
10 a) De Smet, P.; Parys, J. B.; Callewaert, G.; Weidema, A. F.; Hill, E.; De Smedt, H.; Erneux, C.; 
Sorrentino, V.; Missiaen, L. Cell Calcium 1999, 26, 9-13. b) Miyamoto, S.; Izumi, M.; Hori, M.; 
Kobayashi, M.; Ozaki, H.; Karaki, H. J. Pharmacol. 2000, 130, 650-654. 
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product total synthesis. This section will highlight what is known about the origin of 
several important 3-alkylpyridine natural products. 
 
Biosynthesis of Manzamine A 
The most well studied of the 3-alkylpyridine natural products is manzamine A 
(1.1). Since its isolation in 1986 by Higa and Sakai from the marine sponge Haliclona 
sp.11 the structure and origin of the manzamines have been studied extensively but a 
biosynthetic path remained elusive. Several years after its isolation, Baldwin and 
Whitehead proposed a hypothetical biosynthesis that, on paper, finally provided a 
pathway by which nature may make the manzamine family of natural products. They 
proposed that manzamine A (1.1) is the product of oxidative manipulations and a ring 
closure starting from related metabolite, manzamine B (1.11) (Scheme 1.1). From here, 
excision of tryptophan would lead back to the hypothetical aldehyde, ircinal A (1.12). 
Loss of water and redox exchange leads to pentacyclic iminium salt 1.13, which would 
give keramaphidin B (1.15) upon hydride addition. Iminium salt 1.14 would result from a 
novel intramolecular [4+2] cycloaddition of a bis-hydropyridine salt 1.16. This last 
disconnection was important because it led to a symmetric bis-hydropyridine starting 
material (1.17), suggesting a common biosynthetic precursor for related 3-alkylpyridine 
natural products. 
As for the origin of the bis-hydropyridinium salt 1.17, Baldwin and Whitehead 
initially proposed a condensation/reduction sequence starting from two equivalents of 
acrolein, ammonia, and dialdehyde moieties. This proposal seemed unlikely due to the 
toxicity of these moieties in living organisms, Baldwin quotes “its provenance is 
                                                
11 Sakai, R.; Higa, T. J. Am. Chem. Soc. 1986, 108, 6404-6405. 
 5 
problematical as there appears to be no obvious biogenetic path”12 and it has inspired 
some interesting investigations into this biosynthetic path that will be discussed later in 
this document. 
 
 
Scheme 1.1. Proposed Biosynthetic Pathway for Manzamine A (1.1), Manzamine B (1.11),  
Ircinal B (1.12), and keramaphidin B (1.15). 
 
In 1992, ircinals A and B were isolated by Kobayashi and coworkers from the 
marine sponge Iricina sp.13 This naturally occurring ircinal B (1.12) was indeed amenable 
to conversion to manzamine B (1.11) via a Pictet-Spengler reaction with tryptamine, thus 
confirming this step in Baldwin and Whitehead’s biosynthetic proposal. However, it was 
found that the isolated iricinals A and B were actually the enantiomers of the ircinals 
                                                
12 Baldwin, J. E.; Whitehead, R.C. Tetrahedron Lett. 1992, 33, 2059-2062. 
13 Kondo, K.; Shigemori, H.; Kikuchi, Y.; Ishibashi, M.; Sasaki, T.; Kobayashi, J. J. Org. Chem. 1992, 57, 
2480-2483. 
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required for the production of manzamine B (1.11), suggesting that the proposed 
biosynthetic [4+2] might require further refinement.14  
In 1994, Kobayashi and coworkers isolated keramaphidin B (1.15)15 and, in 1999, 
Baldwin and coworkers undertook its synthesis to support their biosynthetic proposal 
(Scheme 1.2).16  Dimerization, macrocyclization was accomplished by alkylation of the 
requisite pyridine ring (1.18) and subsequent reduction gave bis-tetrahydropyridine 1.19. 
N-oxidation with mCPBA and elimination with TFAA gave bis-dihydropyridine 1.20. 
Diels-Alder cyclization of the bis-dihydropyridine 1.20 in buffered methanol and 
subsequent reduction gave keramaphidin B (1.15), establishing it as a plausible 
intermediate in the biosynthesis of the manzamines, albeit in a yield of less than 1%. 
 
 
Scheme 1.2. Baldwin’s Biomimetic Synthesis of Keramaphidin B (1.15). 
 
Biosynthesis of Sarain A 
At the same time as the manzamines were being studied, new marine alkaloid 
secondary metabolites were being isolated and were discovered to contain related core 
structures. These new metabolites were proposed to originate from the same biosynthetic 
                                                
14 Tsuda, M.; Kawasaki, N.; and Kobayashi, J. Tetrahedron 1994, 50, 7957-7960. 
15 Kobayashi, J.; Tsuda, M.; Kawasaki, N.; Matsumoto, K.; Adachi, T. Tetrahedron Lett. 1994, 35, 4383-
4386. 
16 Baldwin, J. E.; Claridge, T. D. W.; Culshaw, A. J.; Heupel, F. A.; Lee, V.; Spring, D. R.; Whitehead, R. 
C.; Boughtflower, R. J.; Mutton, I. M.; Upton, R. J. Angew. Chem. Int. Ed. 1998, 37, 2661-2663. 
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pathway as the manzamines. One important class of these alkaloids is the sarains, first 
isolated in 1986 by Cimino and coworkers from the marine sponge Reniera sarai.17 The 
proposed biosynthesis of sarain A (1.7) begins with the bis-dihydropyridine 1.21 
(Scheme 1.3).  The 3,4-linked macrocycle 1.23 forms upon protonation, leading to olefin 
activation and subsequent Mannich-like macrocyclization to give 1.25. Hydrolysis, 
subsequent nucleophilic displacement, and, finally, dihydroxylation give sarain A (1.7).  
 
 
Scheme 1.3. Proposed Biosynthesis of Sarain A (1.7). 
 
                                                
17 Cimino, G.; De Stefano, D.; Scognamiglio, G.; Sodano, G.; Trivellone, E. Bull. Soc. Chim. Belg. 1986, 
95, 783-800. 
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Biosynthesis of Madangamine A 
Madangamine A (1.6) was isolated from the marine sponge Xestospongia ingens 
in 1994 by Anderson and Kong.18 Its biosynthesis also resembles the biosynthesis of 
manzamine and begins with a related bis-dihydropyridine, 1.28 (Scheme 1.4). From here, 
Diels-Alder cyclization installs the central bridged core of intermediate 1.29. Allylic 
activation gives intermediate 1.30, which provides iminium intermediate 1.31 upon 
fragmentation. Redox exchange and Mannich-like interception of the iminium ion and 
subsequent oxidation provides madangamine A (1.6). 
 
 
Scheme 1.4. Proposed Biosynthesis of Madangamine A (1.6). 
 
Biosynthesis of Xestospongins and Related Natural Products 
The xestospongins, araguspongins, and petrosins are additional natural products 
derived from the 3-alkylpyridines related to the theoretical manzamine bis-
dihydropyridine macrocycle 1.17. Bis-keto dihydropyridine 1.33 can cyclize onto the 
                                                
18 Kong, F.; Andersen, R. J. J. Am. Chem. Soc. 1994, 116, 6007-6008. 
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imine in one of two ways forming the tetracyclic natural products (Scheme 1.5). Mannich 
cyclization will yield both bicyclic rings of petrosin A (1.37) and one bicycle of 
aragupetrosine A (1.36) and nucleophilic addition of the keto oxygen will give the 
hemiaminal rings of xestospongin A (1.34) and araguspongine H (1.35) and the other 
bicycle of aragupetrosine A (1.36). 
 
 
Scheme 1.5. Proposed Biosynthetic Pathway for the Synthesis of Xestospongin A (1.34),  
Araguspongine A (1.36) and H (1.35), and Petrosin A (1.37). 
 
These investigations into the biological origins of these natural products have lead 
to investigations into biomimetic strategies to synthesize important intermediates of 
several secondary metabolites from the 3-alkylpyridine family, however, full elucidation 
of the biosynthetic pathway remains difficult as gene sequencing is not a viable pathway 
since it is not known if the origin of these secondary metabolites is the sponge or one of 
the many possible symbionts. 
 
Synthetic Approaches to 3-Alkylpyridine Natural Products 
The wide range of biological activities and intriguing scaffolds of the many 3-
alkylpyridine natural products have inspired several attempts at total synthesis over the 
years. Various attempts by many groups have ultimately led to novel and creative 
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approaches to this challenging family of natural products. This section will highlight 
some of these syntheses. 
 
Winkler’s Total Synthesis of Manzamine A 
In 1998, Winkler and coworkers completed the total synthesis of manzamine A 
(1.1), and en route, the synthesis of ircinol and ircinal A (1.12).19 Their synthesis involves 
a Pictet-Spengler cyclization, like the one proposed by Baldwin and Whitehead, and a 
Mannich cyclization to install the requisite ring motif of intermediate 1.38. The Winkler 
synthesis begins with pseudoephedrine glycinamide (1.40) (Scheme 1.6).  
 
 
Scheme 1.6. Winkler’s Retrosynthetic Approach to the Synthesis of Manzamine A (1.1). 
 
Starting from pyridine-3-methanol (1.41), ylide 1.42, and pseudoephedrine 
glycinamide (1.40) the Winkler group was able to elaborate to the 8-membered ring 
intermediate 1.43 in 17 steps (Scheme 1.7). Michael addition of amine 1.43 to alkynone 
1.44 (readily accessed from 10-hydroxy-5-decanoate in 2 steps) gave them enamine 1.39. 
Upon irradiation of 1.39, a [2+2] photocyclization occurred, followed by a retro-Mannich 
and subsequent Mannich cyclization to afford the manzamine core tetracycle 1.38. 
 
                                                
19 a) Winkler, J. D.; Axtena, J.; Hammacha, A. H.; Kwaka, Y.-S.; Lengweilera, U.; Lucerob, M. J.; Houk, 
K. N. Tetrahedron 1998, 54, 7045-7056. b) Winkler, J. D.; Axten, J. M. J. Am. Chem. Soc. 1998, 120, 
6425-6426. 
N
N
H
H
H
OH
N N
H
BocN
N
H O
H
H
HO
BocN
N
O
H
OH
OH
N
Me
Me
O
NH2
manzamine A
(1.1)
1.38 1.39
1.40
 11 
 
Scheme 1.7. Winkler's Synthesis of the Manzamine A Intermediate 1.38. 
 
From tetracycle 1.38, installation of an intermediate β-keto ester was 
accomplished using Mander’s reagent and, following keto reduction and subsequent 
dehydration, yielded alkene 1.46 (Scheme 1.8). Epoxidation of the latter, followed by 
basic elimination-ring opening, installed the tertiary hydroxyl group of 1.47, thus setting 
the stage for the final macrocyclization. Upon Boc deprotection and conversion of the 
TBS ether to the tosylate, installation of the final ring system was accomplished by 
simple N-alkylation and then semi-hydrogenation to give 1.48. The total synthesis was 
completed by condensation with tryptamine and oxidation with DDQ to give manzamine 
A (1.1).  
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Scheme 1.8. Winkler’s Completion of the Total Synthesis of Manzamine A (1.1). 
 
Martin’s Total Synthesis of Manzamine A 
In 1999, Martin and coworkers also completed the total synthesis of manzamine 
A (1.1).20 While their strategy also included a final Pictet-Spengler, their approach was 
unique in that the two macrocycles were envisioned to come from two ring-closing 
metatheses (Scheme 1.9). 
 
 
Scheme 1.9. Martin’s Retrosynthetic Approach to the Synthesis of Manzamine A (1.1). 
 
Elaboration of 5-aminopentanol (1.52) over 5 steps, and, (R)-5-
(methoxycarbonyl)-2-pyrrolidinone (1.54) over 4 steps, allowed access to vinyl bromide 
                                                
20 a) Martin, S. F.; Humphrey, J. M.; Ali, A.; Hillier, M. C. J. Am. Chem. Soc. 1999, 121, 866-867. b) 
Humphrey, J. M.; Liao, Y.; Ali, A.; Rein, T.; Wong, Y.-L.; Chen, H.-J.; Courtney, A. K.; Martin, S. F. J. 
Am. Chem. Soc. 2002, 124, 8584-8592. 
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intermediate 1.51 (Scheme 1.10). From here, a Stille cross-coupling and Diels-Alder 
cyclization cascade ensued to give tricyclic intermediate 1.56 as a single stereoisomer.  
 
 
Scheme 1.10. Martin’s Synthesis of the Manzamine A Intermediate 1.56. 
 
Oxidation of the allylic methylene was accomplished upon treatment with CrO3 
and dimethylpyrazole to give enone 1.56 (Scheme 1.11). Next, elaboration of the TBS 
ethers to the olefin via simultaneous Wittig reactions gave bis-olefin 1.57. Reduction of 
the ester and the keto groups was accomplished with diisobutylaluminum hydride and 
subsequent reoxidation with Dess Martin gave keto-aldehyde 1.58. Acetal protection of 
the aldehyde left the ketone available for alkylation with 4-butenyllithium in a 1,2-
fashion, leaving the resulting alkoxide to form the carbamate with the Boc group, 
expelling t-butoxide and yielding carbamate 1.59. From here the 13-membered 
macrocycle was installed using first generation Grubbs catalyst to give intermediate 1.60 
as an 8:1 mixture of Z and E isomers. Base-induced cleavage of the carbamate revealed 
the free amine, which was subsequently acylated with 5-hexenoyl chloride to give bis-
olefin 1.61. While the first ring-closing metathesis was accomplished rather smoothly, the 
final ring-closing metathesis proved to be more difficult resulting in only a 26% yield of 
macrocycle 1.62 upon extensive optimization. From here, Martin and coworkers were 
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able to complete their total synthesis of manzamine A (1.1) upon condensation with 
tryptamine and subsequent oxidation with DDQ. 
 
 
Scheme 1.11. Martin’s Completion of Total Synthesis of Manzamine A (1.1). 
 
Overman’s Progress Toward Manzamine A 
Prior to the accomplishment of these total syntheses, access to the tricyclic core of 
manzamine A (1.1) was established by the Overman group via a Mannich cyclization 
sequence beginning with D-(-)-quinic acid (1.65) (Scheme 1.12).21  
 
                                                
21 Kamenecka, T. M.; Overman, L. E. Tetrahedron Lett. 1994, 35, 4279-4282. 
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Scheme 1.12. Overman’s Retrosynthetic Approach to the Synthesis of Manzamine A (1.1). 
 
Overman and coworkers were able to access tricyclic intermediate 1.63 in 17 
steps overall from D-(-)-quinic acid (1.65) and in an enantiopure fashion (Scheme 1.13). 
A published 4 step procedure served to convert D-(-)-quinic acid (1.65) to enone 1.66, 
selective allylation and subsequent dehydration of the β-hydroxy group and concomitant 
TBS protection gave enone 1.68. From here, α-alkylation with an iodoacetamide and 
subsequent enone reduction gave olefin 1.69. The latter underwent a Lemieux alkene 
oxidative cleavage and subsequent reductive amination of the derived aldehyde, and in 
situ Boc protection gave the protected amine 1.70. Mannich cyclization was 
accomplished by treatment with aqueous formaldehyde and formic acid to give bicycle 
1.64. A protection, deprotection, and dehydration synthetic sequence provided tricycle 
1.71. Epoxidation and acid-catalyzed rearrangement then yielded enone 1.72. The 
completion of their intermediate 1.63 was accomplished via 1,4-cuprate addition, benzyl 
deprotection, and oxidation of the released primary alcohol, which gave enone 1.67. 
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Scheme 1.13. Overman’s Synthesis of the Manzamine A Intermediate 1.63. 
 
Fukuyama’s Total Synthesis of Manzamine A 
Ten years after Martin and coworkers published their total synthesis, in 2010, 
Fukuyama and coworkers published the next total synthesis of manzamine A (1.1) 
(Scheme 1.14).22 In their work they employed a Diels-Alder cycloaddition (1.75) to 
access a cyclohexenone and they installed the 15-membered macrocycle 1.74 early in the 
synthesis as a way of accessing the core cyclic structure in a stereocontrolled manner via 
a sigmatropic rearrangement. 
 
 
Scheme 1.14. Fukuyama’s Retrosynthetic Approach to the Synthesis of Manzamine A (1.1). 
                                                
22 Toma, T.; Kita, Y.; Fukuyama, T. J. Am. Chem. Soc. 2010, 132, 10233-10235. 
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The Fukuyama synthesis started with the synthesis of vinylogous ester 1.77 from 
bromide 1.76 (Scheme 1.15) and, following formation of the diene, a Diels-Alder 
cyclization with butenolide 1.78 gave bicycle 1.79 as a 2:1 mixture of endo and exo 
products. Methanolysis, followed by one-pot Wittig reaction, and methylation gave the 
methyl ester, which was then reduced and the resulting alcohol protected as the silyl 
ether. Hydrolysis of the enol ethers and selective reduction of the aldehyde yielded 
alcohol 1.80. The p-nitrosulfonamide (nosyl) was introduced via a Mitsunobu reaction. 
Simultaneous deprotection of the Boc protected amine and the PMP protected alcohol 
followed by an intramolecular Mitsunobu reaction gave macrocycle 1.74. The β-ketoester 
was accessed via Mander’s protocol followed by alkylation with vinyl iodide 1.81, and 
epoxidation gave epoxyketone 1.82 stereoselectively. Dehydration with TFAA yielded an 
intermediate allyl cyanate that underwent the key [3,3]-sigmatropic rearrangement 
leading to an amine following loss of CO2. Upon condensation with the ketone the 
intermediate amine afforded imine 1.83. Reduction of imine 1.83 and acylation with 5-
hexenoyl chloride gave the amide that was subsequently reduced with alane to give 
secondary amine 1.84. Oxidation of the primary alcohol, nosyl removal, and subsequent 
reduction of the resulting hemiaminal gave diamine 1.85. Ring-closing metathesis gave 
the pentacyclic core, then simultaneous silyl ether deprotection and alkyne semi-
hydrogenation, and subsequent Dess Martin oxidation and concurrent epoxide opening, 
gave γ-hydroxy-α,β-saturated aldehyde 1.49. Finally, Pictet-Spengler reaction with 
tryptamine and subsequent oxidation with DDQ provided manzamine A (1.1). 
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Scheme 1.15. Fukuyama’s Completion of Total Synthesis of Manzamine A (1.1). 
 
Dixon’s Total Synthesis of Manzamine A 
Soon after the Fukuyama group published their synthesis, in 2012, Dixon and 
coworkers published their synthesis of manzamine A (1.1) via a novel route utilizing a 
Michael addition in to an unsaturated nitro group (Scheme 1.16).23  
 
                                                
23 Jakubec, P.; Cockfield, D. M.; Dixon, D. J. J. Am. Chem. Soc. 2009, 131, 16632-16633. 
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Scheme 1.16. Dixon’s Retrosynthetic Approach to the Synthesis of Manzamine A (1.1). 
 
Nitroalkene 1.87 was accessed in 5 steps overall starting with the non-trivial 
nucleophilic substitution of the neopentylic bromide of acetal 1.89, which required neat 
Aliquat 336 and potassium acetate (Scheme 1.17). Subsequent methanolysis and Swern 
oxidation gave aldehyde 1.90, which provided nitroalkene 1.87 upon Henry reaction with 
nitromethane and subsequent dehydration. 
 
 
Scheme 1.17. Dixon’s Synthesis of the Manzamine A Intermediate 1.87. 
 
Bicyclic amide 1.88, an intermediate previously used by Dixon and coworkers in 
their synthesis of nakadomarin A, was constructed in 7 steps overall starting with tosyl 
pyroglutamol 1.91 (Scheme 1.18).24 Nucleophilic substitution with sodium thiolate 1.92 
and alkylation of the amide nitrogen with bromide 1.93 gave sulfide 1.94. Oxidation to 
the sulfones and acetal deprotection followed by intramolecular Julia-Kocienski 
olefination gave the 8-membered (Z)-alkene-containing ring 1.95. α-Acylation with 
methyl carbonate completed intermediate bicyclic amide 1.88. 
 
                                                
24 Jakubec, P.; Hawkins, A.; Felzmann, W.; Dixon, D. J. J. Am. Chem. Soc. 2012, 134, 17482-17485. 
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Scheme 1.18. Dixon’s Synthesis of the Nakadomarin A and Manzamine A Intermediate 1.88. 
 
The Michael addition of bicyclic amide 1.88 to nitroalkene 1.87 gave intermediate 
1.96 as a 3:1 mixture of separable diastereomers (Scheme 1.19). Treatment of pure 
intermediate 1.96 with hex-5-en-1-amine 1.97 and formaldehyde affected a nitro-
Mannich lactamization cascade to provide nitro piperidinone 1.98 as a single 
diastereomer. Nitro group removal was accomplished using Ono’s conditions and the 
vinyl acetal was converted to alkyl nitro 1.99 via anti-Markovnikov addition of HI across 
the olefin and subsequent silver-promoted substitution with a nitro group. Selective 
reduction of the piperidinone carbonyl followed by reductive nitro-Mannich cascade 
using Buchwald’s titanium tetraisopropoxide/diphenylsilane reducing conditions 
provided the tetracyclic intermediate 1.100. Efficient conversion of the nitro group to the 
ketone using McMurry’s modification of a reductive Nef reaction gave the tetracyclic 
ketone, which underwent 1,2-addition of homoallylic Grignard 1.101 and subsequent 
protection of the resulting alcohol as the silyl ether gave enone 1.102. Conversion to the 
vinyl triflate using Comins’ reagent and subsequent ring-closing metathesis using second 
generation Grubbs catalyst gave vinyl triflate coupling partner 1.03, which underwent 
smooth Stille coupling with tributylstannylated β-carboline 1.104 to give manzamine A 
(1.1). 
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Scheme 1.19. Dixon’s Completion of Total Synthesis of Manzamine A (1.1). 
 
Heathcock’s Progress Toward Sarain A 
This family of 3-alkylpyridine natural products contains several interesting targets 
for total synthesis, another one of which is sarain A (1.7). Heathcock and coworkers 
made progress toward its total synthesis utilizing an intramolecular Grigg azomethine 
ylide cyclization starting with bicycle 1.107 (Scheme 1.20).25  
 
 
Scheme 1.20. Heathcock’s Retrosynthetic Approach to the Synthesis of Sarain A (1.7). 
 
                                                
25 Denhart, D. J.; Griffith, D. A.; Heathcock, C. H. J. Org. Chem. 1998, 63, 9616-9617. 
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Amide 1.113 was prepared efficiently starting with phosporane 1.108, aldehyde 
1.109, and monoethyl malonate 1.112 (Scheme 1.21). Boc deprotection followed by 
Grigg azomethine ylide formation, and subsequent cyclization via refluxing with 
formaldehyde in toluene, yielded bicycle 1.114. Benzylation and a two-step, complete 
reduction of the angular ester and subsequent protection as the TBS ether provided 
intermediate 1.115, which then underwent selective deprotection of the primary and 
amide benzyls and subsequent protection of the primary alcohol as the TES ether to give 
1.116. Removal of the benzyl groups and subsequent acylation provided carbamate 
1.117. Protection of the amide nitrogen with a nosyl group and selective deprotection of 
the TES ether gave alcohol 1.118, which provided methyl ester 1.107 upon Moffat-Swern 
oxidation followed by Pinnick oxidation and subsequent methylation. Isomerization to 
the β-keto ester and reduction of the keto carbonyl gave alcohol 1.106, which smoothly 
underwent dehydration, Michael addition of the nosyl amine, and subsequent nosyl 
deprotection yielded their final intermediate 1.105. 
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Scheme 1.21. Heathcock’s Synthesis of the Sarain A Intermediate 1.105. 
 
Cha’s Progress Toward Sarain A 
In 1999, Cha and coworkers published their route to the core of sarain A (1.7).26 
They used “spectator rings” to control the stereochemistry in the construction of the core 
tricycle (Scheme 1.22). 
 
 
Scheme 1.22. Cha’s Retrosynthetic Approach to the Synthesis of Sarain A (1.7). 
 
Beginning with 3-oxidopyridinium betaine (1.122) and cyclopentadiene, Cha and 
coworkers employed Katrizky’s cycloaddition to build the bridged core enamine 1.123 
                                                
26 a) Sung, M. J.; Lee, H. I.; Chong, Y.; Cha, J. K. Org. Lett. 1999, 1, 2017-2019. b) Sung, M. J.; Lee, H. I.; 
Lee, H. B.; Cha, J. K. J. Org. Chem. 2003, 68, 2205-2208. 
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(Scheme 1.23). Next, sequential reduction of the enamine and nitro groups, followed by 
Boc protection of the aniline, yielded ketone 1.124. Dihydroxylation and oxidative 
cleavage using Lemieux-Johnson conditions and subsequent reduction of both the 
aldehydes and the keto group and subsequent acylation of both primary alcohols provided 
diacetate 1.125. Reoxidation of the secondary alcohol and subsequent Wittig olefination 
and deacetylation provided diol 1.126. Ley oxidation followed by ring opening with N-p-
methoxybenzyl amide successfully differentiated the two essentially equivalent alcohols 
to give amide 1.127. Tricycle 1.121 was formed upon Michael addition of the amide 
nitrogen to the unsaturated ester. 
 
 
Scheme 1.23. Cha’s Synthesis of the Sarain A Intermediate 1.121. 
 
Later, in 2003, Cha and coworkers published their further progress toward the 
total synthesis sarain A (1.7) (Scheme 1.24). Building from their earlier work they began 
with tricyclic ester 1.128 accessed as previously described. They were able to construct 
unsaturated lactone 1.120 utilizing the Tischenko method to install a formaldehyde unit 
α- to the aldehyde followed subsequent acylation and ring closing Wittig. Hydrogenation 
of the unsaturated lactone and deprotection, then acylation of the cyclic amine, followed 
by lactone reduction with sodium borohydride and indium-mediated allylation gave bis-
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olefin 1.119. The 13-membered ring was then completed using second generation Grubbs 
catalyst followed by dehydration using Martin’s sulfurane. Hydrogenation of the 
resulting olefin gave the western macrocycle of sarain A (intermediate 1.130). 
 
 
Scheme 1.24. Cha’s Synthesis of the Sarain A Intermediate 1.130. 
 
Weinreb’s Progress Toward Sarain A 
Weinreb and coworkers approached sarain A beginning with N-benzyllactam 
1.133 and using the Ohfune protocol to access cyclic carbamate 1.132, which was then 
elaborated to intermediate 1.131 via a chelation-controlled Grignard addition to set the 
diol relative stereochemistry (Scheme 1.25).27  
 
 
Scheme 1.25. Weinreb’s Retrosynthetic Approach to the Synthesis of Sarain A (1.7). 
 
                                                
27 a) Sisko, J.; Weinreb, S. M. J. Org. Chem. 1991, 56, 3210-3211. b) Sisko, J.; Henry, J. R.; Weinreb, S. 
M. J. Org. Chem. 1993, 58, 4945-4951. c) Irie, O.; Samizu, K.; Henry, J. R.; Weinreb, S. M. J. Org. Chem. 
1999, 64, 587-595. d) Hong, S.; Yang, J.; Weinreb, S. M. J. Org. Chem. 2006, 71, 2078-2089. 
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The preparation of N-benzyllactam 1.133 was accomplished via the 
intramolecular 1,3-dipolar cycloaddition of an azomethine ylide derived from aziridine 
1.137, prepared in 8 steps from 1-methoxy-1,4-cyclohexadiene 1.134 and aziridine 1.136 
(Scheme 1.26). Selective hydrogenolysis of the secondary benzyl amine and in situ Boc 
protection gave lactam 1.138. α-Alkylation and subsequent treatment with zinc 
borohydride followed by TIPS protection of the derived alcohol, gave β-ketolactam 1.139 
as a single stereoisomer. Protecting group manipulation gave access to N-tosyllactam 
1.140, which, upon exchange of the Boc group for a TBS carbamate set the stage of 
fluoride induced cyclization to carbamate 1.141. Hydrolysis of the acetal and subsequent 
Grignard addition and acetate protection gave allyl acetate 1.142. Allyl silane 1.143 was 
accessed as a mixture of geometrical isomers using the Fleming silyl cuprate reagent. 
Reduction of the N-tosyllactam and subsequent cyclization of the allylsilane and N-
sulfonyliminium catalyzed by ferric chloride gave the sarain core 1.144 as a 2:1 mixture 
of inconsequential epimers. Conversion of the methyl ether to the TBS ether gave 1.145, 
which underwent oxidative cleavage and condensation with hydroxylamine to give the 
oxime. Dehydration of the oxime proceeded upon treatment with triphosgene to afford 
nitrile 1.146. Stereoselective alkylation of the derived nitrile anion with mesylate 1.147 
from the less hindered equatorial face and subsequent reduction gave aldehyde 1.148. 
The aldehyde was then reduced to the corresponding alcohol, which was protected as its 
MOM ether. Subsequently, the cyclic amine was deprotected and acylated to give bis-
olefin 1.132. The bis-olefin then underwent ring-closing metathesis reaction on treatment 
with Grubbs second generation catalyst and the resulting olefin reduced. Silyl 
deprotection then gave alcohol 1.149 and Swern oxidation provided the corresponding 
 27 
aldehyde poised for a chelation-controlled Grignard addition. To this end, treatment with 
ethynyl Grignard gave alkyne 1.150 as a single diastereomer. Finally, the carbamate is 
converted to the cyclic carbonate, completing Weinreb and coworker’s synthesis of 
intermediate 1.131. 
 
 
Scheme 1.26. Weinreb’s Synthesis of the Sarain A Intermediate 1.131. 
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Marazano’s Progress Toward Sarain A 
Marazano and coworkers proposed to synthesize sarain A (1.7) in a proposed 
biomimetic manner via successive condensations as illustrated in Scheme 1.27.28  
 
 
Scheme 1.27. Marazano’s Retrosynthetic Approach to the Synthesis of Sarain A (1.7). 
 
Starting from L-Alanine, imino derivative 1.155 was deprotonated and treated 
with bromoacrylamide derivative 1.154 to give enone 1.153 via a Michael-addition-
cyclization sequence (Scheme 1.28). Enaminal formation via treatment with 
malonaldehyde salt 1.156 and subsequent cyclization and methylation of the nitrogen 
gave bicycle 1.157. Full reduction of the enaminal gave alcohol 1.158, which provided 
bridged ether 1.159 upon regioselective reduction of the more accessible imide carbonyl. 
Opening of the ether, reduction of the resulting enamine, followed by benzyl 
deprotection, and tosylation of the resulting alcohol gave amide 1.160. Displacement with 
sodium cyanide and subsequent reduction gave aldehyde 1.161. Wittig olefination, 
tosylation of the amide nitrogen, and reduction with diisobutylaluminum hydride gave 
aminal 1.152. Cyclization with ferric chloride gave their final sarain A core intermediate 
1.151.  
 
                                                
28 a) Hourcade, S.; Ferdenzi, A.; Retailleau, P.; Mons, S.; Marazano, C. Eur. J. Org. Chem. 2005, 1302-
1310. b) Ge, C. S.; Hourcade, S.; Ferdenzi, A.; Chiaroni, A.; Mons, S.; Delpech, B.; Marazano, C. Eur. J. 
Org. Chem. 2006, 4106-4114. 
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Scheme 1.28. Marazano’s Synthesis of the Sarain A Intermediate 1.151. 
 
Overman’s Total Synthesis of Sarain A 
The first total synthesis of sarain A (1.7) was reported by Overman and coworkers 
in 2007. Their synthesis featured a novel stereoselective Michael addition to install the 
stereotriad of the bridged ring system core (Scheme 1.29).29  
 
 
Scheme 1.29. Overman’s Retrosynthetic Approach to the Synthesis of Sarain A (1.7). 
 
Starting from (-)-diethyl D-tartrate (1.163) (Scheme 1.30), Overman and 
coworkers were able to access oxazoline 1.165 in 5 steps. From here, Michael addition of 
the lithium enolate to unsaturated ester 1.164 gave lactam 1.165, which gave access to the 
                                                
29 a) Garg, N. K.; Hiebert, S.; Overman, L. E. Angew. Chem. Int. Ed. 2006, 45, 2912-2915. b) Becker, M. 
H.; Chua, P.; Downham, R.; Douglas, C. J.; Garg, N. K.; Hiebert, S.; Jaroch, S.; Matsuoka, R. T.; 
Middleton, J. A.; Ng, F. W.; Overman, L. E. J. Am. Chem. Soc. 2007, 129, 11987-12002. 
NPh
Me
NH3
O
Cl
NH BrPh
O
EtO Ph
O
Me N N
O MeMe
H OO
Ph
N N
O MeMe
H OHO
Ph
N N
O MeMe
H
Ph
O
HN N
O MeMe
H OTs
HN N
O MeMe
H CHO
N N
OH
Ts
MeMe
H
TMS
N N
Ts
Me
Me
1. LDA
2. HCl
O ONa1. 
2. NaH
3. MeI
H2, PtO2, 
SnCl2
DiBAlH
1. BF3 Et2O
2. H2, Raney Ni
3. Na, NH3
4. TsCl
1. NaCN, DMF
2. DiBAlH, H2O
1. Ph3P=CHCH2TMS
2. LiHMDS, TsCl
3. DiBAlH
FeCl3
1.154
1.155
O1.153
1.156
1.157
1.158 1.159
1.160
1.161 1.152 1.151
N N
H
O
HO
OH N
N
H
O
Ts
O
O
OH
EtO2C
CO2Et
OH
OH
CO2Me
N
Ts
Boc
sarain A 
(1.7) 1.162
1.163
1.164
 30 
TIPS enol ether 1.166 following a 17 steps reaction sequence. Next, they installed the 
congested quaternary center of 1.162 upon treatment with BCl3 affecting a cyclization of 
the enol ether on to the sulfonyliminium. In 5 steps they were able to elaborate 
sulfonamide 1.162 to the bis-olefin 1.167. Ring closure proceeded cleanly using the first 
generation Grubbs catalyst to give macrocycle 1.168 as an inconsequential mixture of Z 
and E olefins. Then, over four steps, they were able to reduce the macrocyclic olefin, 
deprotect, and open the carbonate to yield diamine diol 1.169. Condensation with 
aldehyde 1.170 and subsequent oxidation provided aldehyde 1.171, which was then 
converted to the vinyl stannane via Grignard addition of 1.172. The TBS ether was then 
extended to the vinyl iodide via Wittig reaction, which then provided the necessary Stille 
coupling substrate 1.173. After Stille coupling to install the 14-membered triene product 
1.174, only reduction of the N,O-acetal, subsequent oxidation, and global deprotected 
remained, leading to the first total synthesis of sarain A (1.7). 
 
 31 
 
Scheme 1.30. Overman’s Completion of Total Synthesis of Sarain A (1.7). 
 
Weinreb’s Progress Toward Madangamine A 
There were also efforts made toward the total synthesis of another 3-alkylpyridine 
secondary metabolite, madangamine A (1.6). In 1997, Weinreb and coworkers 
approached madangamine A (1.6) taking advantage of a Diels-Alder cycloaddition and 
mercury-mediated electrophilic cyclization to install the core tricycle (Scheme 1.31).30  
 
                                                
30 Matzanke, N.; Gregg, R. J.; Weinreb, S. M. J. Org. Chem. 1997, 62, 1920-1921. 
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Scheme 1.31. Weinreb’s Retrosynthetic Approach to the Synthesis of Madangamine A (1.6). 
 
Protected enone 1.176 was accessed via two routes, Claisen condensation and a 
ring expansion/dehydration sequence (Scheme 1.32).  
 
 
Scheme 1.32. Weinreb’s Synthesis of the Madangamine A Intermediate 1.176. 
 
High-pressure cyclization of enone 1.176 and 1,3-butadiene gave the cis-decalin 
system 1.182, which then underwent homologation followed by aza-Claisen 
rearrangement to give aldehyde 1.183. Formation of the benzyloxime, followed by 
hydroboration-oxidation, PMB protection of the resulting alcohol, and finally, treatment 
with lithium aluminum hydride, gave free amine 1.184. Mercury-mediated electrophilic 
cyclization and subsequent oxidative cleavage of the organomercury yielded Weinreb’s 
final tricyclic madangamine A intermediate 1.175.  
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Scheme 1.33. Weinreb’s Synthesis of the Madangamine A Intermediate 1.175. 
 
Yamazaki’s Progress Toward Madangamine A 
Later, in 2008, Yamazaki and coworkers accessed the core of madangamine A 
(1.6) via intramolecular reductive amination N,O-acetylation starting with cyano ester 
1.187 (Scheme 1.34).31  
 
 
Scheme 1.34. Yamazaki’s Retrosynthetic Approach to the Synthesis of Madangamine A (1.6). 
 
Starting with cyano ester 1.187 (Scheme 1.35), formation of the 7-membered 
acetal and hydroxymethylation and subsequent silyl protection gave ester 1.188. 
Reduction with lithium borohydride and protecting group manipulation gave 
cyclohexanone 1.189, which was then converted to α-silyloxy acetal 1.190 via a modified 
Rubottom oxidation and subsequent TBS protection. Reduction of the nitrile to the 
primary amine and subsequent reductive amination with salicylaldehyde gave 
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3492. b) Yoshimura, Y.; Kusanagi, T.; Kibayashi, C.; Yamazaki, N.; Aoyagi, S. Heterocycles 2008, 75, 
1329-1354. 
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intermediate 1.191. Treatment with hydrochloric acid gave N,O-acetal 1.192, which, 
upon treatment with alane and subsequent deprotection of the benzyl groups, gave 
bicycle 1.186. Boc protection of the secondary amine, Dess Martin oxidation of the 
secondary alcohol and subsequent Wittig and ester reduction gave (Z)-allyl alcohol 1.193. 
Methoxycarbonylation followed by Stille cross-coupling afforded skipped-diene 1.194 as 
a single diastereomer. Deprotection and reductive amination completed Yamazaki’s 
synthesis of intermediate 1.185. 
 
 
Scheme 1.35. Yamazaki’s Synthesis of the Madangamine A Intermediate 1.185. 
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haliclonacyclamine C (1.9) accessed from the coupled bis-piperidine 1.186 (Scheme 
1.36).32  
 
 
Scheme 1.36. Sulikowski’s Retrosynthetic Approach to the Synthesis of Haliclonacyclamine C (1.9). 
 
Iodoenamide 1.189 was prepared in 6 steps from glutarimide (1.187) and cross-
coupled via Stille with stannane 1.190, prepared in 4 steps from β-keto ester 1.188, to 
give bis-piperidine 1.186 (Scheme 1.37). Deprotection of the TBS ether and acetylation 
gave allylic acetate that underwent Stille coupling with (E)-6-(tributylstannyl)hex-5-en-1-
ol to give bis-olefin 1.191. Ring-closing metathesis was accomplished from the 
hydrochloride salt of 1.191 using Fürstner’s ruthenium indenylidene catalyst to give Z-
olefin-containing macrocycle 1.192. Exhaustive hydrogenation with Pearlman’s catalyst 
and subsequent oxidation gave di-aldehyde 1.193. Conversion of both aldehydes to the 
alkyne via homologation with Bestmann-Ohira reagent and Red-Al reduction of both 
lactams gave intermediate 1.185. Methylation of the alkynes also resulted in the 
methylation of both nitrogens, therefore subsequent treatment with an excess of sodium 
thiophenoxide in dimethylformamide provided amine 1.194. Ring-closing alkyne 
metathesis and subsequent semi-hydrogenation with Lindlar’s catalyst gave 
haliclonacyclamine C (1.9). 
 
                                                
32 Smith, B. J.; Sulikowski, G. A. Angew. Chem. Int. Ed. 2010, 49, 1599-1602. 
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Scheme 1.37. Sulikowski’s Completion of the Total Synthesis of Haliclonacyclamine C (1.9). 
 
Molander’s Progress Toward Halicyclamine A 
With this total synthesis as inspiration, Molander and Cadoret envisioned 
installing the three stereocenters of halicyclamine A (1.4) at once utilizing a 
diastereoselective intramolecular Diels-Alder to ultimately access their halicyclamine A 
intermediate 1.195 (Scheme 1.38).33  
 
                                                
33 Molander, G. A.; Cadoret, F. Tetrahedron Lett. 2011, 52, 2199-2202. 
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Scheme 1.38. Molander’s Retrosynthetic Approach to the Synthesis of Halicyclamine A (1.4). 
 
Boc protected propargyl amine (1.196) was elaborated to ethyl acetal 1.197 in two 
steps (Scheme 1.39). Sniekus hydroboration and quenching with potassium hydrogen 
fluoride gave potassium alkenyltrifluoroborate 1.198. Suzuki-Miyaura cross-coupling 
with vinyl bromide 1.199 gave diene 1.200. Acetal deprotection followed by Wittig 
olefination and silyl deprotection gave enal 1.201, which underwent Diels-Alder 
cycloaddition upon heating in toluene to yield bicycle 1.202 as a single diastereomer. 
Reductive amination with benzyl amine, protection of the free alcohol as the TBS ether, 
and final protection of the benzyl amine with a Cbz group gave 1.203. Next, ozonolysis 
provided the keto-aldehyde, which underwent selective reduction of the aldehyde and 
subsequent protection as the TBDPS either to give ketone 1.204. Selective deprotection 
of the TBS ether and hydrogenolysis of the Cbz group gave hydroxy ketone 1.195. 
Attempts at Mitsunobu cyclization were unsuccessful at providing bicycle 1.205. 
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Scheme 1.39. Molander’s Synthesis of the Halicyclamine A Intermediate 1.195. 
 
Huang’s Progress Toward Haliclonin A 
Recently, efforts by Huang and coworkers to synthesize haliclonin A led to the 
development of an intramolecular transition-metal-mediated cyclization to install the keto 
amide bicycle of their ultimate intermediate 1.206 (Scheme 1.40).34  
 
 
Scheme 1.40. Huang’s Retrosynthetic Approach to the Synthesis of Haliclonin A (1.3). 
 
Acetal 1.209 was accessed in 4 steps starting from 3-ethoxycyclohex-2-enone 
(1.208) (Scheme 1.41). Full reduction of the nitro group and reductive amination with p-
anisaldehyde gave PMB protected amine 1.210. Acylation of the amine with phenyl 
                                                
34 Luo, S.-P.; Guo, L.-D.; Gao, L.-H.; Li, S.; Huang, P.-Q. Chem. Eur. J. 2013, 19, 87-91. 
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chlorothiolformate, acetal protection, and olefin isomerization with DBU provided enone 
1.207, which then underwent palladium-mediated cyclization to give keto amide 1.211. 
Aldol addition of aldehyde 1.212 to cyclic 1.211 gave β-hydroxy ketone 1.213, which 
subsequently underwent ring-closing metathesis with first generation Grubbs catalyst 
followed by hydrogenation to give their final haliclonin A intermediate 1.206. 
 
 
Scheme 1.41. Huang’s Synthesis of the Haliclonin A Intermediate 1.206. 
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CHAPTER 2  
 
THE NATURAL PRODUCT UPENAMIDE 
 
Isolation and Structural Determination 
Upenamide (2.1) (Figure 2.1) is a unique macrocyclic diamine alkaloid natural 
product from the 3-alkylpyridine family of natural products that was isolated from the 
extract of a marine sponge Echinochalina sp. Protolithospongia in 2000 by Scheuer and 
coworkers.35  
 
 
Figure 2.1. The Two Possible Structures of Upenamide 2.1a and 2.1b. 
 
Upenamide (2.1) was obtained as an amorphous white solid and determined to 
have a molecular formula of C32H46N2O4 by high-resolution mass spectrometry. Efforts 
toward structural elucidation revealed 32 distinct 13C NMR resonances accounting for all 
of the carbons of upenamide (2.1). IR bands at 3411 and 1676 cm-1 paired with observed 
13C NMR resonances at δ 70.0 and 169.4 suggested the presence of a secondary alcohol 
and amide functional groups. The 13C NMR spectrum also indicated 8 distinct sp2 
                                                
35 Jiménez, J. I.; Goetz, G.; Mau, C. M. S.; Yoshida, W. Y.; Scheuer, P. J.; Williamson, R. T.; Kelly, M. J. 
Org. Chem. 2000, 65, 8465-8469. 
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methine carbons, suggesting the presence of 4 double bonds. The well-resolved 1H NMR 
resonances between δ 6.72 and δ 5.48 correlated with these double bonds. Through 1H-1H 
COSY and TOCSY analysis they were able to construct core fragments of a conjugated 
triene and isolated alkene. With isolated 1H spin systems defined, they were able to 
connect these fragments further using long-range correlation data revealed by HMBC 
analysis and supported by 1H-1H COSY data to construct the two-dimensional structure 
of upenamide (2.1).  
With the structure of upenamide (2.1) built, the relative stereochemistry was 
tentatively assigned using NOESY correlations (Figure 2.2). Strong NOESY correlations 
were observed between H10 and H2 indicating that the substitution on the 
oxaquinolizidine ring adopts a cis relationship. Additional NOESY correlations between 
H11 and H15 indicate a 1,3-equatorial relationship between the C11 hydroxyl and the 
C15 tether. NOESY correlations between H27, H32, and H30 indicate the hemiaminal 
bicycle is a cis-decalin ring system with the alkyl tether at C30 in the equatorial position. 
This is also supported by the very small coupling constant observed for H32. If the 
hemiaminal bicycle were a trans-decalin ring system then H32 would be expected to 
display a larger coupling constant with H27, as CH32-CH27 would approach a 180° 
dihedral angle. 
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Figure 2.2. Important NOESY Correlations for the Assignment of Relative Stereochemistry. 
 
Next, in an effort to define the overall stereochemistry of upenamide, they 
subjected the C10 hydroxyl to Mosher ester analysis (Figure 2.3). This analysis led to 
assignment of the absolute configuration of the ABC tricycle as shown in Figure 2.2. 
However, Mosher ester analysis of the C30 hydroxyl released upon reductive ring 
opening of the hemiaminal was inconclusive and so only the relative stereochemistry of 
the DE bicycle could be assigned. Thus, upenamide was assigned as one of two possible 
isomeric structures shown in Figure 2.1 [27S, 30R, 32R (2.1a) or the 27R, 30S, 32S 
(2.1b)]. 
 
 
Figure 2.3. Mosher Ester Analysis for the Assignment of Absolute Stereochemistry. 
 
Upenamide did not show in vitro growth inhibition activity against P388, A549, 
or HT29 cancer cell lines in preliminary screening, and because only 7.2 mg of 
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upenamide (2.1) was isolated, more extensive biological screening was not possible. 
Upenamide (2.1) represents a new class of macrocyclic diamine alkaloids with both a 
spirooxaquinolizidinone ring system and a unique cis-fused bicyclic aminal making it an 
interesting target for total synthesis. 
 
Proposed Biosynthesis of Upenamide 
Scheuer and coworkers extended the proposed manzamine biosynthesis of 
Baldwin and Whitehead to develop a hypothetic biosynthetic route to upenamide (2.1) 
(Scheme 2.1).36 To this end, a reductive condensation of two equivalents of ammonia, 
two equivalents of acrolein, and two dialdehyde units 2.3 and 2.4 form the theoretical bis-
hydropyridine haliclamine 2.5. Haliclamine 2.5 is then proposed to undergo oxidation to 
give cyclic alkylpyridine 2.6, which, upon cyclization leads to upenamide (2.1). 
 
 
Scheme 2.1. Scheuer’s Proposal for the Biosynthesis of Upenamide (2.1). 
 
More recently, Fontana and coworkers undertook studies to elucidate the 3-alkylpyridine 
biosynthetic pathway (Scheme 2.2). They looked at the marine mollusk Haminoea 
orbignyana, the natural producer of haminol-1 (2.8), an alarm pheromone. It was 
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discovered through feeding studies that 14C-labeled nicotinic acid (2.7) could be 
incorporated into the polyketide pathway as the starter unit to make haminol-1 (2.8).37 
This incorporation of labeled nicotinic acid was also observed in other haminol-
producing mollusks. Then, to confirm these results, Fontana and coworkers used 13C-
labeled acetic acid to confirm that the polyketide synthase pathway accepted nicotinic 
acid as a starter unit. After feeding studies where the mollusk had only access to nicotinic 
acid and the 13C-labeled acetic acid they isolated haminol-1 (2.8) and observed 
enrichment at the C-2, C-4, C-6, C-8, and C-10 sites of its 13C NMR spectra. 
 
 
Scheme 2.2. Fontana’s Elucidation of the Haminol-1 (2.8) Biosynthetic Pathway. 
 
Previously, while trying to affect a biomimetic assembly by which the proposed 
bis-pyridinium intermediate common to the 3-alkylpyridines might be formed, the 
Marazano group found that the dimerization of two alkylated pyridines was easily 
accomplished via formation of the Zincke pyridinium salt (2.10) and subsequent 
displacement with the nucleophilic free amine (Scheme 2.3).38  
 
                                                
37 (a) Cutignano, A.; Tramice, A.; De Caro, S.; Villani, G.; Cimino, G.; Fontana, A. Angew. Chem. Int. Ed. 
2003, 42, 2633-2636. (b) Cutignano, A.; Cimino, G.; Giordano, A.; d’Ippolito, G.; Fontana, A. Tetrahedron 
Lett. 2004, 45, 2627-2629. 
38 Kaiser, A.; Billot, X.; Gateau-Olesker, A.; Marazano, C.; Das, B. C. J. Am. Chem. Soc. 1998, 120, 8026-
8034. 
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Scheme 2.3. Marazano’s Approach to the Bis-pyridinium Biosynthetic Intermediate 2.12. 
 
Accordingly, the revised biosynthetic pathway for upenamide would now include 
the incorporation of a nicotinic acid starter unit into a PKS pathway whereby nicotinic 
acid is extended (Scheme 2.4). The two alkylated pyridine units then dimerize to give the 
alkyl pyridine dimer 2.6. At this point, upenamide demonstrates a unique departure from 
the accepted biosynthetic pathways of manzamine A (1.1), sarain A (1.6), and 
madangamine A (1.6). Here, the macrocyclic pyridine dimer (2.6) undergoes capture of a 
cation formed at C15 by the C9 carbon constructing the C ring; this then generates a 
cation on C10 that is then captured by the C2 carbonyl oxygen to form the A ring and 
ultimately assembling upenamide (2.1).  
 
 
Scheme 2.4. Revised Proposal for the Biosynthesis of Upenamide (2.1). 
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Synthetic Approaches to the Total Synthesis of Upenamide 
Sponge collection from the Derewan Islands is currently strongly restricted so it is 
unlikely that more upenamide (2.1) will be isolated from its Echinochalina sponge 
source. Therefore, total synthesis remains the only method for further structure of 
elucidation and biological study. Several research groups have now reported on progress 
toward the total synthesis of upenamide. 
 
Marazano’s Progress Toward Upenamide  
In 2004, the Marazano group sought to design a model for the cyclization to 
access the interesting DE hemiaminal of upenamide (2.1) (Scheme 2.5).39  Their intent 
was to establish whether a cyclization of iminium 2.16 would provide selectivity for the 
natural isomer of the four possible diastereomers of aminal 2.15 under thermodynamic 
conditions. 
 
 
Scheme 2.5. Marazano’s Retrosynthetic Approach to the Synthesis of the  
DE Bicycle of Upenamide (2.1). 
 
Beginning with 3-(3-pyridyl)propanol (2.17), alkylation of the pyridinyl nitrogen 
and subsequent reduction with sodium borohydride gave tetrahydropyridine 2.18 
                                                
39 Maia, A. A.; Mons, S.; de Freitas Gil, R. P.; Marazano, C. Eur. J. Org. Chem. 2004, 1057-1062 
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(Scheme 2.6). Formation of the N-oxide of 2.19 on treatment with mCPBA followed by 
treatment with TFAA gave iminium salt 2.20. Addition of potassium cyanide at a pH of 1 
and subsequent hydrogenation gave aminonitrile 2.21. Treatment of 2.21 with silver 
tetrafluoroborate induced ionization and cyclization to give an 81:16 mixture of aminal 
epimers with hemiaminal 2.15 as the major isomer. Comparison of spectral data indicated 
the major isomer matched the relative stereochemistry of upenamide (2.1). 
 
 
Scheme 2.6. Marazano’s Synthesis of the Upenamide DE Bicycle Intermediate 2.15. 
 
Ong and Han’s Progress Toward Upenamide  
In 2006, Ong and Han proposed a nitrile addition and stannous ion-induced 
cyclization approach toward the ABC spirooxaquinolizidinone of upenamide (2.1) 
(Scheme 2.7). 40  Through this method they were able to successfully demonstrate 
installation of the quaternary carbon with incorporation of a functional handle for further 
elaboration of the C-ring. 
 
                                                
40 Han, J. L.; Ong, C. W. Tetrahedron. 2007, 63, 609-614. 
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Scheme 2.7. Ong’s Retrosynthetic Approach to the Synthesis of the ABC Spirocyclic Tricycle of 
Upenamide (2.1). 
 
Starting with 4-methoxycinnamic acid (2.25) Ong and Han derived iron salt 2.26 
in 6 steps (Scheme 2.8) via exhaustive reduction of the unsaturated carboxylic acid 
followed by Birch reduction of the aromatic ring and protection of the primary alcohol as 
the acetate. Isomerization of the Birch product to the conjugated 1,4-diene and 
subsequent complex formation with iron pentacarbonyl followed hydride abstraction with 
trityl perchlorate gave iron salt 2.26. Treatment with TMS cyanide gave tertiary nitrile 
2.27. Subsequent hydrolysis of the acetate and Appel reaction gave bromide 2.24. 
 
 
Scheme 2.8. Ong’s Synthesis of the Upenamide Intermediate 2.24. 
 
As a proof-of-concept Ong and Han found that conversion of the nitrile to the 
aldehyde treatment with 3-aminopropanol under Hoye conditions provided hemiaminal 
2.28 as a 1:1 mixture of diastereomers (Scheme 2.9). Unfortunately, using 3-
hydroxypropionamide under these same conditions did not produce 2.23. Instead they 
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had to use an alternative procedure to access the desired intermediate 2.23. Conversion of 
the nitrile to the aldehyde and subsequent formation of the acetal followed by Gabriel 
amine synthesis and subsequent acylation of the resulting primary amine with β-
propiolactone (2.29) gave β-hydroxyamide 2.10. Treatment with stannous chloride 
provided the aminal 2.23 as a 1.5:1 mixture of diastereomers favoring the desired 
stereochemistry. 
 
 
Scheme 2.9. Ong’s Synthesis of the Upenamide ABC Tricycle Intermediate 2.23. 
 
Concurrently, efforts toward the synthesis of upenamide (2.1) were being made in 
the lab of Richard J. K. Taylor beginning in 2004 and these efforts culminated in its total 
synthesis in 2013.  
 
Taylor’s Total Synthesis of Upenamide and Structural Comparisons 
The Taylor group has maintained an interest in developing methodologies by 
which they could make ‘privileged scaffolds’ for use in pharmaceutical and agrochemical 
drug discovery.41 Inspired by a report by the Blaauw group on the synthesis of (-)-
dysibetaine PP (2.31) 42 (Scheme 2.10) and other reports toward the synthesis of similar 
                                                
41 a) Cayley, A. N.; Cox, R. J.; Ménard-Moyon, C.; Schmidt, J. P.; Taylor, R. J. K. Tetrahedron Lett. 2007, 
48, 6556-6560. b) Cayley, A. N.; Gallagher, K. A.; Ménard-Moyon, C.; Schmidt, J. P; Diorazio, L. J.; 
Taylor, R. J. K. Synthesis 2008, 3846-3856. 
42 Ijzendoorn, D. R.; Botman, P. N. M.; Blaauw, R. H. Org. Lett. 2006, 8, 239-242. 
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N,N-bicyclic systems 43  Taylor and coworkers developed a metal-catalyzed 
deacetalization-cyclization to access a range of N,O- and N,S-polycyclic and heterocyclic 
compounds (Scheme 2.11).   
 
 
Scheme 2.10. Blaauw’s Synthesis of (-)-Dysibetaine PP (2.31). 
 
They began by coupling dioxolane acid 2.35 and L-cysteine methyl ester 2.36 and 
treating the resulting amide with various acid conditions to optimize the yield of 2.37 as a 
single diastereomer. They were most successful using tin (II) chloride dihydrate, 
presumably due to the slow release of hydrochloric acid effecting a slow and mild 
deprotection of the acetal while maintaining the tin Lewis acid in order to drive the 
cyclization.  
 
                                                
43 a) Mizutani, N.; Chiou, W.-H.; Ojima, I. Org. Lett. 2002, 4, 4575-4578. b) Armorde, S. M.; Judd, A. S.; 
Martin, S. F. Org. Lett. 2005, 7, 2031-2033. 
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Table 2.1. Taylor’s Optimization of Acid Catalyst for  
Deacetalization-Cyclization Methodology. 
 
 
They were then able to expand this methodology to give access to wide variety of 
scaffolds using a range of dioxolane acids (2.35) and ω-functionalized aliphatic or 
aromatic amines, or, dioxolane amines (2.38) and ω-functionalized aliphatic or aromatic 
carboxylic acids (Scheme 2.11). 
 
 
Scheme 2.11. Taylor’s Deacetalization-Cyclization Methodology 
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Taylor and coworkers found that their deacetalization-cyclization methodology 
could also be applied successfully to the installation of both AB oxaquinolizidinone core 
2.44 and the DE hemiaminal 2.46 (Scheme 2.12).44  
 
 
Scheme 2.12. Taylor’s Deacetalization-Cyclization Methodology. 
 
First, they committed their efforts to the synthesis of the ABC 
spirooxaquinolizidinone (Scheme 2.13). Starting with meso-anhydride 2.47 they accessed 
enantiomerically pure mono-acetate 2.48 via a three-step procedure employing porcine 
pancreatic lipase. The free alcohol was then protected as the benzyl ether using Dudley’s 
reagent (2.49) and the acetate was converted to the methyl ester via oxidation with Jones’ 
reagent followed by Fisher esterification to give ester 2.50. Installation of the quaternary 
carbon was accomplished via α-alkylation with iodide 2.51 to provide the resulting ester 
as a single diastereomer. Reduction of the ester and subsequent formation of the TIPS 
ether, followed by PMB deprotection and conversion of the resulting primary alcohol to 
the azide gave azido intermediate 2.52. The azide was reduced under Staudinger reaction 
conditions and the resulting amine coupled with (S)-malic acid derived ester 2.53 to give 
                                                
44 a) Reid, M.; Taylor, R. J. K. Tetrahedron Lett. 2004, 45, 4181-4183. b) Ménard-Moyon, C.; Taylor, R. J. 
K. Eur. J. Org. Chem. 2007, 3698-3706. c) Schmidt, J. P.; Beltrán-Rodil, S.; Cox, R. J.; McAllister, G. D.; 
Reid, M.; Taylor, R. J. K. Org. Lett. 2007, 9, 4041-4044.  
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the corresponding amide. The TIPS ether was deprotected and the released alcohol was 
subjected to Ley oxidization to give aldehyde 2.54. Their developed deprotection-
cyclization methodology proceeded smoothly providing spirocycle 2.55, which 
underwent TIPS protection of the resulting primary alcohol and next an allylic oxidation. 
As this provided the correct regiochemistry but the wrong stereochemistry, they were 
successful at inverting the stereocenter via an oxidation-reduction sequence to provide 
spirooxaquinolizidinone 2.56. 
 
 
Scheme 2.13. Taylor’s First Synthesis of Spirooxaquinolizidinone 2.56. 
 
With this spirooxaquinolizidinone intermediate 2.56 in hand they compared its 
spectral data to the published NMR data for the corresponding region of upenamide. 
They found that the 1H, 13C, and NOESY data did indeed match that for upenamide 
(Tables 2.2 and 2.3). This also confirmed the construction of the ABC spirocyclic 
tricycle by the Scheuer group. 
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Table 2.2. Comparison of 1H, 13C, and NOESY NMR Data  
for C11 of Taylor’s Spirooxaquinolizidinone 2.56. 
 
 
Table 2.3. Comparison of 13C NMR Data for Taylor’s Spirooxaquinolizidinone 2.56. 
 
 
Concurrent to these efforts, and in alignment with their interest in novel 
polycyclic heterocyclic scaffolds, the Taylor group also developed a direct imine 
acylation methodology using propylphosphonic acid anhydride (T3P) to effect a one-pot 
coupling and cyclization, thus eliminating the need to isolate the amide or thioester 
intermediate before treatment with acid to promote cyclization and also providing access 
to a more broad range of heterocycles (Scheme 2.14).45 They found that this methodology 
could also be used to provide access to the AB oxaquinolizidinone core of upenamide 
(2.1).  
 
                                                
45 Unsworth, W. P.; Kitsiou, C.; Taylor, R. J. K. Org. Lett. 2013, 15, 258-261. 
compound 13C	(C11) 1H	(H11) nOe	(H11)
upenamide	(2.1) 70.0 4.82 H12,	H15
intermediate	2.56 70.1 4.22 H12,	H15
a	The	spectrum	of	upenamide	(2.1)	was	recorded	in	CD3OD	at	500	
MHz	for	1H	NMR	and	at	125	MHz	for	13C	NMR,	the	spectra	for	
Taylor's	intermediate	2.56	was	recorded	in	CD3OD	at	400	MHz	for	
1H	NMR	and	100	mHz	for	13C	NMR.
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Scheme 2.14. Taylor’s Direct Imine Acylation Methodology. 
 
The Taylor group then focused their efforts on the total synthesis of the proposed 
27S, 30R, 32R structure of upenamide (2.1a) utilizing their deacetalization-cyclization 
methodology to install the DE hemiaminal and their direct imine acylation methodology 
to install the ABC spirocycle (Scheme 2.15).46  
 
 
Scheme 2.15. Taylor’s Retrosynthetic Approach to the Synthesis of Upenamide (2.1a). 
 
Applying the chemistry previously optimized in their first synthesis of the ABC 
spirocycle (see Scheme 2.13) they accessed ester 2.50 from meso-anhydride 2.47 in 7 
steps (Scheme 2.16). Installation of the quaternary carbon via α-alkylation with azido 
iodide 2.67 proceeded smoothly and subsequent Staudinger reduction of the azide and 
                                                
46 Unsworth, W. P.; Gallagher, K. A.; Jean, M.; Schmidt, J. P.; Diorazio, L. J.; Taylor, R. J. K. Org. Lett. 
2013, 15, 258-261. 
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cyclization onto the methyl ester provided amide 2.68. Allylic oxidation and inversion of 
the resulting alcohol via an oxidation-reduction sequence and subsequent TIPS protection 
gave intermediate 2.69. Benzyl deprotection, Ley oxidation, and subsequent Takai 
olefination gave vinyl iodide 2.70, which was then treated with Meerwein’s salt and 
reduced to cyclic imine 2.64 using sodium borohydride catalyzed by the addition of 
catalytic hydrochloric acid. 
 
 
Scheme 2.16. Taylor’s Synthesis of the Upenamide Intermediate 2.64. 
 
With cyclic imine intermediate 2.64 in hand, the Taylor group then turned their 
attention to the synthesis of carboxylic acid 2.65 so as to utilize their direct imine 
acylation methodology to install the C ring (Scheme 2.17). Starting with optically active 
propargyl alcohol 2.71 and vinyl triflate 2.72, they accessed alkyne 2.73 via Sonogashira 
coupling. Full reduction provided the requisite alkyl enecarbamate (the synthetic route to 
this intermediate was developed previously in our lab47), which underwent smooth 
cyclization and concurrent TBS deprotection upon treatment with tin (II) chloride 
dihydrate to give hemiaminal 2.74. Ley oxidation and Roskamp reaction afforded 1,3-
dicarbonyl 2.75 and subsequent Noyori reduction, saponification and TBS protection of 
the alcohol gave hemiaminal acid 2.65.   
                                                
47 Kiewel, K.; Luo, Z.; Sulikowski, G. A. Org. Lett. 2005, 7, 5163-5165. 
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Scheme 2.17. Taylor’s Synthesis of the Upenamide Intermediate 2.65. 
 
With cyclic imine 2.64 and carboxylic acid 2.65 in hand, Taylor and coworkers 
were able to apply their direct imine acylation cyclization to access tricycle 2.76 using 
either propylphosphonic acid anhydride (T3P) or tin (II) chloride dihydrate. A three-step 
gentle deprotection of both the Boc protected amine and the TIPS protected alcohol 
followed by alkylation of the free amine with stannane 2.77 gave the Stille precursor 
2.63, which smoothly underwent Stille coupling to give the proposed structure of 
upenamide 2.78a. 
 
 
Scheme 2.18. Taylor’s Completion of Total Synthesis of the Proposed Structure of Upenamide 2.1a. 
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Upon isolation, Taylor and coworkers were disappointed to find that, while their 
synthetic 2.78a had the same optical sign as the natural upenamide, it was not soluble in 
d-MeOH therefore making direct NMR comparison not possible. Instead, Taylor and 
coworkers obtained the NMR spectra of their synthetic 2.78a in d-chloroform and found 
that there were considerable differences in the 13C NMR shifts compared to the d-MeOH 
13C NMR spectrum of natural upenamide 2.1a (table 2.4). 
 
Table 2.4. Comparison of Taylor’s Synthetic Upenamide 2.78a and Natural Upenamide (2.1). 
 
 
This information prompted Taylor and coworkers to access the proposed 27R, 
30S, 32S structure of upenamide (2.1b). To this end they synthesized the other 
enantiomer of carboxylic acid 2.79, and, using the previously described route, they 
gained access to synthetic 2.78b (Scheme 2.19).  
 
2 3 4 6 7 8 9 10 11 12 13 14 15 16 17 18
natural	upenamide	(2.1) 73.3 39.6 169.4 41.9 21.7 22.2 44.3 88.7 70.0 133.1 126.6 30.8 44.8 135.8 129.3 130.6
synthetic	upenamide	2.78a 71.4 39.5 172.1 42.9 b b 41.3 85.2 70.7 132.4 131.7 30.3 39.3 134.7 130.0 129.6
19 20 21 22 24 25 26 27 28 29 30 32 33 34 35 36
natural	upenamide	(2.1) 128.8 131.3 130.2 56.4 49.0 25.9 23.9 35.7 29.8 28.1 76.3 86.3 34.8 24.2 21.2 34.5
synthetic	upenamide	2.78a 127.1 126.7 126.4 59.5 44.3 b b 35.0 b b 76.6 90.9 b b b b
δ 13C	(ppm)
δ 13C	(ppm)
a	The	spectrum	of	natural	upenamide	(2.1a)	was	recorded	in	CD3OD	at	125	MHz,	the	spectra	for	Taylor's	synthetic	upenamide	2.78a	was	recorded	in	CDCl3	at	100	mHz.
b	Ten	CH2	signals	were	recorded	by	the	Taylor	group	for	2.78a	but	not	assigned	to	a	specific	carbon:	37.7,	36.9,	36.6,	29.1,	27.9,	27.7,	27.1,	25.0,	22.9,	19.4.
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Scheme 2.19. Taylor’s Total Synthesis of the Proposed Structure of Upenamide 2.1b. 
 
Unfortunately, synthetic 2.78b was isolated as a 10:3:1 mixture of synthetic 
2.78b, N,O-acetal diastereomer (C10, C2, epi-2.80), and triphenylarsine. Taylor and 
coworkers were surprised to find that synthetic 2.78b was soluble in d-MeOH, making 
direct comparison possible, but they found that there were still significant discrepancies 
in the spectra (Table 2.5) and therefore concluded that neither synthetic 2.78a nor 
synthetic 2.78b corresponded to the natural product. 
 
Table 2.5. Comparison of Taylor’s Synthetic Upenamide 2.78b and Natural Upenamide (2.1). 
 
 
Since neither synthetic 2.78a nor synthetic 2.78b were able to be characterized by 
X-ray analysis due to their instability, it is not possible to confirm that their structures are 
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exactly as described. Thus, it can’t be said that upenamide was definitely misassigned, 
therefore more work is needed to confirm the correct structure of upenamide (2.1) and 
where possible misassignments may have occurred leading to the current proposed 
structure.   
 61 
CHAPTER 3  
 
EFFORTS TOWARD THE TOTAL SYNTHESIS OF UPENAMIDE BY 
SULIKOWSKI AND COWORKERS 
 
As discussed in Chapter 2, spectral data on upenamide (3.1) tentatively assigns its 
structure as one of the two isomers shown in Figure 3.1. Mosher ester analysis of the C11 
secondary alcohol of upenamide found the absolute stereochemistry of the ABC tricycle 
is as indicated, but only the relative stereochemistry for the DE bicycle has been 
assigned. This information leads to the tentative assignment of (-)-upenamide as one of 
the two diastereomers shown (3.1a and 3.1b) (Figure 3.1). 
 
 
Figure 3.1. The Current State of the Structural Information for Upenamide (3.1). 
 
Synthetic Analysis Toward Upenamide  
When undertaking the total synthesis of a natural product with incomplete 
structural information there are two possible strategies to consider: synthesize one of the 
possible structures as a single isomer, or, employ a more concise and simultaneous 
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approach to both isomers via a common synthetic intermediate and reaction pathway.48 
Meaning, that while the synthesis of a single one of the two possible diastereomers of (-)-
upenamide (3.1a or 3.1b) would provide, in principle, a 50% chance of preparing the 
natural diastereomer; a more concise synthetic approach to (-)-upenamide (3.1) must 
involve the parallel synthesis of two defined diastereomers (3.1a and ent-3.1b) (Figure 
3.2). The latter approach allows for simultaneous production and spectral comparison of 
the assigned possible diastereomers of (-)-upenamide (3.1a and 3.1b).  
 
 
Figure 3.2. The Defined Diastereomers of Upenamide Accessible by a Concise Synthetic Route. 
 
Synthetic diastereomers 3.1a and ent-3.1b will be assembled via the coupling of a 
racemic ABC tricycle and a single enantiomer of the DE hemiaminal bicycle (Figure 
3.3). Assuming natural (-)-upenamide is indeed either isomer 3.1a or 3.1b, direct NMR 
comparison of synthetic diastereomers (3.1a and ent-3.1b) to natural (-)-upenamide will 
conclude one of the two is the natural product. The assignment of the correlating 
diastereomer will depend on comparison of optical rotation, in other words, synthetic 
3.1a will match the optical rotation of [α]D = -9.44° for natural (-)-upenamide 3.1a and 
                                                
48 Nicolaou, K. C.; Vourloumis, D.; Winssinger, N.; Baran, P. S. Angew. Chem. Int. Ed. 2000, 39, 44-122. 
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match by NMR analysis, while isomer ent-3.1b will also match (-)-upenamide by NMR 
but possess the opposite optical rotation. 
 
 
Figure 3.3. The Convergent Route for Accessing Defined Diastereomers 3.1a and ent-3.1b. 
 
To this end, we intend to access both upenamide diastereomers via a late-stage 
macrocyclization. The A ring oxaquinolizidine will be accessed via aldol reaction 
followed by dehydration. This takes us back to racemic acylated spirocyclic amide 3.6 
and optically active hemiaminal 3.7 (Scheme 3.1). 
 
 
Scheme 3.1. The Retrosynthetic Approach to the Final Upenamide Macrocycle. 
 
It was very crucial to our overall strategy that we access DE hemiaminal 3.7 in a 
highly stereoselective manner. To this end, we access hemiaminal aldehyde 3.8 via acid-
promoted cyclization from optically active enecarbamate 3.9 accessed via the cross-
coupling of Boc enecarbamate 3.10 and ε-caprolactone 3.11 (Scheme 3.2).  
N
O
OH
O
X
R
H
A
B
C
N
O
OH
O
X
R
H
A
B
C
R
N O R
H
H
H
D E
N
O
OH
O
N
O
H
H
H
H
A
B
C
D
E
N
O
OH
O
N
O
H
H
H
H
A
B
C
D
E
3.1a
3.3a 3.3b
3.4ent-3.1b
N
O
OH
O
N
O
H
H
H
H[M]X
aldol/redox
N
O
OH
O
N
O
H
H
H
H
OH
N
O
H
H
H
N
M[X]M[X]
[M]X
macrocyclization O
O
O
3.2 3.5 3.7
3.6
 64 
 
Scheme 3.2. Retrosynthetic Approach to the Optically Active DE Hemiaminal 3.8. 
 
With this strategy in mind, a previous lab member, Dr. Kurt Kiewel, pioneered 
the synthesis of optically active aldehyde 3.8.49 Dr. Kiewel’s work was employed by 
Taylor and coworkers to access the DE hemiaminal in their total synthesis of the 
proposed structure of upenamide (see Chapter 2). 
 
Kiewel’s Synthesis of the DE Hemiaminal 
Synthesis of the optically active DE hemiaminal began from inexpensive ε-
caprolactone 3.11 (Scheme 3.3). Reaction with the Weinreb salt and subsequent 
protection as the silyl ether gives amide 3.12. Addition of ethynyl Grignard provides 
access to propargyl ketone 3.13 and Midland reduction50 gives propargyl alcohol 3.14 in 
92% enantiomeric excess.  
 
 
Scheme 3.3. Synthesis of Enantiopure Propargyl Alcohol 3.14. 
 
                                                
49 Kiewel, K.; Luo, Z.; Sulikowski, G. A. Org. Lett. 2005, 7, 5163-5165. 
50 Midland, M. M.; Tramontano, A.; Kazubski, A.; Graham, R. S.; Tsai, D. J. S.; Gardin, D. B. Tetrahedron 
1984, 40, 1371-1380. 
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The Sonogashira coupling partner, β-iodoenecarbamate 3.16, was synthesized 
from enecarbamate 3.10 (Scheme 3.4) via iodomethoxylation followed by careful 
elimination of methanol. Sonogashira coupling 51  of β-iodoenecarbamate 3.16 with 
propargyl alcohol 3.14 gave the alkynyl enecarbamate, which underwent alkyne 
reduction while maintaining the enecarbamate carbon-carbon double bond to give alkyl 
enecarbamate 3.9 when subject to hydrogenation in the presence of triethylamine.  
 
 
Scheme 3.4. Synthesis of Enecarbamate 3.9. 
 
Preliminary investigations into the selective cyclization of alkylated cyclic 
enamines indicated that use of a carbamate protecting group52 would increase the 
reactivity of the enamine and, under kinetic conditions, would lead to the related 
hemiaminal as a single isomer. The stereoselectivity of the acid-promoted cyclization can 
be rationalized by considering the protonated immonium intermediates 3.17a and 3.17b 
(Scheme 3.5). Protonation could occur from either face of the enamine, but under kinetic 
conditions, cyclization of 3.18b would be favored relative to 3.18a, as the C30 alkyl 
group is in the pseudoequatorial position. Indeed, acid-promoted cyclization gave 
hemiaminal 3.20 in good yield and excellent enantiomeric excess. The ring fusion 
stereochemistry was assigned based on the small coupling constant observed for H27 and 
                                                
51 Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett. 1975, 50, 4467-4470. 
52 a) Ungureanu, I.; Klotz, P.; Schoenfelder, A.; Mann, A. Tetrahedron Lett. 2001, 42, 6087-6091. b) Suh, 
Y. G.; Kim, S.-H.; Jung, J.-K.; Shin, D.-Y. Tetrahedron Lett. 2002, 43, 3165-3167. 
N
Boc
I
PdCl2(PPh3)2, 
CuI, Et2NH
2. H2, Pd/C
Et3N, EtOAc
N
Boc
ICl, NaOMe
MeOH N
Boc
OMe
I
TFA, 140 °C
tol
93% 98%
94% over 2 steps
TBSO
HO
1.
N
OTBSBoc
OH
3.10 3.15 3.16
3.14
3.9
 66 
the relative stereochemistry of H30 was then confirmed based on observed nOe coupling 
between H30 and H32.  
 
 
Scheme 3.5. Mechanistic Rational for the Cyclization Stereoselectivity. 
 
With optically active hemiaminal in hand, deprotection of the silyl ether followed 
by Swern oxidation cleanly produced aldehyde 3.19 (Scheme 3.6). 
 
 
Scheme 3.6. Synthesis of Aldehyde 3.19. 
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Concurrent with the successful synthesis of a single DE hemiaminal isomer by 
Dr. Kiewel, work toward the synthesis of the ABC tricycle was being undertaken by 
postdoctoral fellow Dr. Zhushou Luo.53 
 
Luo’s Synthesis of the BC Spirocycle and Progress Toward  
The Total Synthesis of Upenamide 
Dr. Luo focused on the interesting synthetic challenge of construction of the BC 
spirocyclic ring system that incorporates a central spirocyclic stereocenter flanked by two 
adjacent stereocenters 54  (Scheme 3.7). In approaching these three contiguous 
stereocenters, a Diels-Alder reaction was envisioned to provide access to bicycle 3.23,55 
which would then provide 3.22 via allylation eventually elaborated to a three carbon side-
chain terminating in an azido group. Staudinger cyclization56 of 3.22 would complete the 
spirocyclic core 3.21, and the carboxylic acid would be further elaborated to vinyl iodide 
3.20 via Takai olefination.53 
 
                                                
53 a) Luo, Z.; Peplowski, K.; Sulikowski, G. A. Org. Lett. 2007, 9, 5051-5054. b) Luo, Z.; Sulikowski, G. 
A. unpublished data. 
54 a) Corey, E. J.; Guzman-Perez, A. Angew. Chem. Int. Ed. 1998, 37, 388-401. b) Trost, B. M.; Jiang, C. 
Synthesis 2006, 369-396. c) Denissova, I.; Barriault, L. Tetrahedron 2003, 59, 10105-10146. 
55 a) Jauch, J. Angew. Chem. Int. Ed. 2000, 39, 2764-2765. b) Feringa, B. L.; de Jong, J. C. J. Org. Chem. 
1988, 53, 1125-1127. c) Trost, B. M.; Toste, F. D. J. Am. Chem. Soc. 1999, 121, 3543-3544. d) Trost, B. 
M.; Crawley, M. L. J. Am. Chem. Soc. 2002, 124, 9328-9329. e) Maestro, M. C.; Barquilla, M. C.; Martín, 
M. R. Tetrahedron: Asymm. 1999, 10, 3593-3599. 
56 a) Bosch, I.; Romea, P.; Urpf, F.; Vilarrasa, J. Tetrahedron Lett. 1993, 34, 4611-4674. b) Wang, J.; 
Sakamoto, S.; Kamada, K.; Nitta, A.; Noda, T.; Oguri, H.; Hirama, M. Synlett. 2003, 891-893. c) Jiang, B.; 
Yang, C.-G.; Wang, J. J. Org. Chem. 2002, 67, 1396-1398. d) Neubert, B. J.; Snider, B. B. Org. Lett. 2003, 
5, 765-768. 
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Scheme 3.7. Retrosynthetic Approach to Spirocyclic Amide 3.23. 
 
The Luo synthesis started with a stereoselective Diels-Alder reaction between 
diene 3.2457 and bromofuranone 3.25. In this way the three contiguous stereocenters of 
the upenamide C ring were set (Scheme 3.8). Keck allylation58 of bromide 3.23 yielded a 
3:1 mixture of cis and trans isomers and provided 3.26 in 63% yield following separation 
by flash chromatography. Alkene 3.26 was converted to azide 3.2259 by way of alcohol 
3.27, derived from the alkene via hydroboration and oxidation. The proposed Staudinger 
cyclization occurred upon treatment with triphenylphosphine, but, unfortunately, the 
cyclization was accompanied by aldehyde epimerization, leading to 3.28b as the major 
isolated product. 
 
 
Scheme 3.8. Synthesis of Spirocyclic Amide 3.28. 
 
                                                
57 Trost, B. M.; Chupak, L. S.; Lübbers, T. J. Org. Chem. 1997, 62, 736. 
58 Keck, G. E.; Yates, J. B. J. Am. Chem. Soc. 1982, 104, 5829-5831. 
59 Thompson, A. S.; Humphrey, G. R.; DeMarco, A. M.; Mathre, D. J.; Grabowski, E. J. J. J. Org. Chem. 
1993, 58, 5886-5888. 
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To suppress the undesired epimerization the spirocyclic amide was accessed by 
way of an anhydride (3.30), in anticipation of the carboxylic acid product being less 
prone to isomerization as the α-hydrogen would be less acidic. To this end, hydrolysis of 
the methyl acetal of 3.22 afforded lactol 3.29 followed by oxidation to give anhydride 
3.30 (Scheme 3.9). Azide 3.30 was readily converted to amide 3.31 upon treatment with 
trimethylphosphine. The Staudinger cyclization proceeded cleanly without any observed 
loss of stereochemistry due to epimerization. The carboxylic acid was converted to 
aldehyde 3.32 via reduction oxidation sequence and subsequent Takai olefination 
provided vinyl iodide 3.33.60 
 
 
Scheme 3.9. Revision of the Spirocycle Synthesis and Installation of the Vinyl Iodide. 
 
Next, the merger of the acylated racemic spirocycle 3.20 and the optically active 
hemiaminal 3.19 was accomplished employing a stereoselective aldol reaction. After 
screening various metal enolates, it was determined the derived titanium-enolate reaction 
with aldehyde 3.19 in a stereocontrolled manner to give two inseparable products, 
tentatively assigned the stereochemistry 3.34a and 3.34b (Scheme 3.10). Notably, the 
assigned stereochemistry of C31 is of the correct relative configuration to afford 3.1a 
                                                
60 Augé, J.; Boucard, V.; Gil, R.; Lubin-Germain, N.; Picard, J.; Uziel, J. Synth. Comm. 2003, 33, 3733-
3739. 
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(from 3.34a) and ent-3.1b (from 3.34b). It was anticipated that the isomers may be 
separated en route to the final products. 
 
 
Scheme 3.10. Aldol Coupling of Spirocycle 3.20 and Hemiaminal 3.19. 
 
Next, efforts were undertaken toward completion of the A ring (Scheme 3.11) 
which required semi-reduction of the lactam to the hemiaminal followed by 
cyclodehydration. Lactam reduction, which required protection of the secondary alcohol 
as the p-methoxybenzyloxymethyl ether, gave 3.35. The silyl ether was then removed so 
that the resulting free hydroxyl group would direct Red-Al reduction of the lactam. 
Reduction proceeded with high stereoselectivity and was followed by PMB removal to 
give 3.36. A variety of conditions were examined to effect dehydration of 3.36 to 
complete the ABC tricycle (3.37), however none of the desired product was observed. An 
alternate route where the triene-containing macrocycle was formed prior to the 
cyclodehydration was pursued. 
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Scheme 3.11. Initial Attempts At A Ring Formation. 
 
The strategy at this point shifted toward macrocyclization followed by cyclization 
with the intention of making the formation of the A ring more favorable (Scheme 3.12). 
To this end, a bis-Stille cross-coupling to install the key triene and form the macrocyclic 
core was examined. bis-Stille ‘stitching’ reaction was first employed by Nicolaou and co-
workers in their total synthesis of rapamycin and has gained further use in other natural 
product total synthesis. 61  Removal of the Boc group of 3.34b was accomplished 
following Ohfune’s two-step protocol62 and subsequent N-alkylation with vinyl iodide 
3.38 gave bis-vinyl iodide 3.39. However, under a variety of conditions the key bis-Stille 
coupling was unsuccessful at providing macrocycle 3.41, leading instead to 
decomposition. 
 
                                                
61 a) K. C. Nicolaou, K. C.; Chakraborty, T. K.; Piscopio, A. D.; Minowa, N.; Bertinato, P. J. Am. Chem. 
Soc. 1993, 115, 4419-4420. b) Shair, M. D.; Yoon, T.; Danishefsky, S. J. J. Org. Chem. 1994, 59, 3755-
3757. c) Takahashi, T.; Sakamoto, Y.; Yamada, H.; Usui, S.; Fukazawa, Y. Angew. Chem. Int. Ed. Engl. 
1995, 34, 1345-1348. d) Shair, M. D.; Yoon, T.; Danishefsky, S. J. Angew. Chem. Int. Ed. Engl. 1995, 34, 
1721-1723. e) Ronson, T. O.; Taylor, R. J. K.; Fairlamb, I. J. S. Tetrahedron 2015, 71, 989-1009. 
62 Sakaitani, M.; Ohfune, Y. Tetrahedron Lett. 1985, 26, 5543-5546. 
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Scheme 3.12. Initial Attempts at Macrocyclization. 
 
Moving forward, it was assumed that decomposition was due to the sensitive 
trans,trans,trans-triene, so the strategy was revised to begin first with the installation of 
the triene motif, followed by closing the macrocycle (Scheme 3.13). Intermolecular Stille 
coupling of vinyl iodide 3.34b with vinyl tin 3.42 followed by acylation gave triene 3.43. 
Gentle Boc deprotection gave free amine and palladium-catalyzed intramolecular 
amination gave macrocycle 3.41. However, macrocycle production via cross-coupling 
was unreliable and produced, at best, irreproducible yields approaching only 30% of 
macrocycle 3.41. 
 
 
Scheme 3.13. Triene Installation and Macrocyclization. 
 
As the triene moiety appeared to be the factor leading to poor yields or 
decomposition, focus was turned toward formation of an alkyne-containing macrocycle 
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via Sonogashira coupling with the intention of late stage reduction under mild conditions 
to access the triene (Scheme 3.14). Once again, Boc deprotection of 3.34b, followed by 
alkylation of the free amine with vinyl alkyne 3.42, gave 3.43. Sonogashira coupling to 
give the alkyne macrocycle 3.44 was more reliable, however yields remained consistently 
poor. 
 
 
Scheme 3.14. Synthesis of Macrocyclic Alkyne 3.44 via Sonogashira Coupling. 
 
Moving forward with alkyne macrocycle 3.44, the intention was to first install the 
A ring, then semi-hydrogenate and isomerize the alkene (Scheme 3.15). Desilylation gave 
free alcohol 3.45 and Red-Al reduction of the cyclic carbonyl gave 3.46. Subsequent 
deprotection of the PMB with TFA gave triol 3.47. However, despite trying a variety of 
conditions, the alkyne did not succumb to reduction and isomerization to give the triene-
containing macrocycle 3.48.63  
 
                                                
63 a) Crousse, B.; Alami, M.; Linstrumelle, G. Synlett 1997, 992-994. b) Alami, M.; Linstrumelle G. 
Tetrahedron Lett. 1997, 38, 5297-5300. 
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Scheme 3.15. Attempts at Alkyne Semi-Hydrogenation. 
 
The difficulties faced en route to the macrocycle led to the revision of our 
synthetic approach. As installation of the A ring via the aldol reaction, reduction, 
cyclization and dehydration proved difficult, we reimagined the synthesis to access a 
more highly reactive intermediate to make the A ring installation more favorable. To 
avoid epimerization of the aldehyde required oxidation state manipulations; we envision 
avoiding these problems by going into the Diels-Alder step with the correct oxidation 
state (Scheme 3.16). To this end, we envision starting with the inexpensive bromomaleic 
anhydride (3.50).  
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Scheme 3.16. Revision of the Route to ABC Spirocycle 3.31. 
 
Triene formation was also a problem, and so we envision installing the triene after 
the installation of the ABC ring. However, cyclodehydration to install the A ring was also 
problematic. Thus we will focus our strategy on new methods to close the A ring. These 
should also consider any methods for stereocontrolled reduction. This new approach will 
be discussed in detail in the following chapter. 
 
Experimental Methods 
General procedure. All reactions were performed in flame-dried or oven dried round-
bottomed flasks under an atmosphere of argon unless otherwise noted. Stainless steel 
syringes or cannula were used to transfer air- and moisture-sensitive liquids. Reaction 
temperatures were controlled using a thermocouple thermometer and analog hotplate 
stirrer. Reactions were conducted at room temperature (approximately 22 °C) unless 
otherwise noted. Flash column chromatography was conducted as described Still et. al. 
using silica gel 230-400 mesh. 64  Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV light (254 nm) 
                                                
64 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925. 
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and ceric ammonium molybdate, potassium permanganate, or anisaldehyde stains. Yields 
were reported as spectroscopically pure compounds.  
Materials. Reagents and solvents used were of commercial grade and purified prior to 
use when necessary. Tetrahydrofuran, toluene, and dichloromethane were obtained from 
either an MBraun MB-SPS solvent system, where they were dried using activated 
alumina columns, or freshly distilled (tetrahydrofuran and ether were both distilled from 
sodium metal with benzophenone indicator), and when necessary solvents were further 
dried over activated 4 Å molecular sieves under an atmosphere of argon. Triethylamine 
was distilled from calcium hydride and stored over sodium hydroxide. The molarity of 
commercial n-butyllithium solutions was determined by titration using 2,2,2′-
Trimethylpropionanilide65 as an indicator (average of three determinations). 
Instrumentation. Nuclear magnetic resonance (NMR) spectra were acquired on Bruker 
DRX-400 (400 MHz), DRX-500 (500 MHz), or (600 MHz) spectrometers and are 
reported relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16; MeOD: 3.31). 
Data for 1H NMR spectra are reported as follows: chemical shift δ (ppm), multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septet, m = multiplet, br = 
broad singlet, app = apparent). Infrared (IR) spectra were obtained as thin films on NaCl 
plates using a Thermo Electron IR100 series spectrophotometer and are reported in 
wavenumbers (cm-1). High-resolution mass spectra were obtained from the Department 
of Chemistry and Biochemistry, University of Notre Dame using a micrOTOF QII mass 
spectrometer. Optical rotations were measured on a Perkin-Elmer 341 digital polarimeter 
at ambient temperature (zeroed with pure, solvent-grade chloroform). 
                                                
65 Suffert, J. J. Org. Chem. 1989, 54, 509-510. 
 77 
3.45. A solution of ε-caprolactone (2.30 g, 20.1 mmol) and N,O-dimethyl 
hydroxylamine hydrochloride (3.90 g, 40.2 mmol) in dichloromethane 
(40 mL) was cooled to 0 °C and trimethyl aluminum (20 mL, 40.2 mmol, 
2.0 M solution in toluene) was added dropwise and the reaction was allowed to stir 24 h 
at 0 °C. The reaction was then quenched with ethyl acetate (100 mL) and water (5 mL). 
The resulting precipitate was filtered off and the filtrate was then concentrated to 20 mL. 
Silica gel (5 g) was added to the concentrated filtrate and the slurry was allowed to stir 
for an additional 1 h. The slurry was then filtered and washed with excess 
dichloromethane (ca. 200 mL). The organics were concentrated to yield spectroscopically 
pure amide 3.45 (3.40 g, 96%) as a yellow oil. Spectral data matched reported values.49  
 
3.12. A solution of amide 3.45 (3.00 g, 17.1 mmol), TBS chloride (3.23 
g, 21.4 mmol), and imidazole (2.91 g, 42.8 mmol) in DMF (8 mL) was 
allowed to stir 16 h. The reaction was then diluted with ether (400 mL) 
and washed with water (4 x 100 mL). The combined organic layers were dried (MgSO4), 
concentrated, and the residue was purified by flash chromatography (SiO2, 10% ethyl 
acetate, hexanes) to yield TBS ether 3.12 (4.90 g, 98%) as a light yellow oil. Spectral 
data matched reported values.49  
 
3.13. To neat TBS ether 3.12 (3.75 g, 13.0 mmol) was added ethynyl 
magnesiumbromide (31 mL, 15.5 mmol, 0.5 M solution in THF) and the 
solution was heated to 50 °C for 45 min. The reaction was then cooled to RT 
and quenched with saturated NH4Cl (75 mL) and extracted with ether (2 x 250 mL). The 
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combined organic layers were washed with water (3 x 100 mL), brine (100 mL), and then 
dried (MgSO4) and concentrated. The residue was purified by flash chromatography 
(SiO2, 10% ethyl acetate, hexanes) to yield alkynone 3.13 (2.55 g, 77%) as a orange oil. 
Spectral data matched reported values.49  
 
3.14. To neat (R)-alpine borane66 (7.23 g, 28.0 mmol) at 0 °C was added neat 
alkynone 3.13 (5.09 g, 20.0 mmol). After 30 min at 0 °C the reaction was 
warmed to room temperature and allowed to stir 8 h. Excess (R)-alpine 
borane was quenched by the addition of propionaldehyde (1.08 mL, 15.0 mmol) at 0 °C 
and the reaction was allowed to stir an additional 1 h. The solution was then concentrated 
and subjected to heat under high vacuum (1 mmHg, 40 °C) for 4 h with stirring to 
liberate α-pinene. The resulting viscous oil was then taken up in THF (10 mL), and 
cooled to 0 °C. To this solution was added 3 M aqueous NaOH (7.5 mL) and H2O2 (7.5 
mL, 30% solution in water) and then solution was heated to 40 °C and allowed to stir 4 h. 
The reaction was then extracted with ether (3 x 100 mL) and the combined organic layers 
were washed with brine, dried (MgSO4), and concentrated. The residue was purified by 
flash chromatography (SiO2, 12% ethyl acetate, hexanes) to yield propargyl alcohol 3.14 
(3.78 g, 74%) as a light yellow oil. Spectral data matched reported values.49  
 
3.15. To a solution of tert-butyl 3,4-dihydropyridine-1(2H)-carboxylate (1.00 
g, 5.46 mmol) and NaOMe (2.08 mL, 10.91 mmol, 5 M solution in MeOH) in 
MeOH (6 mL) was added dropwise iodine monochloride (6 mL, 6.00 mmol, 1 M solution 
                                                
66 Neat (R)-alpine borane was obtained by evaporation of a commercially available 0.5 M solution in 
tetrahydrofuran at 40 °C and 1mmHg with stirring. 
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in DCM) and let stir 30 min. To the reaction was then added 10% aqueous Na2S2O3 (20 
mL) and let stir an additional 30 min. The mixture was then extracted with ether (3 x 30 
mL) and the combined organics were diluted with an equal amount of hexanes (ca. 100 
mL). The solution was then washed with brine (75 mL), dried (MgSO4), and concentrated 
to yield spectroscopically pure iodomethoxide 3.15 (1.76 g, 95%) as a yellow oil. 
Spectral data matched reported values.49  
 
3.16. To a solution of iodomethoxide 3.15 (2.00 g, 5.87 mmol) in toluene (125 
mL) was added trifluoroacetic acid (40 µL) and the flask was immediately 
lowered into a large oil bath that was preheated to 145 °C. The solution was stirred for 
5.0 min after the internal temperature reached 90 °C, during which time the solution 
turned purple. The flask was then transferred to an ice bath. When the internal 
temperature reached 22 °C triethylamine (120 µL) was added and the purple color 
discharged to light yellow. The entire solution was then passed through a 4-inch column 
of silica gel followed by excess 10% ethyl acetate, hexanes (ca. 250 mL). Triethylamine 
(250 µL) was added to the eluent and concentrated to yield vinyl iodide 3.16 (1.95 g, 
98%) as a yellow oil. Spectral data matched reported values.49  
 
3.46. To a mixture of vinyl iodide 3.16 (1.37 g, 4.45 mmol), propargyl 
alcohol 3.14 (1.71 g, 6.67 mmol), trans-dichlorobis 
(triphenylphosphine)palladium (156 mg, 0.22 mmol), and copper (I) 
iodide (85 mg, 0.44 mmol) was added diethylamine (28 mL) and DMF (7 mL) without 
the rigorous exclusion of moisture or oxygen. The reaction was then heated to 40 °C for 
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60 min and the resulting red mixture was concentrated to ca. 8 mL and taken up in 
hexanes (100 mL) and water (100 mL).  The organic layer was washed with brine (100 
mL), dried (MgSO4), and concentrated. The resulting black oil was loaded onto silica gel 
and then purified by flash chromatography (SiO2, 20% ethyl acetate, hexanes) to yield 
vinyl alkyne 3.46 (1.76 g, 95%) as a red oil. Spectral data matched reported values.49  
 
3.9. To a solution of vinyl alkyne 3.46 (1.90 g, 4.34 mmol) in ethyl 
acetate (50 mL) was added triethylamine (1.82 mL, 13.0 mmol) and 
palladium on carbon (5%, 900 mg, 0.434 mmol). Approximately 2 L of 
hydrogen gas was bubbled through the solution to purge with reaction and the flask. The 
mixture was then stirred vigorously under an atmosphere of hydrogen for 36 h. The 
mixture was filtered through Celite with excess ethyl acetate (75 mL) and then 
concentrated to yield a spectroscopically pure alkyl alcohol 3.9 (1.88 g, 97%) as a yellow 
oil. Spectral data matched reported values.49  
 
3.8. A solution of hydrochloric acid (0.4 mL, 0.1 M solution in 20:1 
dichloromethane, methanol) was added to a solution of alkyl alcohol 3.9 
(925 mg, 2.09 mmol) in dichloromethane (22 mL). The reaction was 
judged completed within 5 min by TLC analysis and then silica gel (2.0 g) was added and 
the mixture was concentrated. The residue was purified by flash chromatography (SiO2, 
6% ethyl acetate, hexanes) to afford 737 mg (82%) of hemiaminal 3.8 as a colorless oil. 
Spectral data matched reported values.49 
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Figure 3.4. 600 MHz 1H NMR spectrum of 3.45 in CDCl3. 
 
Figure 3.5. 150 MHz 13C NMR spectrum of 3.45 in CDCl3. 
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Figure 3.6. 600 MHz 1H NMR spectrum of 3.12 in CDCl3. 
 
Figure 3.7. 150 MHz 13C NMR spectrum of 3.12 in CDCl3. 
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Figure 3.8. 600 MHz 1H NMR spectrum of 3.13 in CDCl3. 
 
Figure 3.9. 150 MHz 13C NMR spectrum of 3.13 in CDCl3. 
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Figure 3.10. 600 MHz 1H NMR spectrum of 3.15 in CDCl3. 
 
Figure 3.11. 150 MHz 13C NMR spectrum of 3.15 in CDCl3. 
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Figure 3.12. 600 MHz 1H NMR spectrum of 3.16 in CDCl3. 
 
Figure 3.13. 150 MHz 13C NMR spectrum of 3.16 in CDCl3. 
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Figure 3.14. 600 MHz 1H NMR spectrum of 3.46 in CDCl3. 
 
Figure 3.15. 150 MHz 13C NMR spectrum of 3.46 in CDCl3. 
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CHAPTER 4  
 
RECENT PROGRESS TOWARD THE TOTAL SYNTHESIS OF UPENAMIDE 
 
An Improved Retrosynthetic Approach to A-Ring Installation 
Due to the significant difficulties encountered upon attempts to install the A ring 
and the triene, and the subsequent macrocyclization, our strategy for accessing 
upenamide 4.1 required revision (Figure 4.1). As triene installation was found to be 
difficult, at least in part due to its anticipated liability, we elected to install the 
macrocycle last and install the A ring first. As cyclodehydration proved to be an 
unworkable solution to installing the A ring, we elected to examine a completely different 
ring assembly. Imagining other disconnections to access the A ring, an acyl ketene 4.5 
and cyclic imine 4.4 would potentially favor the formation of the A ring oxazinone by 
employing a reactive acyl ketene intermediate.  
 
 
Figure 4.1. Revising the Synthetic Approach to Upenamide (4.1). 
 
In organic synthesis, ketenes have found a wide application due to the ease with 
which they are accessed and to their high reactivity even with relatively weak 
OH
R
N
O
H
H
H
N
X
O
O
O
formal [4+2]
N
O
OH
O
N
O
H
H
H
H
OH
N
O
H
H
H
N
O
O
M[X]
[M]X
N
O
OH
O
N
O
H
H
H
H
aldol/redox
4.1 4.1
4.2
4.3
4.4
4.5
X
 88 
nucleophiles. 67, 68 Crimmins’s group applied an interesting overall [4+2] cycloaddition in 
the synthesis of spongistatin AB spiroketal 4.12 utilizing an acyl ketene (4.10) and vinyl 
ether 4.9 (Scheme 4.1).69 They were able to accomplish an overall hetero-Diels-Alder 
cyclization of alkylated dioxinone 4.8 (an acyl ketene precursor) and butyl vinyl ether 4.9 
in good yields with the rigorous exclusion of water to yield pyrone 4.12 via intermediate 
4.11.  
 
 
Scheme 4.1. Crimmins’s Utilization of an Acyl Ketene [4+2] en Route to Spongistatin AB. 
 
Similarly, Rodriguez, Coquerel, and coworkers developed a methodology by 
which they could access oxazinones and oxazinediones from various cyclic 2-diazo-1,3-
diketones, amines, and aldehydes (Scheme 4.2).70 Their overall reaction progressed via 
condensation of amine 4.14 on to aldehyde 4.15 to give imine 4.18, and Wolf-
rearrangement of diazodiketone 4.13 to give acyl ketene 4.17. Subsequent nucleophilic 
addition of the imine nitrogen to the ketene, followed by cyclization onto the intermediate 
iminium 4.19, gave oxazinone 4.16. They found that this reaction is amenable to a range 
of substitutions on each of the starting materials. 
                                                
67 a) Kirmse, W. Eur. J. Org. Chem. 2002, 2193-2256. b) Reber, K. P.; Tilley, S. D.; Sorensen, E. J. Chem. 
Soc. Rev. 2009, 38, 3022-3034. 
68 Wentrup, C.; Heilmayer, W.; Kollenz, G. Synthesis 1994, 1219-1248.  
69 Crimmins, M. T.; Smith, A. C. Org. Lett. 2006, 8, 1003-1006. 
70 a) Presset, M.; Coquerel, Y.; Rodriguez, J. Org. Lett. 2009, 11, 5706-5709. b) Presset, M.; Coquerel, Y.; 
Rodriguez, J. Org. Lett. 2010, 12, 4212-4215. 
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Scheme 4.2. Rodriguez and Coquerel’s Methodology for Rapid Access to Novel  
Heterocyclic Scaffolds via an Acyl Ketene [4+2]. 
 
Incorporating this into a new A ring incorporation strategy, A ring synthesis 
would proceed through a formal [4+2] cyclization to yield dihydrooxazinone A ring 4.21 
(Scheme 4.3). The oxazinone A ring, 4.20, is revealed upon stereocontrolled hydride 
delivery and the synthesis of upenamide 4.1 is accomplished upon the closure of the 
macrocyclic core by a metal-mediated coupling reaction. 
 
 
              
Scheme 4.3. Revised Retrosynthetic Approach to Upenamide (4.1). 
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With synthetic access to aldehyde 4.24 previously optimized by Dr. Kurt Kiewel 
(discussed in detail in Chapter 3) we envision accessing acyl ketene 4.22 via Roskamp 
homologation and subsequent dehydration (Scheme 4.4).71 
 
 
Scheme 4.4. Retrosynthetic Approach to Acyl Ketene 4.22. 
 
Toward an Improved Route: Utilizing a Bromomaleic Anhydride Diels-Alder 
The first synthetic route developed Dr. Zhushou Lou encountered issues with the 
epimerization of the aldehyde upon Staudinger cyclization (Scheme 4.5). To this end, the 
route was revised to begin with the anhydride oxidation state starting with a Diels-Alder 
with inexpensive bromomaleic anhydride (4.30), with the intent of accessing a cyclic 
imine 4.28 from amide 4.27 via dehydration (Scheme 4.6).  
 
 
Scheme 4.5. Luo’s Synthesis of the Spirocyclic Amide 4.27. 
 
Scheme 4.6. Retrosynthetic Approach Incorporating Bromomaleic Anhydride (4.30). 
 
                                                
71 Holmquist, C. R.; Roskamp, E. J. J. Org. Chem. 1989, 54, 3258-3260. 
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The anhydride product 4.33 is prepared from Diels-Alder cycloaddition of known 
diene 4.32 and bromomaleic anhydride (4.30),72 which proceeded at room temperature 
with high stereoselectivity (Scheme 4.7). Subsequent Keck allylation73 gave alkene 4.34 
as a 3:1 mixture of cis to trans isomers. Opening of the anhydride with sodium methoxide 
and methyl iodide and subsequent reprotection of the allylic alcohol gave diester 4.36. 
Hydroboration-oxidation of the terminal alkene provided alcohol 4.37 that was readily 
converted to azide 4.38 with diphenyl phosphoryl azide. 
 
 
Scheme 4.7. Melancon’s Synthesis of Azido Diester 4.38. 
 
Moving forward with azido diester 4.38 (Scheme 4.8), vinyl iodide spirocycle 
4.42 was envisioned to be accessed via Takai olefination as in the earlier route developed 
by Dr. Luo. Unfortunately, Staudinger cyclization with trimethyl phosphine did not 
provide spirocycle 4.39. This observed difference in reactivity was attributed to the 
decreased electrophilicity of the ester moiety as compared to the previous anhydride. 
 
                                                
72 Apponyi, M. A.; Bowie, J. H.; Skelton, B. W.; White, A. H. Aust. J. Chem. 2002, 55, 343-348. 
73 Keck, G. E.; Yates, J. B. J. Am. Chem. Soc. 1982, 104, 5829-5831.  
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Scheme 4.8. Failed Attempt to Access Vinyl Iodide Spirocycle 4.42. 
 
New Strategies for Accessing the Cyclic Imine 
The decreased electrophilicity of the ester was problematic and the Staudinger 
cyclization on to the ester would ultimately lead to an amide intermediate that would 
require oxidation state manipulation to access the imine oxidation state for use in the 
proposed [4+2] cyclization. Thus, we instead envisioned a route to access the spirocycle 
by employing an aza-Wittig reaction to directly provide a cyclic imine upon Staudinger 
cyclization.  
In Carter and coworker’s syntheses of lycopodine (4.46), paniculine (4.47), and 
related analogs they were able access the common tricyclic core 4.45 via the formation of 
a cyclic imine through an “aza-Wittig” reaction starting with azido aldehyde 4.43 
(Scheme 4.9).74 Subsequent Mannich cyclization of the vinyl silyl ether onto the imine 
then gave tricyclic core 4.45.  
 
 
Scheme 4.9. Carter’s Utilization of an Acyl Ketene [4+2] en Route to 
Lycopodine (4.46), Paniculine (4.47), and Related Analogs. 
                                                
74 a) Yang, H.; Carter, R. G. J. Org. Chem. 2010, 75, 4929-4938. b) Saha, M.; Carter, R. G. Org. Lett. 
2013, 15, 736-739. 
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We envisioned cyclic imine 4.48 could be accessed via an aza-Wittig cyclization 
from azido aldehyde 4.49 (Scheme 4.10). Azido aldehyde 4.49 could be accessed via 
oxidation state manipulations from the previously established Diels-Alder anhydride 
4.34. However, this approach requires the development of a route that will allow the two 
anhydride carbonyl carbons to be differentiated. 
 
 
Scheme 4.10. Retrosynthetic Approach to Cyclic Imine 4.48. 
 
Reduction of the anhydride, protection of the less sterically hindered primary 
alcohol, and subsequent acetate protection of the remaining alcohol gave the fully 
protected 4.53 (Scheme 4.11). Hydroboration-oxidation of the terminal alkene provided 
alcohol 4.54 that was readily converted to azide 4.55 upon treatment with 
diphenylphosphoryl azide. Acetate removal and subsequent oxidation gave azido 
aldehyde 4.57. 
 
 
Scheme 4.11. Synthesis of Azido Aldehyde 4.57. 
 
TBSO
O
H
N3
O
O
O
TBSO
Br
H
X
N
RO
Staudinger-like
cyclization
X
TBSO
H
N3
O
X
Y
alkylation
oxidation 
manipulations
4.48
4.49 4.50 4.34
O
TBSO
H
O
O
LiAlH4, 
THF
TBSO
H
OH
OH
TrCl, Et3N, 
DMAP, DMF
Ac2O, pyr
TBSO
H
OAc
OTr
TBSO
H
OH
OTr
i. 9-BBN
ii. H2O2, NaOH
TBSO
H
OAc
OTr
OH
DPPA, DBU
tol
TBSO
H
OAc
OTr
N3
TBSO
H
N3
OTr
OHNaOH, H2O
     EtOH
TBSO
H
N3
OTr
OSO3  pyr,
DCM
DMSO, DCM
97% 86% 91%
95% 94% 72%
15-30%
4.34 4.51 4.52 4.53
4.54 4.55 4.56 4.57
 94 
While Staudinger cyclization of azido aldehyde 4.57 proceeded smoothly to give 
cyclic imine 4.58 (Scheme 4.12), the alcohol revealed upon the removal of the trityl 
group underwent an undesired cyclization to give hemiaminal 4.59. Attempts at oxidative 
opening of the hemiaminal to access aldehyde 4.61 were unsuccessful. 
 
 
Scheme 4.12. Formation of 6,5-Hemiaminal 4.59. 
 
To avoid undesired hemiaminal formation, we envisioned converting the trityl 
protected primary alcohol to the alkyne prior to Staudinger cyclization to install the 
cyclic imine (Scheme 4.13). As route would also require the installation of the 
macrocycle coupling partner prior to Staudinger cyclization, we envisioned accessing the 
more stable alkyne for late-stage elaboration to the vinyl iodide or vinyl stannane. The 
alkyne would also be favorable to a vinyl iodide as it would impart less steric interaction 
in the proposed [4+2] cycloaddition. 
 
 
Scheme 4.13. Revised Retrosynthetic Approach to Imine 4.62. 
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Variable and consistently poor yields of TBS diol 4.51 also led us to optimize, the 
anhydride reduction to make our route more viable for accomplishing a multistep total 
synthesis. It is known that TBS ethers adjacent to reducible groups are susceptible to 
concurrent deprotection, 75 and we found that reaction yields did indeed favor triol 4.68 
under a wide range of reaction conditions and varying methods of quenching the reaction 
(table 4.1). 
 
Table 4.1. Reducing Reagents Surveyed for the Reduction of Anhydride 4.34. 
 
 
Interestingly, treatment of anhydride 4.34 with lithium tri(t-butoxy)aluminum 
hydride provided lactone 4.65 (Table 4.1, entry 5). This lactone, 4.65, could potentially 
lead to a more facile differentiation of the anhydride carbonyl carbons without the use of 
a more complicated protection and deprotection scheme (Scheme 4.14). Spirocyclic 
                                                
75 a) Reynaud, C.; Giorgi, M.; Doucet, H.; Santelli, M. Synthesis 2001, 674-680. b) Wender, P. A.; Bi, F. 
C.; Brodney, M. A.; Gosselin, F. Org. Lett. 2001, 3, 2105-2108. c) de Vries, E. F. J.; Brussee, J.; van der 
Gen, A. J. Org. Chem. 1994, 59, 7133-7137. 
entry reducing	agent solvent temperature %	4.65 %	4.66 %	4.67 %	4.51 %	4.68
1 NaBH4 MeOH 0	°C 3 14 14 0 0
2 LiBH4 THF 0	°C 0 0 0 5 13
3 L-Selectride THF 0	°C 0 0 0 43 0
4 DiBAlH DCM 0	°C 7 0 0 15 0
5 Li(OtBu)3AlH THF 0	°C 42 16 16 0 0
6 LAH THF 0	°C 0 0 0 9 70
7 LAH Et2O 0	°C 0 0 0 17 13
8 AlH3 Et2O 0	°C 0 0 0 19 26
9 AlH3 THF 0	°C 0 0 0 17 65
10 LAH THF 21	°C 0 0 0 13 15
11 LAH THF reflux 0 0 0 20 39
12 AlH3 Et2O 21	°C 0 0 0 9 30
13 AlH3 Et2O reflux 0 0 0 10 22
a	all	reactions	were	run	on	a	1.00	mmol	scale	using	4	equivalents	of	the	reducing	agent	under	the	conditions	listed.
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imine 4.62 would be accessed via the same azido alcohol, 4.63, which could be accessed 
through elaboration of the terminal alkene to the azide and homologation of the lactol 
with Bestmann-Ohira reagent. 
 
 
Scheme 4.14. Retrosynthetic Approach via Lactone 4.65. 
 
To this end, lactone 4.65 was reduced to lactol 4.70 with diisobutylaluminum 
hydride (Scheme 4.15). Acetate protection provided lactol acetate 4.71. Unfortunately, 
hydroboration of the terminal alkene to give 4.72 was unproductive. 
 
 
Scheme 4.15. Synthesis of  Lactol Acetate 4.71. 
 
Optimizing the yield of either TBS diol 4.51 or triol 4.68 was not a complete 
success (Table 4.1, entries 6-13). However, we did find that TBS diol 4.51 could be 
converted to triol 4.68 upon treatment with hydrofluoric acid pyridine complex, thus 
increasing the overall production of triol 4.68 (Scheme 4.16).  
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Scheme 4.16. Conversion of TBS Diol 4.51 to Triol 4.68. 
 
Revising the Route to the ABC Tricycle 
Taking advantage of the opportunity provided by triol 4.68, a second-generation 
synthetic route was envisioned (Scheme 4.17). The differentiation of the two primary 
alcohols could be accomplished through formation and subsequent reductive cleavage of 
the 6-membered acetal 4.75. This would allow easy conversion to the alkyne and 
subsequently provide access to azido aldehyde 4.74 and finally, cyclic imine 4.73. 
 
 
Scheme 4.17. Retrosynthetic Approach Starting from Triol 4.68. 
 
Moving forward with triol 4.68, the p-methoxyphenyl (PMP) acetal was formed 
using p-toluenesulfonic acid and p-anisaldehyde. Introduction of this stereocenter gave 
two separable, acetal diastereomers in a 2:1 ratio of 4.75a to 4.75b (Scheme 4.18).  
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Scheme 4.18. p-Methoxyphenyl Acetal (4.75a and 4.75b) Formation. 
 
Proceeding with the major isomer, α-PMP acetal 4.75a, oxidation and 
homologation under Bestmann-Ohira conditions proceeded smoothly to give alkyne 4.77 
(Scheme 4.19).76 
 
 
Scheme 4.19. Installation of Alkyne 4.77. 
 
Several attempts were made to selectively cleave the PMP acetal to yield the 
desired C11 PMB ether 4.78  (Scheme 4.20), however these attempts were unsuccessful, 
either returning starting material or yielding only the undesired isomer 4.79.77  
 
 
Scheme 4.20. α-PMP Acetal Cleavage. 
                                                
76 Müller, S.; Liepold, B.; Roth, G. J.; Bestmann, H. J. Synthesis Lett. 1996, 521-522. 
77 a) Smith III, A. B.; Friestad, G. K.; Barbosa, J.; Bertounesque, E.; Hull, K. G.; Iwashima, M.; Qiu, Y.; 
Salvatore, B. A.; Spoors, P. G.; Duan, J. J.-W. J. Am. Chem. Soc. 1999, 121, 10468-10477. b) Munakata, 
R.; Katakai, H.; Ueki, T.; Kurosaka, J.; Takao, K.-I.; Tadano, K.-I. J. Am. Chem. Soc. 2004, 126, 11254-
11267. c) Mulzer, J.; Mantoulidis, A.; Öhler, E. J. Org. Chem. 2000, 65, 7456-7467. d) Fürstner, A.; 
Nagano, T. J. Am. Chem. Soc. 2007, 129, 1906-1907. e) Sato, I.; Akahori, Y.; Iida, K.-I.; Hirama, M. 
Tetrahedron Lett. 1996, 37, 5135-5138. 
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As the reductive cleavage was possible under select conditions, we turned our 
focus to the β-PMP acetal 4.75b (Scheme 4.22). Oxidation with IBX gave aldehyde 4.80, 
however, upon homologation under mildly basic Bestmann-Ohira conditions, 
epimerization of the aldehyde occurred to give a 2:1 mixture of β:α alkyne products.  
 
 
Scheme 4.21. Synthetic Route to Alkyne 4.81. 
 
Moving forward with desired alkyne 4.81a, treatment with diisobutylaluminum 
hydride (Scheme 4.23) proceeded smoothly to selectively give the desired PMB ether 
product (4.78). 
 
 
Scheme 4.22. Selective Cleavage of the β-PMP Acetal. 
 
This change in reactivity can be supported by analysis of the overall confirmation 
of alkyne intermediate 4.77. We suggest that the orientation of the aryl group in the axial 
position sterically prevented the coordination of the Lewis acid on the desired primary 
alcohol, leading to the cleavage of the PMB acetal in the undesired sense to give isomer 
4.79 (Scheme 4.21).  
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Scheme 4.23. Conformational Rationale for the Selective Cleavage of the α-PMP Acetal. 
 
Accordingly, reduction of the β-PMP acetal 4.75b should reduce steric congestion 
and allow for Lewis acid coordination at the secondary alcohol and lead to preferential 
reductive cleavage at the primary oxygen. With the aryl ring in the axial position, 
diisobutylaluminum hydride coordinates preferentially with the primary alcohol, favoring 
the production of the desired PMB protected C11 hydroxyl 4.78 (Scheme 4.24). 
 
 
Scheme 4.24. Conformational Rationale for the Selective Cleavage of the β-PMP Acetal. 
 
As the desired β-PMP acetal was only the minor product under thermodynamic 
conditions, we followed Noyori’s kinetic protocol78 to access our desired acetal in higher 
yields. Therefore, PMP acetal protection began with the per-silylation of triol 4.68 to give 
per-TMS ether 4.82 (Scheme 4.25). Treatment with p-anisaldehyde dimethyl acetal and 
catalytic TMS triflate at -78 °C gave β-PMP acetal 4.75b in a 5:1 ratio of β to α (4.75b to 
4.75a). 
 
                                                
78 Tsunoda, T.; Suzuki, M.; Noyori, R. Tetrahedron Lett. 1980, 21, 1357-1358. 
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Scheme 4.25. Kinetic Conditions for PMP Acetal Formation. 
 
With this success, our focus turned to other methods for homologation of 
aldehyde 4.80 so as to prevent the observed epimerization of the aldehyde. Neutral 
Corey-Fuchs conditions were unsuccessful, only yielding starting material. Only 
epimerization of aldehyde 4.80 was observed upon evaluating the Colvin rearrangement. 
Ultimately, we were able to optimize the homologation using the Bestmann-Ohira 
reagent and sodium methoxide at -78 °C 79 (Scheme 4.26), eliminating all observed 
epimerization of the aldehyde. Acetal cleavage with diisobutylaluminum hydride led to 
the desired C11 PMB ether 4.78 in an overall yield of 43% over 5 steps from triol 4.68. 
 
 
Scheme 4.26. Optimization of Alkyne Formation. 
 
With this material in hand, we envisioned accessing the spirocyclic imine via our 
previously established Staudinger cyclization. However, hydration of the terminal alkene 
proved difficult (Scheme 4.27). Upon treatment with a variety of hydroborating 
                                                
79 Habrant, D.; Rauhala, V.; Koskinen, A. M. P. Chem. Soc. Rev., 2010, 39, 2007-2017. 
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reagents80 and under several oxidation conditions81 with the acetal intact (4.75) or 
cleaved (4.78), only complicated decomposition of starting materials was observed. 
 
 
Scheme 4.27. Attempts at Hydroboration of the Terminal Alkene. 
 
To determine whether complex decomposition was due to the possibility of 
forming borate ethers with the free alcohol, we attempted hydroboration-oxidation with 
the alcohol protected as the silyl ether (4.85) or as the acetate (4.87) (Scheme 4.28). 
Unfortunately these conditions (see above) also led to a complicated mixture of 
decomposition products.  
 
 
Scheme 4.28. Attempts at Hydroboration of the Terminal Alkene  
Employing Various Protecting Groups. 
 
                                                
80 a) Brown, H. C.; Liotta, R.; Scouten, C. G. J. Am. Chem. Soc. 1976, 98, 5297-5301. b) Suzuki, A.; 
Dhillon, R. S. Synth. Org. Chem. 1986, 2, 23-88. c) Evans, D. A.; Fu, G. C.; Hoveyda, A. H. J. Am. Chem. 
Soc. 1988, 110, 6917-6918. d) Kalinin, A. V.; Scherer, S.; Snieckus, V. Angew. Chem. Int. Ed. 2003, 42, 
3399-3404. 
81 Kabalka, G. W.; Shoup, T. M.; Goudgaon, N. M. J. Org. Chem. 1989, 54, 5930-5933. 
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Other methods for selective hydration of the terminal alkene were then explored 
using our previous α-PMP acetal-containing alkyne 4.75a (Scheme 4.29). While 
epoxidation proved somewhat difficult, we were successful in forming 4.89 as a mixture 
of epoxide epimers upon treatment with m-chloroperoxybenzoate. With this intermediate 
in hand, we sought to explore methods for selective opening to yield primary alcohol 
4.90, unfortunately attempts with radical promoted conditions, and base or acid catalyzed 
conditions, produced no desired product.82 
 
 
Scheme 4.29. Attempts at the Selective Cleavage of the α-PMP Acetal Epoxide 4.75a. 
 
As the acetal diastereomer played a pivotal role in the selectivity of its cleavage, 
we attempted to epoxidize our desired β-PMP acetal-containing alkyne 4.75b to no avail 
(Scheme 4.30).  To ascertain whether the acetal was sterically blocking the epoxidation 
of the alkene, attempts were made to epoxidize the cleaved acetal 4.78 and aldehyde 4.92. 
Unfortunately, these attempts were also unsuccessful, only returning starting material 
after treatment with several epoxidizing reagents under a variety of conditions. 83 
 
                                                
82 a) Takekoshi, N.; Miyashita, K.; Shoji, N.; Okamoto, S. Adv. Synth. Catal. 2013, 355, 2151-2157. b) 
Kawaji, T.; Shohji, N.; Miyashita, K.; Okamoto, S. Chem. Commun. 2011, 47, 7857-7859. c) Jiménez, T.; 
Campaña, A. G.; Bazdi, B.; Paradas, M.; Arráez-Román, D.; Segura-Carretero, A.; Fernández-Gutiérrez, 
A.; Oltra, J. E.; Robles, R.; Justicia, J.; Cuerva, J. M. Eur. J. Org. Chem. 2010, 4288-4295. d) Cuerva, J. 
M.; Campaña, A. G.; Justicia, J.; Rosales, A.; Oller-López, J. L.; Robles, R.; Cárdenas, D. J.; Buñuel, E.; 
Oltra, J. E. Angew. Chem. Int. Ed. 2006, 45, 5522-5526. e) Eisch, J. J.; Liu, Z. R.; Singh, M. J. Org. Chem. 
1992, 57, 1618-1621. f) Hutchins, R. O.; Taffer, I. M.; Burgoyne, W. J. Org. Chem. 1981, 46, 5214-5215. 
83 a) Wang, B.; Wong, O. A.; Zhao, M.-X.; Shi, Y. J. Org. Chem., 2008, 73, 9539-9543. b) Ziegler, F. E.; 
Metcalf III, C. A.; Nangia, A.; Schulte, G. J. Am. Chem. Soc. 1993, 115, 2581-2589. 
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Scheme 4.30. Attempts At Epoxidation. 
 
Summary of Progress Toward the Synthesis of Upenamide 
In summary, we were delighted to find that we could apply the work of Carter and 
coworkers74 to successfully install the cyclic imine 4.58 from the azido aldehyde 4.57 
(Scheme 4.31), however, we were unable to elaborate this intermediate (4.58) to our 
desired coupling partner vinyl iodide 4.48.  
 
 
Scheme 4.31. Successful Installation of the Cyclic Imine. 
 
Attempts at either removing the trityl protecting group of cyclic imine 4.58 to 
give the free alcohol 4.60, or, accessing pyrone 4.94 via formal [4+2] cycloaddition using 
a model acylketene (4.95) were unsuccessful (scheme 4.32). This led us to reimagine our 
route to install a sterically less encumbering alkyne (4.62) prior to the installation of the 
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cyclic imine to improve the steric conditions that would possibly allow the [4+2] 
cycloaddition to occur at the imine to give pyrone 4.96 (Scheme 4.33).  
 
  
Scheme 4.32. Attempts at Elaboration of Trityl Ether 4.58. 
 
Scheme 4.33. Proposed Synthesis of Pyrone 4.96. 
 
Difficulties encountered in accessing TBS protected diol 4.51 also forced us to 
first optimize the reduction of the anhydride intermediate 4.34. This anhydride reduction 
was highly variable, but it ultimately led us to triol 4.68 as a more viable option for our 
route to the total synthesis. We could convert the lower yielding TBS diol 4.51 to the triol 
4.68 via deprotection with hydrogen fluoride pyridine complex to provided triol 4.68 in a 
35-75% yield in 2 steps overall from anhydride 4.34.  
 
 
Scheme 4.34. Optimized Reduction of Anhydride 4.34. 
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Revising our route beginning with triol 4.68 and utilizing a protecting scheme that 
would simultaneously protect the secondary alcohol and the upper primary alcohol as the 
acetal to leave the lower primary alcohol free for elaboration to the alkyne led us to 
successfully optimize the route to the desired PMB protected alkyne 4.78, accessing it in 
5 steps from triol 4.68 in an overall yield of 48% (Scheme 4.35).  
 
 
Scheme 4.35. Optimized Overall Yield of Secondary PMB 4.78. 
 
This optimization required first the improvement of the diastereomeric ratio of the 
PMP acetal formation, and then, screening alkyne homologation conditions to prevent 
undesired epimerization, as we discovered that only one of the PMP acetal diastereomers 
was amenable to selective cleavage to yield primarily the desired secondary PMB ether 
(Scheme 4.36). 
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Scheme 4.36. Summary of the Route to Secondary PMB Ether 4.78. 
 
However, while we had successfully accessed PMB-protected alkyne 4.78, all 
attempts at elaboration to the necessary primary alcohol from the terminal alkene via 
either hydroboration-oxidation, or, epoxidation and selective epoxide cleavage were 
unsuccessful.  
Moving forward with our synthesis, our method for accessing the desire cyclic 
imine 4.62 must be revised, as installation of the azide via hydration of the alkene is not 
easily accomplished via PMB substrate 4.78. Imagining other disconnections we propose 
to access cyclic imine via cyclization of an acyclic imine onto the terminal alkene of 4.97 
(Scheme 4.37). This new disconnection will be discussed in detail in Chapter 5. 
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Scheme 4.37. Revision of the Retrosynthetic Approach to Imine Spirocycle 4.62. 
 
Experimental Methods 
General procedure. All reactions were performed in flame-dried or oven dried round-
bottomed flasks under an atmosphere of argon unless otherwise noted. Stainless steel 
syringes or cannula were used to transfer air- and moisture-sensitive liquids. Reaction 
temperatures were controlled using a thermocouple thermometer and analog hotplate 
stirrer. Reactions were conducted at room temperature (approximately 22 °C) unless 
otherwise noted. Flash column chromatography was conducted as described Still et. al. 
using silica gel 230-400 mesh.64 Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV light (254 nm) 
and ceric ammonium molybdate, potassium permanganate, or anisaldehyde stains. Yields 
were reported as spectroscopically pure compounds.  
Materials. Reagents and solvents used were of commercial grade and purified prior to 
use when necessary. Tetrahydrofuran, toluene, and dichloromethane were obtained from 
either an MBraun MB-SPS solvent system, where they were dried using activated 
alumina columns, or freshly distilled (tetrahydrofuran and ether were both distilled from 
sodium metal with benzophenone indicator), and when necessary solvents were further 
dried over activated 4 Å molecular sieves under an atmosphere of argon. Triethylamine 
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was distilled from calcium hydride and stored over sodium hydroxide. The molarity of 
commercial n-butyllithium solutions was determined by titration using 2,2,2′-
Trimethylpropionanilide65 as an indicator (average of three determinations). 
Instrumentation. Nuclear magnetic resonance (NMR) spectra were acquired on Bruker 
DRX-400 (400 MHz), DRX-500 (500 MHz), or (600 MHz) spectrometers and are 
reported relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16; MeOD: 3.31). 
Data for 1H NMR spectra are reported as follows: chemical shift d (ppm), multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septet, m = multiplet, br = 
broad singlet, app = apparent). Infrared (IR) spectra were obtained as thin films on NaCl 
plates using a Thermo Electron IR100 series spectrophotometer and are reported in 
wavenumbers (cm-1). High-resolution mass spectra were obtained from the Department 
of Chemistry and Biochemistry, University of Notre Dame using a microTOF QII mass 
spectrometer. Optical rotations were measured on a Perkin-Elmer 341 digital polarimeter 
at ambient temperature (zeroed with pure, solvent-grade chloroform). X-ray crystal 
structures were obtained from the X-ray Diffraction Laboratory in the Department of 
Chemistry at Texas A & M University using a Bruker single-crystal APEXii CCD 
Diffractometer. 
 
4.32. A solution of crotonaldehyde (4.31) (32.5 mL, 416 mmol) and 
triethylamine (79.4 mL, 570 mmol) in dichloromethane (174 mL) was cooled to 
0 °C. TBS triflate (86.9 mL, 378 mmol) was added dropwise to the solution at 0 °C and 
then the reaction warmed to reflux for 16 h. The reaction was cooled to RT and washed 
with saturated aqueous sodium bicarbonate (75 mL) and saturated aqueous copper sulfate 
OTBS
O TBSOTf, Et3N
DCM
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(75 mL). The organic layer was dried (MgSO4) and concentrated product was purified by 
distillation under vacuum with a vigreux column (12 mmHg, 62-64 °C) to yield TBS 
dienyl ether 4.32 (54.4 g, 78%) as a colorless oil. Spectral data matched reported 
values.84  
 
4.33. Bromomaleic anhydride (27.4 mL, 295 mmol) was added to cooled 
solution of TBS dienyl ether 4.32 (54.4 g, 295 mmol) in DCM (295 mL) at 
0 °C. After 4 h the reaction mixture was concentrated and the crude product 
was recrystallized from hexanes to yield anhydride 4.33 (81.2 g, 76%) as a white solid. 
M.P. 84-91°C; IR (neat) νmax = 2931, 2859, 1878, 1794, 1467; 1H NMR (600 MHz, 
CDCl3) δ 6.12-6.04 (m, 2H), 4.60 (d, 1H, J = 5.46), 3.56 (dd, 1H, J = 10.4, 3.60), 2.84 
(ddd, 1H, J = 18.6, 6.15, 3.09), 2.63 (ddd, 1H, J = 18.9, 10.5, 5.24); 13C NMR (150 MHz, 
CDCl3) δ 170.1, 169.1, 129.2, 126.4, 68.8, 56.2, 45.8, 25.4, 20.3, 17.9, -4.2, -5.4; HRMS 
(ESI) calc’d. for C14H21BrO4Si [M+H]+: 361.0392, measured 361.0485. 
 
4.34. Allyltributylstannane (171 mL, 0.554 mmol) was added to anhydride 
4.33 (100 mg, 0.277 mmol) and AIBN (0.4 mg, 0.003 mmol) in toluene (700 
µL) in a closed microwave vial and the reaction mixture was heated via 
microwave irradiation at 90 °C for 45 min. The resulting mixture was diluted with ethyl 
acetate (300 µL) and washed with saturated aqueous KF (1 mL) until there was no further 
precipitation of the tin salt. The organic phase was filtered through Celite, dried 
(MgSO4), and concentrated to yield allyl anhydride 4.34 (90 mg, 100%) as a colorless oil 
                                                
84 Trost, B. M.; Chupak, L. S.; Lubbers, T. J. Org. Chem. 1997, 62, 736. 
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that was carried forward with no further purification. Attempts at purification resulted in 
the epimerization of stereochemistry. Purified for characterization purposes only by flash 
chromatography (SiO2, 1% ethyl acetate, hexanes). IR (neat) νmax = 3325, 2899, 2360, 
1440, 1034; 1H NMR (400 MHz, CDCl3) δ 6.05-5.93 (m, 2H), 5.79-5.66 (m, 1H), 5.21 
(d, 1H, J = 10.1), 5.12 (d, 1H, J = 17.0), 4.21 (d, 1H, J = 5.5), 3.09 (dd, 1H, J = 10.5, 3.3), 
2.80 (ddd, 1H, J = 18.9, 2.8, 2.8), 2.68 (dd, 1H, J = 14.0, 5.9), 2.39 (ddd, 1H, J = 18.7, 
5.2, 5.2), 2.06 (dd, 1H, 14.0, 9.0), 0.82 (s, 9H), 0.03 (s, 3H), -0.01 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 174.2, 173.3, 131.7, 129.6, 127.3, 121.2, 68.1, 55.5, 37.8, 36.7, 25.5, 
20.5, 17.9, -4.0, -5.4; HRMS (ESI) calc’d for C17H26O4Si [M+H]+: 323.1600, measured 
323.1651. 
 
epi-4.34. 1H NMR (400 MHz, CDCl3) δ 6.02-5.93 (m, 2H), 5.74-5.62 (m, 
1H), 5.18 (d, 1H, J = 12.0), 5.18 (d, 1H, J = 14.2), 4.35 (d, 1H, J = 3.9), 3.09 
(dd, 1H, J = 8.1, 2.5), 2.67 (dd, 1H, J = 13.8, 6.3), 2.59-2.51 (m, 2H), 2.46 
(dd, 1H, J = 13.8, 8.9), 0.85 (s, 9H), 0.06 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 173.8, 173.5, 131.9, 131.5, 129.5, 121.3, 67.4, 55.5, 41.9, 37.1, 25.7, 18.0, -4.4, 
-5.2. 
 
4.35. Methyl iodide (345 mL, 5.54 mmol) and sodium methoxide (150 µL, 
0.416 mmol, 30% in methanol) was added to anhydride 4.34 (90 mg, 0.277) 
in methanol (650 mL) and the reaction was then heated via microwave 
irradiation at 105 °C for 30 min. The reaction was dissolved in methanol (1 mL) and 
concentrated three times, then taken up in water (1 mL) and extracted with diethyl ether 
CO2Me
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(3 x 2 ml). The combined organic layers were dried (MgSO4), concentrated, and the 
residue was purified by flash chromatography (SiO2, 20% ethyl acetate, hexanes) to yield 
diester 4.35 (50.4 mg, 72% over two steps) as a light yellow oil. IR (neat) νmax = 3410, 
2953, 1731, 1439. 1H NMR (600 MHz, CDCl3) δ 5.95-5.92 (m, 1H), 5.75-5.72 (m, 1H), 
5.63-5.56 (m, 1H), 5.13 (s, OH), 5.11 (d, 1H, J = 5.58), 5.02 (d, 1H, J = 10.8), 3.98 (dd, 
1H, J = 10.8, 4.56), 3.78 (s, 3H), 3.72 (s, 3H), 3.06 (dd, 1H, J = 6.87, 2.07), 2.61 (ddd, 
1H, J = 14.2, 5.76, 1.41), 2.35-2.32 (m, 2H), 2.21 (dd, 1H, J = 14.2, 9.09). 13C NMR (150 
MHz, CDCl3) δ 177.4, 132.8, 128.3, 124.6, 119.4, 68.4, 52.8, 52.6, 52.4, 39.2, 25.1). 
HRMS (ESI) calc’d for C13H18O5 [M+H]+: 255.1154, found 255.1257. 
 
4.36. To a solution of diester 4.35 (224 mg, 0.881 mmol) in DCM (9 mL) 
at 0 °C was added 2,6-lutidine (308 µL, 2.64 mmol) then TBS triflate (344 
µL, 1.50 mmol) dropwise. Solution warmed to room temperature and let 
stir 4 h. The reaction was then quenched with saturated aqueous sodium bicarbonate (10 
mL) and extracted with DCM (3 x 15 mL). The combined organic layers were dried 
(MgSO4) and concentrated. The residue was purified by flash chromatography (SiO2, 
10% ethyl acetate, hexanes) to yield TBS ether 4.36 (290 mg, 89%) as a light yellow oil. 
IR (neat) νmax = 3548, 3077, 3034, 2952, 2857, 1740, 1665, 1639, 1465. 1H NMR (400 
MHz, CDCl3) δ 5.80-5.75 (m, 1H), 5.76-5.71 (m, 1H), 5.53 (dd, 1H, J = 10.2, 1.90), 5.11-
5.05 (m, 2H), 4.27 (s, 1H), 3.67 (s, 3H), 2.83 (dd, J = 9.94, 5.98), 2.75-2.67 (m, 1H), 
2.66-2.56 (m, 1H), 2.29-2.22 (m, 1H), 0.85 (s, 9H), 0.070 (s, 3H), 0.065 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 173.4, 172.4, 133.6, 128.7, 126.8, 119.5, 69.7, 51.9, 51.4, 
CO2Me
CO2Me
TBSO
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50.5, 43.5, 37.5, 27.4, 25.8, 18.1, -3.5, -3.8, -4.7. HRMS (ESI) calc’d for C19H32O5Si 
[M+H]+: 369.2019, found 369.2099. 
 
 4.37. To a solution of TBS ether 4.36 (312 mg, 0.847 mmol) in THF (8.5 
mL) was added 9-BBN (0.5 M in THF, 8.5 mL, 4.23 mmol) and the 
reaction was let stir 2 h. Then, to the reaction was added ethanol (4.18 mL) 
and 10% aqueous sodium hydroxide (1.70 mL), and then the reaction was cooled to 0 °C 
and 30% aqueous hydrogen peroxide (1.44 mL) was added dropwise. Reaction let stir 1 h 
at room temp and then diluted with water (10 mL) and extracted with diethyl ether (3 x 
20 mL). The combined organic layers were dried (MgSO4), concentrated, and the residue 
was purified by flash chromatography (SiO2, 40% ethyl acetate, hexanes) to yield alcohol 
4.37 (117 mg, 54%) as a light yellow oil. IR (neat) νmax = 3454, 2951, 2857, 1738, 1436. 
1H NMR (400 MHz, CDCl3) δ 5.81-5.78 (m, 1H), 5.58-5.56 (m, 1H), 4.27 (s, 1H), 3.67 
(s, 3H), 3.64 (s, 3H), 3.63 (t, 2H, J = 6.52), 2.90 (dd, 1H, J = 8.50, 6.12), 2.74 (ddd, 1H, J 
= 8.65, 17.8, 2.16), 2.25 (ddd, 1H, J = 17.8, 5.09, 5.09), 1.94-1.77 (m, 2H), 1.47 (quint, 
2H), 0.85 (s, 9H), 0.084 (s, 3H), 0.059 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.4, 
172.8, 128.6, 126.9, 69.1, 63.3, 52.0, 51.5, 50.7, 43.1, 29.4, 27.4, 26.9, 25.8, 18.1, -4.0, -
4.7. HRMS (ESI) calc’d for C19H34O6Si [M+H]+: 387.2125, found 387.2207. 
 
 4.38. To a solution of alcohol 4.37 (28 mg, 0.0725 mmol) in toluene (800 
µL) at 0 °C was added DBU (32 µL, 0.145 mmol) and then 
diphenylphosphoryl azide (22 µL, 0.145 mmol) dropwise. The reaction 
was then heated to 100 °C for 5 h. The reaction was concentrated and the residue was 
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purified directly by flash chromatography (SiO2, 10% ethyl acetate, hexanes) to yield 
azide 4.38 (30 mg, 98%) as a colorless oil. IR (neat) νmax = 3417, 3034, 2927, 2855, 
2255, 2097, 1737, 1666, 1554, 1461. 1H NMR (400 MHz, CDCl3) δ 5.85-5.79 (m, 1H), 
5.62-5.55 (m, 1H), 4.27 (s, 1H), 3.70 (s, 3H), 3.67 (s, 3H), 3.29 (t, 2H, J = 6.76), 2.89 
(dd, 1H, J = 8.74, 6.02), 2.81-2.73 (m, 1H), 2.31-2.22 (m, 1H), 2.04-1.78 (m, 2H), 1.78-
1.57 (m, 1H), 1.57-1.44 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 173.2, 172.4, 128.48, 
126.9, 69.4, 69.3, 52.1, 51.9, 51.5, 50.7, 43.33, 30.7, 26.9, 26.9, 25.8, 23.9, 18.1, -3.96, -
4.68, -4.77. HRMS (ESI) calc’d for C13H18O5 [M+H]+: 412.2262, found 412.2264.  
 
4.51 and 4.68. A solution of allyl anhydride 4.34 (7.0 g, 
22.14 mmol) in THF (222 mL) was cooled to 0 °C and a 
solution of LAH in THF (89 mL, 88.56 mmol, 1 M solution 
in THF) was added dropwise. The reaction was stirred for 30 min at RT. The reaction 
was then cooled to 0 °C and water (3.4 mL), 15% aqueous NaOH (3.4 mL), and water 
(10.2 mL) were added dropwise. Celite (34.0 g) was then added and the slurry was stirred 
vigorously over 2 h at RT. The slurry was then heated to reflux and the solids were 
filtered. The pellet was then washed with a hot solution of chloroform and methanol 
(95:5, 1 L). The filtrate was concentrated and the residue was purified by flash 
chromatography (SiO2, gradient: 40% ethyl acetate, hexanes to 10% methanol, ethyl 
acetate) to yield diol 4.51 (730 mg, 11%) as a light yellow oil, and triol 4.68 (1.63 g, 
37%) as a clear, sticky oil.   
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Diol 4.51. TLC Rf 0.48 (40% ethyl acetate, hexanes); IR (neat) νmax = 
3270, 2929; 1H NMR (600 MHz, CDCl3) δ 6.91-5.84 (m, 1H), 5.81-5.78 
(m, 1H), 5.57-5.54 (m, 1H), 5.17 (dd, 1H, J = 16.9, 1.0), 5.14 (dd, 1H, J = 
10.1, 1.0), 4.18 (bs, 1H), 3.87 (d, 1H, J = 11.3), 3.77 (dd, 1H, J = 11.5, 4.4), 3.66 (dd, 1H, 
J = 11.4, 2.2), 3.64 (d, 1H, J = 11.2), 2.44-2.36 (m, 2H), 2.20-2.17 (m, 2H), 1.83-1.80 (m, 
1H), 0.91 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 134.3, 128.5, 
128.3, 118.6, 77.1, 71.5, 63.0, 62.8, 43.5, 38.6, 35.7, 26.3, 26.1, 26.0, 18.2, -3.8, -4.7; 
HRMS (ESI) calc’d for C17H32O3Si [M+Na]+: 335.2121, measured 335.2015. 
 
Triol 4.68. TLC Rf 0.05 (40% ethyl acetate, hexanes); IR (neat) νmax = 
3324, 2898; 1H NMR (400 MHz, CDCl3) δ 5.89 (dddd, 1H, J = 17.2, 7.5, 
2.5, 2.2), 5.79 (m, 1H), 5.61 (m, 1H), 5.16 (d, 1H, J = 17.2), 5.12 (d, 1H, J = 
10.2), 4.07 (s, 1H), 3.85 (d, 1H, J = 11.4), 8.82-3.79 (m, 1H), 3.62 (d, 1H, J = 11.5), 3.62-
3.57 (m, 1H), 2.35-2.33 (m, 2H), 2.18-2.17 (m, 2H), 1.75-1.71 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ 134.7, 128.4, 128.3, 118.5, 70.3, 63.0, 62.0, 43.7, 38.3, 36.5, 26.6; 
HRMS (ESI) calc’d for C11H18O3 [M+H]+: 199.1256, measured 199.1329.  
 
4.96. A solution of epi-allyl anhydride epi-4.34 (110 mg, 0.341 mmol) in 
THF (3.4 mL) was cooled to 0 °C and a solution of LAH in THF (1.4 mL, 
1.364 mmol, 1 M solution in THF) was added dropwise. The reaction was 
stirred for 30 min at RT. The reaction was then cooled to 0 °C and water (50 µL), 15% 
aqueous NaOH (50 µL), and water (150 µL) were added dropwise. Celite (500 mg) was 
then added and the slurry was stirred vigorously over 2 h at RT. The slurry was then 
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heated to reflux and the solids were filtered. The pellet was then washed with a hot 
solution of chloroform and methanol (95:5, 1 L). The filtrate was concentrated and the 
residue was then purified by flash chromatography (SiO2, gradient: 40% ethyl acetate, 
hexanes) to yield diol 4.96 (730 mg, 11%) as a light yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 5.98-5.91 (m, 1H), 5.78 (dt, 1H, J = 9.9, 3.5), 5.62 (dt, 1H, J = 9.9, 2.1), 5.18 
(d, 1H, J = 17.0), 5.11 (d, 1H, J = 10.1), 3.93 (d, 1H, J = 4.1), 3.80 (dd, 1H, J = 11.6, 3.1), 
3.62 (dd, 1H, J = 11.6, 4.6), 3.54 (d, 1H, J = 11.5), 3.40 (d, 1H, J = 11.5), 2.42 (dd, 1H, J 
= 13.6, 9.0), 2.31 (dd, 1H, J = 13.9, 5.8), 2.28 (dd, 1H, J = 19.5, 9.0), 2.15-2.04 (m, 2H); 
13C NMR (500 MHz, CDCl3) δ 135.4, 129.6, 128.2, 117.9, 68.4, 63.3, 62.5, 44.9, 38.6, 
34.6, 26.5, 26.1, 26.0, 18.3, -3.1, -4.5. 
 
4.52. To a solution of TBS diol 4.51 (350 m g, 1.110 mmol) in DMF (1.1 
mL) was added triethylamine (465 µL, 3.330 mmol), then was added trityl 
chloride (620 mg, 2.220 mmol). The reaction was stirred for 6 h at RT. 
The reaction was then diluted with brine (3 mL) and extracted with ether (3 x 4 mL). The 
organics were dried (MgSO4) and concentrated, and the residue was purified by flash 
chromatography (SiO2, 10% ethyl acetate, hexanes) to yield trityl ether 4.52 (620 mg, 
97%) as a light yellow oil. IR (neat) νmax = 3437, 3029, 2927; 1H NMR (400 MHz, 
CDCl3) δ 7.42 (d, 6H, J = 7.3), 7.27 (t, 6H, J = 7.5), 7.19 (t, 3H, J = 7.2), 5.78-5.72 (m, 
1H), 5.69-5.53 (m, 2H), 4.92 (d, 1H, J = 10.3), 4.72 (d, 1H, J = 17.0), 4.29 (s, 1H), 3.89 
(dd, 1H, J = 11.3, 3.4), 3.39-3.32 (m, 2H), 3.09-3.00 (m, 2H), 2.51 (dd, 1H, J = 15.0, 6.7), 
2.43-2.33 (m, 1H), 2.18-2.07 (m, 1H), 1.95-1.86 (m, 2H), 0.86 (s, 9H), 0.09 (s, 3H), 0.06 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.2, 133.6, 128.8, 127.9, 127.5, 127.1, 118.4, 
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86.8, 73.4, 63.6, 62.6, 42.5, 37.7, 34.6, 27.1, 25.9, 18.0, -3.9, -4.9; HRMS (ESI) calc’d 
for C36H46O3Si [M+Na]+: 577.3114, measured 577.3108. 
 
4.53. To a solution of trityl ether 4.52 (250 mg, 0.451 mmol) in DCM 
(450 µL) was added pyridine (345 µL, 4.510 mmol) and acetic anhydride 
(430 µL, 4.510 mmol). The reaction was stirred for 12 h at RT. The 
reaction was then diluted with sat aqueous sodium bicarbonate (2 mL) and extracted with 
DCM (3 x 3 mL). The organics were washed with sat aqueous copper sulfate (5 mL) and 
then dried (MgSO4) and concentrated. The residue was purified by flash chromatography 
(SiO2, 5% ethyl acetate, hexanes) to yield acetate 4.53 (230 mg, 86%) as a light yellow 
oil. IR (neat) νmax = 3060, 2929, 2360, 1743; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, 6H, J 
= 7.6), 7.28 (t, 6H, J = 6.7), 7.21 (t, 3H, J = 7.1), 5.76-5.64 (m, 2H), 5.55-5.49 (m, 1H), 
5.03 (d, 1H, J = 10.3), 4.92 (d, 1H, J = 16.9), 4.01 (s, 1H), 3.98 (d, 1H, J = 11.7), 3.92 (d, 
1H, J = 11.4), 3.31 (d, 1H, J = 8.4), 3.21 (t, 1H, J = 9.8), 2.44 (d, 1H, J = 18.6), 2.19-2.04 
(m, 3H), 2.01-1.93 (m, 1H), 1.81 (s, 3H), 0.77 (s, 9H), 0.01 (s, 3H), -0.01 (s, 3H) ; 13C 
NMR (100 MHz, CDCl3) δ 170.9, 144.7, 133.6, 128.9, 128.7, 127.8, 127.3, 127.0, 118.6, 
86.5, 69.7, 65.1, 63.0, 42.4, 37.4, 35.3, 26.5, 25.9, 21.1, 18.1, -3.7, -4.9; HRMS (ESI) 
calc’d for C38H48O4Si [M+Na]+: 619.3218, measured 619.3228. 
 
4.54. To a solution of acetate 4.53 (230 mg, 0.385 mmol) in THF (4 mL) 
was added a solution of 9-BBN (3.85 mL, 1.925 mmol, 0.5 M solution in 
THF) and the reaction was stirred for 2 h at RT. The reaction was then 
cooled to 0 °C and then was added ethanol (2 mL), 3 M aqueous sodium hydroxide (2 
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mL), and 30% aqueous hydrogen peroxide (2 mL) and the reaction was let stir 1 h at 0 
°C. The reaction was then diluted with brine (6 mL) and extracted with ether (3 x 15 mL). 
The organics dried (MgSO4) and concentrated and the residue was purified by flash 
chromatography (SiO2, 20% ethyl acetate, hexanes) to yield alcohol 4.54 (215 mg, 91%) 
as a light yellow oil. IR (neat) νmax = 3420, 2928, 2360, 1740; 1H NMR (600 MHz, 
CDCl3) δ 7.41 (d, 6H, J = 7.3), 7.28 (t, 6H, J = 7.4), 7.21 (t, 3H, J = 7.4), 5.71-5.66 (m, 
1H), 5.54 (dd, 1H, J = 10.2, 2.7), 3.99 (s, 1H), 3.96 (d, 1H, J = 11.3), 3.79 (d, 1H, J = 
11.3), 3.43-3.34 (m, 2H), 3.23-3.18 (m, 1H), 3.15 (dd, 1H, J = 9.2, 3.8), 2.32-2.23 (m, 
2H), 2.11-2.07 (m, 1H), 1.99 (s, 3H), 1.51-1.41 (m, 2H), 1.21-1.14 (m, 2H), 0.76 (s, 9H), 
-0.01 (s, 3H), -0.06 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.0, 144.5, 129.1, 128.8, 
128.1, 127.9, 127.0, 86.6, 65.4, 64.0, 62.5, 41.2, 37.0, 25.9, 21.1, 18.0, -4.0, -5.2; HRMS 
(ESI) calc’d for C38H50O5Si [M+Na]+: 637.3428, measured 637.3333. 
 
 4.55. A solution of alcohol 4.54 (185 mg, 0.299 mmol) in toluene (3 mL) 
was cooled to 0 °C and to the solution was added DBU (130 µL, 0.598 
mmol) and diphenylphosphoryl azide (46 µL, 0.598 mmol) and the 
reaction was refluxed for 12 h. The reaction was then cooled to RT and concentrated and 
the residue was purified by flash chromatography (SiO2, 5% ethyl acetate, hexanes) to 
yield azide 4.55 (180 mg, 95%) as a light yellow oil. IR (neat) νmax = 3031, 2961, 2095, 
1741; 1H NMR (600 MHz, CDCl3) δ 7.41 (d, 6H, J = 7.2), 7.28 (t, 6H, J = 7.1), 7.22 (t, 
3H, J = 7.3), 5.71-5.67 (m, 1H), 5.54 (dd, 1H, J = 10.2, 2.6), 4.01 (s, 1H), 3.95 (d, 1H, J = 
11.3), 3.77 (d, 1H, J = 11.3), 3.22-3.13 (m, 2H), 3.00 (t, 2H, J = 6.8), 2.33-2.19 (m, 2H), 
2.12-2.07 (m, 1H), 1.99 (s, 3H), 1.47-1.36 (m, 2H), 1.30-1.21 (m, 2H), 0.77 (s, 9H), -0.01 
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(s, 3H), -0.05 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.0, 144.5, 128.9, 128.8, 127.9, 
127.0, 126.8, 86.6, 65.4, 64.0, 62.5, 43.1, 41.9, 41.2, 37.0, 25.9, 21.1, 18.0, -4.0, -5.2; 
HRMS (ESI) calc’d for C38H49N3O4Si [M+Na]+: 662.3492, measured 662.3400. 
 
4.56. A solution of azide 4.55 (130 mg, 0.203 mmol) in ethanol (2 mL) 
and 15% aqueous sodium hydroxide was stirred for 16 h. The reaction 
was then diluted with brine (5 mL) and extracted with DCM (3 x 5 mL). 
The organics were washed with brine (10 mL) and concentrated. The residue was purified 
by flash chromatography (SiO2, 10% ethyl acetate, hexanes) to yield azido alcohol 4.56 
(115 mg, 94%) as a light yellow oil. IR (neat) νmax =3471, 3030, 2927, 2094; 1H NMR 
(400 MHz, CDCl3) δ 7.40 (d, 6H, J = 7.7), 7.28 (t, 6H, J = 7.4), 7.21 (t, 3H, J = 7.1), 5.75 
(d, 1H, J = 9.6), 5.53 (d, 1H, J = 10.2), 4.22 (s, 1H), 3.90 (d, 1H, J = 10.8), 3.29 (t, 1H, J 
= 10.0), 3.17 (d, 1H, J = 7.0), 3.03-2.88 (m, 4H), 2.41 (d, 1H, J = 18.5), 2.15-2.08 (m, 
1H), 1.89-1.79 (m, 1H), 1.79-1.67 (m, 1H), 1.05 (t, 1H, J = 12.2), 0.84 (s, 9H), 0.08 (s, 
3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 144.1, 129.8, 128.8, 128.0, 127.5, 
127.2, 86.9, 73.4, 63.8, 62.8, 52.1, 41.8, 37.8, 27.4, 27.2, 25.9, 22.4, 18.0, -4.0, -4.9; 
HRMS (ESI) calc’d for C36H47N3O3Si [M+H]+: 598.3387, measured 598.3459. 
 
4.57. A solution of azido alcohol 4.56 (30 mg, 0.0502 mmol) in DCM 
(200 µL) and DMSO (50 µL) was cooled to -15 °C and to the solution 
was added DIEA (26 µL, 0.151 mmol). The solution was stirred 15 min 
and sulfur trioxide pyridine complex (24 mg, 0.151 mmol) in DMSO (100 µL) was added 
and the reaction was stirred at -15 °C for 1 h. The reaction was then warmed to RT and 
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diluted with DCM (3 mL) and washed with sat aqueous bicarbonate (2 mL), sat aqueous 
copper sulfate (2 mL), and brine (2 mL). The organics were dried and concentrated and 
the residue was purified by flash chromatography (SiO2, 5% ethyl acetate, hexanes) to 
yield azido aldehyde 4.57 (22 mg,72%) as a light yellow oil. IR (neat) νmax = 2940, 2097, 
1723, 1452; 1H NMR (600 MHz, CDCl3) δ 9.72 (s, 1H), 7.41 (d, 6H, J = 7.4), 7.29 (t, 6H, 
J = 7.6), 7.22 (t, 3H, J = 7.3), 5.82-5.79 (m, 1H), 5.70-5.66 (m, 1H), 4.24 (s, 1H), 3.22 
(dd, 1H, J = 9.5, 3.2), 3.11 (t, 1H, J = 8.9), 3.02 (t, 2H, J = 6.8), 2.46-2.40 (m, 1H), 2.33-
2.26 (m, 1H), 2.15-2.09 (m, 1H), 1.75-1.59 (m, 1H), 1.37-1.25 (m, 2H), 1.17-1.03 (m, 
1H), 0.78 (s, 9H), 0.04 (s, 3H), 0.01 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 205.0, 144.3, 
129.4, 128.9, 128.1, 128.0, 127.2, 87.0, 70.0, 62.8, 53.6, 51.9, 36.7, 27.4, 25.8, 25.1, 22.6, 
18.1, -3.7, -5.0; HRMS (ESI) calc’d for C36H45N3O3Si [M+Na]+: 618.3230, measured 
618.3129. 
 
4.58. To a solution of aldehyde 4.57 (80 mg, 0.136 mmol) in DCM (1.4 
mL) was added trimethyl phosphine (28 µL, 0.272 mmol) and the reaction 
was let stir for 30 min. To the reaction was then added water (1 mL) and 
then let stir 1 h. The solution was then diluted with DCM (2 mL) and washed with brine 
(2 x 1 mL). The organics were dried (MgSO4) and concentrated and the residue was 
purified by flash chromatography (SiO2, 2% ethyl acetate, hexanes) to yield imine 4.58 
(76 mg, 98%) as a clear oil. IR (neat) νmax = 3033, 2855, 2359, 1690; 1H NMR (400 
MHz, CDCl3) δ 8.41 (d, 1H, J = 8.8), 7.38 (d, 6H, J = 8.8), 7.36 (t, 6H, J = 8.8), 7.27 (t, 
3H, J = 8.7), 5.71-5.65 (m, 1H), 5.48 (dd, 1H, J = 11.6), 4.44 (s, 1H), 3.52-3.41 (m, 1H), 
3.39-3.30 (m, 1H), 3.18 (dd, 1H, 10.4, 4.7), 2.87 (t, 1H, J = 9.6), 2.15-2.04 (m, 1H), 1.93-
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1.83 (m, 2H), 1.73-1.62 (m, 1H), 1.41-1.30 (m, 1H), 1.30-1.18 (m, 1H), 0.87 (s, 9H), 0.17 
(s, 3H), 0.12 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 180.4, 143.0, 128.9, 128.5, 128.4, 
128.0, 127.5, 126.7, 88.4, 72.0, 64.0, 45.7, 43.8, 40.3, 25.8, 24.8, 18.7, 17.9, 17.8, -4.2, -
4.6; HRMS (ESI) calc’d for C36H45NO2Si [M+H]+: 552.3220, measured 552.3292. 
 
4.59. To a solution of imine 4.58 (30 mg, 0.0544 mmol) in DCM (2 mL) 
was added formic acid (2 mL) and the reaction was let stir for 1 h. To the 
reaction was then diluted with brine (5 mL) and extracted with DCM (2 x 2 
mL). The organics were then washed with sat aqueous sodium bicarbonate until aqueous 
layer pH was around 7 (approx. 6 x 8 mL). The organics were then dried (MgSO4) and 
concentrated and the residue was purified by flash chromatography (SiO2, 5% ethyl 
acetate, hexanes) to yield hemiaminal 4.59 (14 mg, 84%) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 5.70-5.64 (m, 1H), 5.50-5.42 (m, 1H), 4.69 (s, 1H), 4.26 (s, 1H), 3.86 (t, 
1H, J = 7.7), 3.64 (dd, 1H, J = 10.8, 7.7), 2.98 (t, 1H, J = 11.9), 2.68 (d, 1H, J = 9.4), 
2.08-1.76 (m, 5H), 1.43-1.35 (m, 1H), 1.31-1.23 (m, 1H), 0.92 (s, 9H), 0.11 (s, 3H), 0.10 
(s, 3H); 13C NMR (100 MHz, CDCl3) 133.0, 126.8, 76.3, 67.9, 43.9, 40.9, 38.9, 26.2, 
23.9, 22.2, 19.7, 18.5, -4.5, -4.7. 
 
NaBH4 Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in MeOH 
(10 mL) was cooled to 0 °C and sodium borohydride (150 mg, 3.876 mmol) was added 
portion wise. After 30 min at 0 °C the solution was filtered and concentrated. The residue 
was taken up in ether (10 mL) and washed with water (3 x 10 mL). The organics were 
dried (MgSO4) and concentrated, and the residue was purified by flash chromatography 
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(SiO2, 10% ethyl acetate, hexanes) to yield lactone 4.65 (10 mg, 3%) as a clear oil, and a 
1:1 mixture of lactol anhydrides 4.66 and 4.67 (85 mg, 28%) as a clear oil. 
 
LiBH4 Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in THF (10 
mL) was cooled to 0 °C and a solution of lithium borohydride (2.0 mL, 3.876 mmol, 2 M 
solution in THF) was added dropwise. After 30 min at 0 °C the solution was quenched 
with sat aqueous ammonium chloride (10 mL) and extracted with ether (3 x 10 mL). The 
organics were dried (MgSO4) and concentrated, and the residue was purified by flash 
chromatography (SiO2, gradient: 40% ethyl acetate, hexanes to 10% methanol, ethyl 
acetate) to yield diol 4.51 (14 mg, 5%) as a light yellow oil, and triol 4.68 (25 mg, 13%) 
as a clear, sticky oil. 
 
L-Selectride Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in 
THF (10 mL) was cooled to 0 °C and a solution of lithium tri-sec-butylborohydride (3.9 
mL, 3.876 mmol, 1 M solution in THF) was added dropwise. After 30 min at 0 °C the 
solution was quenched with sat aqueous ammonium chloride (10 mL) and extracted with 
ether (3 x 10 mL). The organics were dried (MgSO4) and concentrated, and the residue 
was purified by flash chromatography (SiO2, 40% ethyl acetate, hexanes) to yield diol 
4.51 (130 mg, 43%) as a light yellow oil. 
 
DiBAlH Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in THF 
(10 mL) was cooled to 0 °C and a solution of diisobutylaluminum hydride (3.9 mL, 3.876 
mmol, 1 M solution in hexanes) was added dropwise. After 30 min at 0 °C the solution 
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was quenched with sat aqueous Rochelle’s salt (10 mL) and let stir 4 h, then extracted 
with ether (3 x 10 mL). The organics were dried (MgSO4) and concentrated, and the 
residue was purified by flash chromatography (SiO2, 30% ethyl acetate, hexanes) to yield 
lactone 4.65 (20 mg, 7%) as a clear oil, and diol 4.51 (45 mg, 15%) as a light yellow oil. 
 
Li(OtBu)3AlH Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in 
THF (10 mL) was cooled to 0 °C and a solution of lithium tri-tert-butoxyaluminum 
hydride (3.9 mL, 3.876 mmol, 1 M solution in THF) was added dropwise. After 30 min at 
0 °C the solution was quenched with sat aqueous ammonium chloride (10 mL) and 
extracted with ether (3 x 10 mL). The organics were dried (MgSO4) and concentrated, 
and the residue was purified by flash chromatography (SiO2, 20% ethyl acetate, hexanes) 
to yield lactone 4.65 (130 mg, 42%) as a clear oil, and a 1:1 mixture of lactol anhydrides 
4.66 and 4.67 (110 mg, 32%) as a light yellow oil.  
 
LAH Reduction. A solution of allyl anhydride 4.34 (310 mg, 0.969 mmol) in THF or 
ether (10 mL) was cooled to 0 °C and a solution of lithium aluminum hydride (3.9 mL, 
3.876 mmol, 1 M solution in THF) was added dropwise. The reaction was stirred for 30 
min at either 0 °C, RT, or reflux. The reaction was then cooled to 0 °C and water (150 
µL), 15% aqueous NaOH (150 µL), and water (450 µL) were added dropwise. Celite (1.5 
g) was then added and the slurry was stirred vigorously over 2 h at RT. The slurry was 
then heated to reflux and the solids were filtered. The pellet was then washed with a hot 
solution of chloroform and methanol (95:5, 100 mL). The filtrate was concentrated and 
the residue was then purified by flash chromatography (SiO2, gradient: 40% ethyl acetate, 
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hexanes to 10% methanol, ethyl acetate) to yield diol 4.51 as a light yellow oil, and triol 
4.68 as a clear, sticky oil (see Table 4.1 for yields).  
 
AlH3 Reduction. Lithium aluminum hydride (150 mg, 3.876 mmol) in THF or ether (10 
mL) was cooled to 0 °C and aluminum trichloride (180 mg, 1.357 mmol) was added 
dropwise and let stir 15 min at 0 °C. Then, at 0 °C, allyl anhydride 4.34 (310 mg, 0.969 
mmol) in THF or ether (10 mL) was added dropwise. The reaction was then stirred for 30 
min at either 0 °C, RT, or reflux. The reaction was then cooled to 0 °C and quenched with 
sat aqueous ammonium chloride (10 mL) and extracted with ether (3 x 10 mL). The 
organics were dried (MgSO4) and concentrated, and the residue was purified by flash 
chromatography (SiO2, gradient: 40% ethyl acetate, hexanes to 10% methanol, ethyl 
acetate) to yield diol 4.51 as a light yellow oil, and triol 4.68 as a clear, sticky oil (see 
Table 4.1 for yields). 
 
 Lactone 4.65. TLC Rf 0.59 (10% ethyl acetate, hexanes); IR (neat) νmax = 
2934, 2357, 1774, 1101; 1H NMR (400 MHz, CDCl3) δ 5.87-5.78 (m, 2H), 
5.80-5.69 (m, 1H), 5.17 (d, 1H, J = 10.8), 5.16 (d, 1H, J = 16.8), 4.31 (d, 1H, 
J = 9.4), 4.07 (d, 1H, J = 1.4), 3.98 (d, 1H, J = 9.4), 2.58 (dddd, 2H, J = 13.9, 9.3, 4.6, 
2.2), 2.33 (dq, 2H, J = 14.1, 7.4), 2.26-2.17 (m, 1H), 0.88 (s, 9H), 0.07 (s, 3H), 0.06 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 179.9, 132.5, 131.7, 127.5, 120.1, 74.1, 69.6, 47.3, 
41.1, 41.0, 28.0, 27.0, 25.7, 23.3, 18.0, 17.7, 13.7, -3.9, -4.9; HRMS (ESI) calc’d for 
C17H28O3Si [M+H]+: 309.1808, measured 309.1880. 
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Lactol Anhydride 4.66. TLC Rf 0.21 (10% ethyl acetate, hexanes); 1H 
NMR (400 MHz, CDCl3) δ 5.98 (dt, 1H, J = 10.1, 3.7), 5.87-5.81 (m, 1H), 
5.76-5.63 (m, 1H), 5.65 (d, 1H, J = 13.5), 5.54 (dd, 1H, 13.5, 5.5), 5.13 (d, 
1H, J = 10.1), 5.08 (d, 1H, J = 17.0), 4.07 (d, 1H, J = 5.5), 2.68 (dd, 1H, J = 9.7, 5.6), 
2.58 (dd, 1H, J = 13.8, 6.0), 2.42 (dt, 1H, J = 19.8, 3.8), 2.26-2.16 (m, 1H), 2.12 (dd, 1H, 
J = 13.8, 8.9); 13C NMR (100 MHz, CDCl3) δ 177.7, 132.8, 130.5, 124.9, 119.9, 99.5, 
67.2, 48.3, 39.1, 37.7, 29.8, 28.0, 27.0, 25.7, 23.6, 20.4, 18.1, 17.7, 13.7, -4.4, -5.2. 
 
Lactol anhydrides 4.66 and 4.67. TLC Rf 0.21 (10% ethyl 
acetate, hexanes); 1H NMR (400 MHz, CDCl3) δ 5.98-5.94 (m, 
1H), 5.91-5.76 (m, 2H), 5.67 (d, 1H, J = 12.4), 5.18 (d, 1H, J = 
10.0), 5.10 (d, 1H, J = 18.3), 4.95 (d, 1H, J = 12.4), 4.34 (s, 1H), 4.14 (s, 1H), 2.81-2.60 
(m, 2H), 2.35-2.23 (m, 2H), 2.10 (dd, 1H, J = 14.3, 6.9), 0.88 (s, 9H), 0.86 (s, 9H), 0.14 
(s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 177.9, 
175.6, 134.1, 132.2, 130.9, 129.1, 128.1, 126.1, 120.1, 119.0, 104.0, 100.1, 67.7, 66.9, 
49.4, 49.2, 39.7, 39.3, 38.8, 37.2, 25.8, 25.7, 21.9, 21.2, 18.0, -2.8, -3.7, -4.3, -4.8. 
 
4.97. To a solution of lactol anhydride 4.66 (10 mg, 0.0308 mmol) in DCM 
(100 µL) was added pyridine (25 µL, 0.308 mmol) and acetic anhydride (30 
µL, 0.308 mmol). The reaction was stirred for 12 h at RT. The reaction was 
then diluted with sat aqueous sodium bicarbonate (1 mL) and extracted with DCM (3 x 1 
mL). The organics were washed with sat aqueous copper sulfate (1 mL) and then dried 
(MgSO4) and concentrated. The residue was purified by flash chromatography (SiO2, 5% 
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ethyl acetate, hexanes) to yield acetate 4.97 (230 mg, 86%) as a light yellow oil. TLC Rf 
0.28 (10% ethyl acetate, hexanes); 1H NMR (400 MHz, CDCl3) δ 6.48 (d, 1H, J = 8.0), 
5.94-5.89 (m, 1H), 5.87-5.81 (m, 1H), 5.81-5.70 (m, 1H), 5.14 (d, 1H, J = 10.0), 5.09 (dd, 
1H, J = 17.0, 1.1), 4.03 (d, 1H, J = 5.3), 2.60 (m, 2H), 2.27-2.22 (m, 2H), 2.13 (s, 3H), 
2.03 (dd, 1H, J = 14.0, 8.8), 0.88 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 175.3, 169.7, 132.9, 127.5, 127.4, 119.7, 97.3, 67.2, 52.7, 39.3, 37.8, 29.9, 25.7, 
21.1, 21.0, 17.9, -3.8, -5.3. 
 
4.98. To a solution of a 1:1 mixture of lactol anhydrides 4.66 and 4.67 (54 
mg, 0.165 mmol) in DCM (200 µL) was added pyridine (130 µL, 1.650 
mmol) and acetic anhydride (160 µL, 1.650 mmol). The reaction was stirred 
for 12 h at RT. The reaction was then diluted with sat aqueous sodium bicarbonate (2 
mL) and extracted with DCM (3 x 2 mL). The organics were washed with sat aqueous 
copper sulfate (2 mL) and then dried (MgSO4) and concentrated. The residue was 
purified by flash chromatography (SiO2, 5% ethyl acetate, hexanes) to yield acetate 4.97 
(27 mg, 46%) as a light yellow oil and acetate 4.98 (26 mg, 43%) as a light yellow oil. 
TLC Rf 0.29 (10% ethyl acetate, hexanes); 1H NMR (400 MHz, CDCl3) δ 6.57 (s, 1H), 
5.86-5.82 (m, 2H), 5.77-5.66 (m, 1H), 5.14 (d, 1H, J = 10.5), 5.10 (dd, 1H, J = 16.9, 1.6), 
4.17 (s, 1H), 2.72 (dd, 1H, J = 9.3, 1.7), 2.66 (d, 1H, J = 18.3), 2.35 (d, 2H, J = 5.7), 2.24 
(dd, 1H, J = 17.7, 9.3), 2.13 (s, 3H), 0.87 (s, 9H), 0.09 (s, 3H), 0.04 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 176.9, 168.9, 132.9, 129.1, 127.9, 119.7, 96.4, 66.9, 48.8, 39.1, 
37.4, 25.7, 22.0, 21.0, 18.0, -3.7, -4.9. 
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4.70. To a solution of lactone 4.65 (30 mg, 0.0972 mmol) in DCM (1 mL) at 
-15 °C was added diisobutylaluminum hydride (200 µL, 0.195 mmol, 1 M 
solution in hexanes) dropwise. After 2 h at -15 °C the solution was 
quenched with sat aqueous Rochelle’s salt (1 mL) and let stir 4 h, then extracted with 
ether (3 x 1 mL). The organics were dried (MgSO4) and concentrated, and the residue 
was purified by flash chromatography (SiO2, 30% ethyl acetate, hexanes) to yield the two 
inseparable diastereomers of lactol 4.70 (20 mg, 66%) as a clear oil. IR (neat) νmax = 
3298, 2933, 1090; 1H NMR (600 MHz, CDCl3) δ 5.97-5.83 (m, 2H), 5.81-5.78 (m, 2H), 
5.58-5.54 (m, 2H), 5.17 (d, 2H, J = 17.0), 5.14 (d, 2H, J = 10.4), 3.86 (d, 1H, J = 11.2), 
3.77, (dd, 1H, J = 11.4, 4.4), 3.66 (dd, 1H, J = 11.4, 4.2), 3.64 (d, 1H, J = 11.1), 2.42-2.34 
(m, 4H), 2.20-2.16 (m, 2H), 0.91 (s, 18H), 0.12 (s, 6H), 0.11 (s, 6H); 13C NMR (150 
MHz, CDCl3) δ 134.3, 128.5, 128.3, 118.6, 71.5, 63.0, 62.9, 62.7, 43.5, 38.6, 35.7, 26.0, 
18.2, -3.83, -4.72; HRMS (ESI) calc’d for C17H30O3Si [M+H]+: 311.1964, measured 
311.2037. 
 
4.71. To a solution of lactol 4.70 (20 mg, 0.0644) in DCM (100 µL) was 
added pyridine (52 µL, 0.644 mmol) and acetic anhydride (61 µL, 0.644 
mmol). The reaction was stirred for 12 h at RT. The reaction was then 
diluted with sat aqueous sodium bicarbonate (1 mL) and extracted with DCM (3 x 1 mL). 
The organics were washed with sat aqueous copper sulfate (1 mL) and then dried 
(MgSO4) and concentrated. The residue was purified by flash chromatography (SiO2, 
10% ethyl acetate, hexanes) to yield the two inseparable diastereomers of lactol acetate 
4.71 (15 mg, 67%) as a clear oil. IR (neat) νmax = 3406, 2933, 2357, 1741, 1242; 1H NMR 
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(600 MHz, CDCl3) δ 5.86-5.78 (m, 2H), 5.71-5.68 (m, 2H), 5.66-5.62 (m, 2H), 5.12 (d, 
2H, J = 8.4), 5.10 (d, 2H, J = 15.5), 4.30 (dd, 2H, J = 11.2, 3.6), 4.20 (bs, 4H), 4.13 (t, 
2H, J = 10.7), 3.99-3.97 (m, 2H), 2.30-2.24 (m, 2H), 2.24-2.19 (m, 2H), 2.07-2.02 (m, 
6H), 2.07 (s, 3H), 2.03 (s, 3H), 2.00-1.96 (m, 2H), 0.88 (s, 18H), 0.08 (s, 6H), 0.05 (s, 
6H); 13C NMR (150 MHz, CDCl3) δ 171.1, 171.0, 133.6, 128.5, 126.6, 118.9, 69.0, 65.1, 
65.0, 42.3, 35.6, 35.4, 25.9, 25.8, 21.2, 21.2, 18.1, -3.7, -4.9; HRMS (ESI) calc’d for 
C19H32O4Si [M+H]+: 353.2070, measured 353.2143. 
 
4.68. To a solution of diol 4.51 (250 mg, 0.792 mmol) in acetonitrile (2 
mL) was added a solution of hydrogen fluoride (115 µL, 3.962 mmol, 70% 
solution in pyridine) dropwise. The reaction was stirred for 6 h at RT. The 
reaction was then quenched with sat. sodium bicarbonate (3 mL) and the aqueous was 
extracted with ether (3 x 4 mL). The organics were combined, concentrated and the 
residue was then purified by flash chromatography (SiO2, gradient: 40% ethyl acetate, 
hexanes to 10% methanol, ethyl acetate) to triol 4.68 (150 mg, 95%) as a clear, sticky oil. 
 
4.82. To a solution of triol 4.68 (350 mg, 1.77 mmol) in pyridine (900 
µL, 10.6 mmol) and ether (2 mL) was added TMS chloride (1.12 mL, 
8.83 mmol). The reaction mixture became a white slurry that was 
allowed to stir overnight. The slurry was then filtered, dried (MgSO4), and concentrated. 
The residue was purified by flash chromatography (SiO2, 10% ethyl acetate, hexanes) to 
yield tri-TMS ether 4.82 (710 mg, 97%) as a light yellow oil. IR (neat) νmax = 2957, 1260; 
1H NMR (600 MHz, CDCl3) δ 5.86 (dddd, 1H, J = 17.3, 7.1, 2.9, 2.7), 5.88-5.65 (m, 1H), 
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5.54-5.48 (m, 1H), 5.09 (d, 1H, J = 16.7), 5.08 (d, 1H, 10.3), 4.00 (s, 1H), 3.71 (s, 1H), 
3.70 (d, 1H, J = 3.8), 3.65 (d, 1H, J = 10.0), 3.55 (d, 1H, J = 10.0), 2.40 (dd, 1H, J = 14.3, 
7.0), 2.30-2.20 (m, 1H), 2.11 (dd, 1H, J = 14.3, 7.7), 2.07-1.98 (m, 1H), 1.81-1.72 (m, 
1H), 0.10 (s, 9H), 0.08 (s, 18H); 13C NMR (150 MHz, CDCl3) δ 135.0, 129.1, 127.5, 
117.8, 69.9, 62.6, 62.2, 43.6, 39.7, 35.1, 26.0, 1.2, 0.7, -0.3, -0.4; HRMS (ESI) calc’d for 
C20H42O3Si3 [M+Na]+: 439.2442, measured 437.2334. 
 
PMP acetal 4.75a/4.75b Method A. To a solution of triol 4.68 (480 mg, 2.42 mmol) and 
p-anisaldehyde (442 mL, 3.63 mmol) in DCM (8 mL) was added p-toluenesulfonic acid 
(ca. 5 mg) and the reaction was allowed to stir 2 h. The reaction was quenched with 
saturated aqueous sodium bicarbonate (4 mL) and the aqueous layer was extracted with 
DCM (2 x 2 mL). The organics were then dried (MgSO4), concentrated, and the residue 
was purified by flash chromatography (SiO2, 15% ethyl acetate, hexanes) to yield acetal 
4.75a (160 mg, 21%) as a light yellow oil and acetal 4.75b (240 mg, 32%) as a light 
yellow oil. 
 
PMP acetal 4.75a/4.75b Method B. A solution of tris-TMS ether 4.82 (560 mg, 1.350 
mmol) and p-anisaldehyde dimethyl acetal (230 µL, 1.350 mmol) in DCM (5.4 mL) was 
cooled to -78 °C and TMS triflate (50 µL, 0.270 mmol) was added dropwise. The 
reaction was then allowed to stir 5 h at -78 °C. The reaction was then quenched with 
pyridine (50 µL) and allowed to warm to RT. The solution was then washed with water 
(5 mL) and then brine (5 mL). The organics were then dried (MgSO4), concentrated, and 
the residue was purified by flash chromatography (SiO2, 20% ethyl acetate, hexanes) to 
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yield acetal 4.75a (510 mg, 88%) as a clear oil and acetal 4.75b (20 mg, 5%) as a light 
yellow oil.  
 
4.75a. TLC Rf 0.46 (40% ethyl acetate, hexanes); IR (neat) νmax = 3444, 
2901, 1615, 1518; 1H NMR (400 MHz, CDCl3) δ 7.39 (d, 2H, J = 8.6), 6.88 
(d, 2H, J = 8.7), 6.02-5.95 (m, 1H), 5.80-5.67 (m, 2H), 5.45 (s, 1H), 5.12 (d, 
1H, J = 10.2), 5.11 (d, 1H, J = 16.7), 4.45 (s, 1H), 4.19 (d, 1H, J = 12.2), 4.16-4.08 (m, 
1H), 4.00-3.95 (m, 2H), 3.94 (d, 1H, J = 12.1), 3.78 (s, 3H), 2.43-2.33 (m, 1H), 2.25-2.15 
(m, 2H), 1.97-1.86 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 160.3, 132.4, 131.7, 130.2, 
127.6, 122.4, 119.0, 113.9, 101.5, 76.7, 75.4, 64.8, 55.4, 40.6, 38.8, 35.1, 26.6; HRMS 
(ESI) calc’d for C19H24O4 [M+Na]+: 339.1675, measured 339.1567. 
 
4.75b. TLC Rf 0.37 (40% ethyl acetate, hexanes); IR (neat) νmax = 3455, 
2927, 1615, 1518; 1H NMR (400 MHz, CDCl3) δ 7.42 (d, 2H, J = 8.7), 
6.89 (d, 2H, J = 8.8), 6.04-5.97 (m, 1H), 5.90 (dddd, 1H, J = 17.2, 7.6, 2.5, 
2.1), 5.82-5.76 (m, 1H), 5.61 (s, 1H), 5.24 (d, 1H, J = 17.0), 5.19 (d, 1H, J = 10.2), 4.47 
(s, 1H), 4.06 (d, 1H, J = 11.4), 3.79-3.75 (m, 2H), 3.79 (s, 3H), 3.54 (dd, 1H, J = 10.6, 
7.3), 3.35 (dd, 1H, J = 14.5, 7.9), 2.32 (dd, 1H, J = 14.5, 7.1), 2.52-2.16 (m, 1H), 2.01-
1.86 (m, 2H), 1.82-1.73 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 160.1, 133.6, 131.3, 
130.2, 127.9, 127.6, 119.1, 113.8, 95.2, 73.4, 69.0, 62.1, 55.4, 39.0, 36.7, 36.3, 26.3; 
HRMS (ESI) calc’d for C19H24O4 [M+Na]+: 339.1675, measured 339.1591.  
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4.99. To a 1L 3-neck flask with a mechanical stirrer attached, open to the air, 
was added 2-iodobenzoic acid (25.0 g, 101 mmol) and water (235 mL). The 
suspension was slowly stirred and Oxone (89.9 g, 146 mmol) was added. The reaction 
was heated in an oil bath to 90 °C (internal temperature 70-73 °C) then maintained 
internal temperature for 3 h with vigorous stirring. Stirring was stopped and the reaction 
was removed from heating. Once the solution was cooled to RT, the reaction was then 
cooled to 0 °C and allowed to stir slowly for 1 h. The reaction precipitated a white solid, 
which was collected by filtration. The solid was washed with water (6 x 50 mL) and 
acetone (3 x 50 mL). The reaction yielded 2-iodoxybenzoic acid 4.99 (22.8 g, 81%) as a 
free-flowing, white, crystalline solid. Spectral data matched reported values.85 
 
4.76. To a solution of PMP acetal 4.75a (210 mg, 0.664 mmol) in DCM 
(6.6 mL) and DMSO (6.6 mL) was added IBX (372 mg, 1.327 mmol) and 
the solution was allowed to stir 2 h. The reaction was then diluted with 
brine (7 mL). The organic layer was then washed with brine (3 x 4 mL) and the aqueous 
layers were then extracted with DCM (3 x 10 mL). The organics were combined, dried 
(MgSO4), concentrated, and the residue was purified by flash chromatography (SiO2, 
20% ethyl acetate, hexanes) to yield aldehyde 4.76 (280 mg, 98%) as a light yellow oil. 
IR (neat) νmax = 3034, 2843, 1712, 1615, 1519; 1H NMR (600 MHz, CDCl3) δ 10.21 (d, 
1H, J = 2.9), 7.33 (d, 2H, J = 8.8), 6.86 (d, 2H, J = 8.8), 6.02-5.98 (m, 1H), 5.85-5.81 (m, 
1H), 5.74 (dddd, 1H, J = 16.9, 8.5, 3.0, 1.5), 5.44 (s, 1H), 5.19 (d, 1H, J = 10.1), 5.16 (d, 
1H, 16.9), 4.30 (d, 1H, J = 12.3), 4.02 (d, 1H, J = 5.9), 4.02 (d, 1H, J = 12.1), 3.77 (s, 
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3H), 2.61-2.52 (m, 2H), 2.31-2.21 (m, 2H), 2.02 (dd, 1H, 14.2, 6.8); 13C NMR (150 MHz, 
CDCl3) δ 203.7, 160.2, 131.7, 130.3, 129.9, 127.7, 123.6, 119.8, 113.8, 102.0, 75.8, 74.8, 
55.4, 50.2, 38.9, 37.8, 22.2; HRMS (ESI) calc’d for C19H22O4 [M+Na]+: 337.1518, 
measured 337.1410. 
 
4.80. To a solution of PMP acetal 4.75b (447 mg, 1.413 mmol) in DCM (14 
mL) and DMSO (14 mL) was added IBX (790 mg, 2.826 mmol) and the 
solution was allowed to stir 2 h. The reaction was then diluted with brine 
(14 mL). The organic layer was then washed with brine (3 x 7 mL) and the aqueous 
layers were then extracted with DCM (3 x 20 mL). The organics were then dried 
(MgSO4), concentrated, and the residue was purified by flash chromatography (SiO2, 
20% ethyl acetate, hexanes) to yield aldehyde 4.80 (430 mg, 96%) as a light yellow oil. 
IR (neat) νmax = 3027, 2840, 1720, 1615, 1517; 1H NMR (600 MHz, CDCl3) δ 9.88 (d, 
1H, J = 2.0), 7.42 (d, 2H, J = 8.7), 6.90 (d, 2H, J = 8.7), 6.06-5.99 (m, 1H), 6.01-5.89 (m, 
1H), 5.89-5.82 (m, 1H), 5.62 (s, 1H), 5.24 (d, 1H, J = 11.9), 5.24 (d, 1H, 14.1), 4.52 (s, 
1H), 4.14 (d, 1H, J = 11.4), 3.88 (d, 1H, J = 11.4), 3.80 (s, 3H), 3.29 (dd, 1H, J = 14.4, 
7.4), 2.82-2.74 (m, 1H), 2.51 (dd, 1H, 14.4, 7.9), 2.31-2.14 (m, 2H); 13C NMR (150 MHz, 
CDCl3) δ 202.1, 133.2, 131.0, 128.6, 128.4, 127.6, 120.3, 95.6, 72.7, 68.3, 55.5, 49.6, 
37.3, 36.8, 22.7; HRMS (ESI) calc’d for C19H22O4 [M+Na]+: 337.1518, measured 
337.1432. 
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4.100. To a solution of sodium azide (11. 3 g, 173 mmol) in EtOH (64 
mL), and water (32 mL) was added a hot solution (~45 °C) of 
toluenesulfonyl chloride (30.0 g, 157 mmol) in EtOH (160 mL), and the reaction 
precipitated NaCl and became slightly orange. After 2.5 h at RT, EtOH was removed in 
vacuo and the residue was added to water (190 mL) and separated. The oil was washed 
with water (2 x 20 mL), dried (NaSO4), and filtered to yield azide 4.100 (28.0 g, 91%) as 
a clear oil that solidified upon storage at 4 °C. Spectral data matched reported values.86 
 
4.101. To a slurry of NaH (60% in mineral oil, 1.60 g, 33.1 mmol) in THF 
(49 mL) and toluene (40 mL) at 0 °C was added neat dimethyl 2-
oxopropylphosphonate (5.00 g, 30.1 mmol) and allowed to stir until gas evolution 
stopped. After 5 min, a solution of azide 4.100 (6.53 g, 33.1 mmol) in THF (21 mL) was 
added via cannula and the reaction was stirred at RT 22 h. The orange slurry was diluted 
with petroleum ether (500 mL) and filtered through a plug of Celite with extensive 
petroleum ether washes. The concentrated filtrate was purified by flash chromatography 
(SiO2, 50% ethyl acetate, petroleum ether (1000 mL) and 50% ethyl acetate, 10% 
methanol, in petroleum ether (600 mL)) to yield the Bestmann-Ohira reagent 4.101 (4.12 
g, 72%) as a light yellow oil. Spectral data matched reported values.87 
 
Alkyne 4.77/epi-4.77 Method A.87 A solution of aldehyde 4.76 (123 mg, 0.391 mmol), 
Bestmann-Ohira reagent (4.101) (113 mg, 0.587 mmol), and potassium carbonate (108 
mg, 0.782 mmol) in THF (4 mL) was allowed to stir 5 h. The reaction was then diluted 
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with brine (6 mL) and the aqueous layer was extracted with ether (2 x 8 mL). The 
organics were then dried (MgSO4), concentrated, and the residue was purified by flash 
chromatography (SiO2, 15% ethyl acetate, hexanes) to yield alkyne 4.77 (65 mg, 66%) as 
a light yellow oil and the alkyne epimer epi-4.77 (36 mg, 30%) as a light yellow oil. 
 
Alkyne 4.77/epi-4.77 Method B.88 A solution of Bestmann-Ohira reagent (4.101) (785 
mg, 4.072 mmol) in THF (2 mL) was cooled to -78 °C and NaOMe (815 µL, 4.072 
mmol, 5 M solution in MeOH) in THF (8 mL) was added dropwise and the solution was 
allowed to stir 30 min. Then aldehyde 4.76 (320 mg, 1.018 mmol) in THF (ca. 1 mL) was 
added dropwise and the solution was allowed to stir 5 h at -78 °C. The reaction was then 
quenched with NH4Cl (8 mL) and the aqueous layer was extracted with ether (2 x 12 
mL). The organics were then dried (MgSO4), concentrated, and the residue was purified 
by flash chromatography (SiO2, 20% ethyl acetate, hexanes) to yield alkyne 4.77 (280 
mg, 98%) as a light yellow oil.  
 
4.77. IR (neat) νmax = 3295, 2921; 1H NMR (600 MHz, CDCl3) δ 7.49 (d, 
2H, J = 8.7), 6.85 (d, 2H, J = 8.8), 5.99-5.94 (m, 1H), 5.93-5.87 (m, 1H), 
5.72 (dddd, 1H, J = 16.7, 8.6, 1.5, 1.5), 5.49 (s, 1H), 5.16 (d, 1H, J = 9.4), 
5.14 (d, 1H, J = 16.9), 4.20 (d, 1H, J = 12.1), 3.94 (t, 1H, J = 17.1), 3.95 (d, 1H, J = 12.2), 
3.75 (s, 3H), 2.84-2.80 (m, 1H), 2.54-2.40 (m, 2H), 2.14 (dd, 1H, J = 14.3, 8.5), 2.12 (d, 
1H, J = 2.7), 1.90 (dd, 1H, J = 14.3, 6.5); 13C NMR (150 MHz, CDCl3) δ 160.0, 132.1, 
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128.7, 128.2, 124.7, 113.7, 101.4, 87.3, 75.4, 74.6, 69.5, 55.4, 39.5, 39.5, 35.7, 30.1, 29.9, 
27.8; HRMS (ESI) calc’d for C20H22O3 [M+H]+: 311.1569, measured 311.1631. 
 
epi-4.77. IR (neat) νmax = 3295, 2921; 1H NMR (600 MHz, CDCl3) δ 7.41 
(d, 2H, J = 8.6), 6.87 (d, 2H, J = 8.8), 5.95-5.91 (m, 1H), 5.93-5.85 (m, 1H), 
5.81-5.77 (m, 1H), 5.42 (s, 1H), 5.12 (d, 1H, J = 10.0), 5.08 (d, 1H, J = 
16.9), 4.39 (d, 1H, J = 11.8), 4.17 (d, 1H, J = 5.64), 3.88 (d, 1H, J = 11.9), 3.79 (s, 3H), 
3.63 (ddd, 1H, J = 11.6, 6.0, 2.5), 2.56 (dt, 1H, J = 19.1, 5.3), 2.31 (ddt, 1H, J = 19.1, 
11.6, 2.1), 2.22 (dd, 1H, J = 14.3, 7.3), 2.14 (d, 1H, J = 2.5), 2.12 (dd, 1H, J = 14.3, 7.9); 
13C NMR (150 MHz, CDCl3) δ 160.0, 133.2, 131.7, 131.0, 127.7, 123.7, 119.0, 113.8, 
101.9, 84.9, 73.9, 71.8, 71.6, 55.5, 36.1, 33.1, 29.9, 29.8, 26.7; HRMS (ESI) calc’d for 
C20H22O3 [M+H]+: 311.1569, measured 311.1624. 
 
4.81.87 To a solution of aldehyde 4.80 (87 mg, 0.277 mmol) and Bestmann-
Ohira reagent (4.101) (80 mg, 0.415 mmol) in MeOH (3 mL) was added 
K2CO3 (115 mg, 0.831 mmol) and the reaction was allowed to stir 4 h. The 
solution was then concentrated, taken up in DCM (5 mL) and washed with water (2 x 4 
mL). The aqueous layers were then extracted with DCM (2 x 6 mL). The organics were 
then dried (MgSO4), concentrated, and the residue was purified by flash chromatography 
(SiO2, 15% ethyl acetate, hexanes) to yield alkyne 4.81 (52 mg, 61%) as a light yellow 
oil. IR (neat) νmax = 3293, 2917, 1615, 1517; 1H NMR (600 MHz, CDCl3) δ 7.43 (d, 2H, J 
= 8.6), 6.90 (d, 2H, J = 8.6), 5.98-5.88 (m, 2H), 5.83-5.8 (m, 1H), 5.56 (s, 1H), 5.30 (d, 
1H, J = 16.0), 5.21 (d, 1H, J = 10.2), 4.49 (s, 1H), 4.04 (d, 1H, J = 11.3), 3.87 (d, 1H, J = 
OO
PMP H
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11.2), 3.80 (s, 3H), 3.24 (dd, 1H, J = 13.7, 8.0), 2.66-2.62 (m, 1H), 2.50 (dd, 1H, J = 13.8, 
7.4), 2.43-2.37 (m, 1H), 2.21-2.16 (m, 1H), 2.15 (d, 1H, J = 2.5); 13C NMR (150 MHz, 
CDCl3) δ 160.2, 113.2, 131.2, 129.0, 128.5, 127.7, 120.0, 113.9, 95.6, 82.7, 72.3, 71.5, 
68.7, 55.5, 37.3, 35.9, 29.9, 29.2; HRMS (ESI) calc’d for C20H22O3 [M+H]+: 311.1569, 
measured 311.1669.  
 
4.79. A solution of alkyne 4.81 (18 mg, 0.0580 mmol) and NaBH3CN (22 
mg, 0.348 mmol) in MeCN (1.2 mL) with 3Å molecular sieves was cooled 
to 0 °C. A solution of TMS chloride (44 µL, 0.348 mmol) in MeCN (340 
µL) was added dropwise. The reaction was then allowed to stir 5 h at RT. The reaction 
mixture was then filtered through Celite and poured into cold saturated aqueous sodium 
bicarbonate (1 mL). The aqueous layer was extracted with DCM (3 x 2 mL). The 
organics were then dried (MgSO4), concentrated, and the residue was purified by flash 
chromatography (SiO2, 20% ethyl acetate, hexanes) to yield primary PMB 4.79 (10 mg, 
55%) as a clear oil. IR (neat) νmax = 3476, 3293, 2912, 1613, 1513; 1H NMR (600 MHz, 
CDCl3) δ 7.25 (d, 2H, J = 8.6), 6.88 (d, 2H, J = 8.6), 5.88 (dddd, 1H, J = 15.4, 7.3, 2.5, 
2.1), 5.83-5.79 (m, 1H), 5.64-5.60 (m, 1H), 5.20 (d, 1H, J = 17.1), 5.14 (d, 1H, J = 10.1), 
4.48 (d, 1H, J = 11.5), 4.43 (d, 1H, J = 12.8), 4.03 (d, 1H, J = 8.7), 3.89 (d, 1H, J = 9.1), 
3.81 (s, 3H), 3.42 (d, 1H, J = 9.6), 2.70-2.62 (m, 2H), 2.34-2.82 (m, 2H), 2.15-2.08 (m, 
1H), 2.10 (d, 1H, J = 2.5); 13C NMR (150 MHz, CDCl3) δ 159.5, 133.7, 131.6, 130.2, 
129.4, 124.7, 119.4, 114.0, 85.0, 73.7, 71.8, 71.2, 70.2, 55.5, 42.4, 36.1, 29.8, 29.3; 
HRMS (ESI) calc’d for C20H24O3 [M+Na]+: 335.1725, measured 335.1632. 
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4.78. A solution of alkyne 4.77 (50 mg, 0.161 mmol) in DCM (2 mL) was 
cooled to -78 °C and diisobutylaluminum hydride (644 µL, 0.644 mmol, 1 
M in hexanes) was added dropwise. The solution was allowed to stir 1 h at -78 °C, 
warmed to 0 °C over 1 h, and then maintained at 0 °C for an additional 1 h. The reaction 
was then quenched with saturated aqueous Rochelle’s salt (2 mL) and allowed to stir over 
night. The slurry was then extracted with DCM (3 x 2 mL) and the combined organics 
were then dried (MgSO4), concentrated, and the resulting residue was purified by flash 
chromatography (SiO2, 10% ethyl acetate, hexanes) to yield secondary PMB 4.78 (36 mg, 
72%) as a light yellow oil. IR (neat) νmax = 3524, 3295, 2909, 1514; 1H NMR (600 MHz, 
CDCl3) δ 7.26 (d, 1H, J = 8.5), 6.89 (d, 1H, J = 8.6), 5.83-5.75 (m, 2H), 5.73-5.69 (m, 
1H), 5.12 (d, 1H, J = 10.1), 5.10 (d, 1H, J = 17.4), 4.64 (d, 1H, J = 11.0), 4.40 (d, 1H, J = 
11.0), 4.08 (s, 1H) 4.04 (dd, 1H, J = 11.2, 2.1), 3.81 (s, 3H), 3.60 (dd, 1H, J = 10.9, 10.9), 
2.84 (dd, 1H, J = 10.6, 2.2), 2.78 (dd, 1H, J = 14.1, 8.6), 2.55 (ddd, 1H, J = 11.4, 5.8, 
2.4), 2.45 (dd, 1H, J = 14.1, 6.7), 2.30-2.24 (m, 1H), 2.15-2.09 (m, 1H), 2.13 (d, 1H, J = 
2.5); 13C NMR (150 MHz, CDCl3) δ .159.7, 133.8, 129.9, 129.8, 126.7, 126.4, 119.5, 
114.1, 83.6, 78.2, 71.7, 71.4, 64.0, 55.5, 42.3, 35.4, 31.0, 29.2; HRMS (ESI) calc’d for 
C20H24O3 [M+Na]+: 335.1725, measured 335.1637.  
 
4.87. To a solution of secondary PMB 4.78 (30 mg, 0.0960 mmol) in 
DCM (100 µL) was added pyridine (78 µL, 0.960 mmol) and acetic 
anhydride (91 µL, 0.960 mmol). The reaction was stirred for 12 h at RT. The reaction 
was then diluted with sat aqueous sodium bicarbonate (1 mL) and extracted with DCM (3 
x 1 mL). The organics were washed with sat aqueous copper sulfate (2 mL) and then 
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dried (MgSO4) and concentrated. The residue was purified by flash chromatography 
(SiO2, 15% ethyl acetate, hexanes) to yield primary acetate 4.87 (28 mg, 82%) as a clear 
oil. IR (neat) νmax = 3288, 2920, 1735, 1242; 1H NMR (600 MHz, CDCl3) δ 7.26 (d, 2H, J 
= 8.5), 6.87 (d, 2H, J = 8.6), 5.84-5.76 (m, 1H), 5.76-5.70 (m, 2H), 5.12 (d, 1H, J = 10.2), 
5.11 (d, 1H, J = 16.9), 4.59 (d, 1H, J = 11.2), 4.43 (d, 1H, J = 11.7), 4.38 (d, 1H, J = 
11.2), 4.25 (d, 1H, J = 11.7), 3.92 (d, 1H, J = 1.6), 3.81 (s, 3H), 2.62 (td, 1H, J = 8.0, 2.6), 
2.58 (dd, 1H, J = 13.8, 6.7), 2.51 (dd, 1H, J = 13.8, 8.5), 2.33-2.30 (m, 2H), 2.09 (d, 1H, J 
= 2.6), 1.99 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 171.3, 159.3, 133.7, 130.7, 129.3, 
126.7, 126.5, 119.4, 113.9, 84.4, 76.1, 71.3, 70.4, 64.3, 55.5, 42.7, 36.2, 30.7, 29.6, 21.2; 
HRMS (ESI) calc’d for C22H26O4 [M+H]+: 355.1831, measured 355.1928. 
 
4.89. meta-Chloroperbenzoic acid (175 mg, 0.773 mmol, 77%) was added 
to alkyne 4.81 (200 mg, 0.644 mmol) in DCM (1 mL). After 8 h the 
reaction was quenched with saturated aqueous sodium bicarbonate (1 mL) 
and extracted with DCM (3 x 1 mL). combined organic layers were dried (MgSO4), 
concentrated, and the residue was purified by flash chromatography (SiO2, 10% ethyl 
acetate, hexanes) to yield an inseparable mixture of epoxide diastereomers 4.89 (145 mg, 
57%) as a light yellow oil. IR (neat) νmax = 3285, 2920, 1251, 1097; 1H NMR (600 MHz, 
CDCl3) δ 7.40 (d, 2H, J = 8.8), 7.40 (d, 2H, J = 8.7), 6.89 (d, 2H, J = 8.8), 6.88 (d, 2H, J 
= 8.8), 5.99-5.93 (m, 2H), 5.86-5.81 (m, 2H), 5.58 (s, 1H), 5.55 (s, 1H), 4.73-4.69 (m, 
2H), 4.05 (d, 1H, J = 12.1), 4.05 (d, 1H, J = 11.5), 3.91 (dd, 1H, 11.0, 0.6), 3.87 (dd, 1H, 
J = 11.4, 0.8), 3.80 (s, 3H), 3.79 (s, 3H), 3.27-3.22 (m, 2H), 2.92-2.84 (m, 2H), 2.83-2.80 
(m, 2H), 2.70-2.63 (m, 2H), 2.63-2.58 (m, 2H), 2.49-2.46 (m, 1H), 2.46-2.43 (m, 1H), 
OO
O
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2.26-2.19 (m, 2H), 2.18 (d, 1H, J = 2.6), 2.17 (d, 1H, J = 2.5), 2.05 (d, 1H, J = 6.6), 2.02 
(d, 1H, J = 6.6), 1.96 (d, 1H, J = 5.2), 1.93 (d, 1H, J = 5.3); 13C NMR (150 MHz, CDCl3) 
δ 129.2, 128.9, 128.3, 128.0, 127.6, 127.6, 113.9, 113.8, 95.5, 95.5, 82.7, 82.6, 74.0, 73.6, 
72.0, 71.9, 68.6, 68.2, 55.4, 49.2, 48.9, 47.5, 47.1, 37.5, 37.3, 35.8, 35.7, 31.5, 30.9, 29.4, 
29.3; HRMS (ESI) calc’d for C20H22O4 [M+H]+: 327.1518, measured 327.1628. 
 
4.92. To a solution of secondary PMB 4.78 (40 mg, 0.128 mmol) in DCM 
(1.3 mL) and DMSO (1.3 mL) was added IBX (72 mg, 0.256 mmol) and 
the solution was allowed to stir 2 h. The reaction was then diluted with brine (3 mL). The 
organic layer was then washed with brine (3 x 3 mL) and the aqueous layers were then 
extracted with DCM (3 x 10 mL). The organics were then dried (MgSO4), concentrated, 
and the residue was purified by flash chromatography (SiO2, 15% ethyl acetate, hexanes) 
to yield aldehyde 4.92 (37 mg, 93%) as a light yellow oil. IR (neat) νmax = 3288, 2847, 
1724, 1612, 1512, 1248; 1H NMR (600 MHz, CDCl3) δ 9.84 (s, 1H), 7.24 (d, 2H, J = 
8.6), 6.87 (d, 2H, J = 8.6), 5.96 (dd, 1H, J = 10.4, 1.9), 5.82-5.78 (m, 1H), 5.70-5.61 (m, 
1H), 5.12 (d, 1H, J = 10.4), 5.10 (d, 1H, J = 17.0), 4.64 (d, 1H, J = 11.4), 4.43 (d, 1H, J = 
11.5), 4.07 (d, 1H, J = 1.3), 3.80 (s, 3H), 2.75-2.67 (m, 2H), 2.55 (dd, 1H, J = 14.0, 8.2), 
2.48-2.36 (m, 2H), 2.17 (d, 1H, J = 2.5); 13C NMR (150 MHz, CDCl3) δ 203.0, 159.5, 
132.6, 130.0, 129.6, 127.2, 126.6, 120.1, 114.0, 82.5, 74.8, 71.7, 71.4, 55.4, 54.7, 33.1, 
30.4, 30.0; HRMS (ESI) calc’d for C20H22O3 [M+H]+: 311.1569, measured 311.1614.  
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Figure 4.2. 400 MHz 1H NMR spectrum of 4.32 in CDCl3. 
 
Figure 4.3. 100 MHz 13C NMR spectrum of 4.32 in CDCl3. 
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Figure 4.4. 600 MHz 1H NMR spectrum of 4.33 in CDCl3. 
 
Figure 4.5. 150 MHz 13C NMR spectrum of 4.33 in CDCl3. 
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Figure 4.6. 400 MHz 1H NMR spectrum of 4.34 in CDCl3. 
 
Figure 4.7. 100 MHz 13C NMR spectrum of 4.34 in CDCl3. 
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Figure 4.8. 400 MHz 1H NMR spectrum of epi-4.34 in CDCl3. 
 
Figure 4.9. 100 MHz 13C NMR spectrum of epi-4.34 in CDCl3. 
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Figure 4.10. 600 MHz 1H NMR spectrum of 4.35 in CDCl3. 
 
Figure 4.11. 150 MHz 13C NMR spectrum of 4.35 in CDCl3. 
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Figure 4.12. 400 MHz 1H NMR spectrum of 4.36 in CDCl3. 
 
Figure 4.13. 100 MHz 13C NMR spectrum of 4.36 in CDCl3. 
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Figure 4.14. 400 MHz 1H NMR spectrum of 4.37 in CDCl3. 
 
Figure 4.15. 100 MHz 13C NMR spectrum of 4.37 in CDCl3. 
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Figure 4.16. 400 MHz 1H NMR spectrum of 4.38 in CDCl3. 
 
Figure 4.17. 100 MHz 13C NMR spectrum of 4.38 in CDCl3. 
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Figure 4.18. 600 MHz 1H NMR spectrum of 4.51 in CDCl3. 
 
Figure 4.19. 150 MHz 13C NMR spectrum of 4.51 in CDCl3. 
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Figure 4.20. 400 MHz 1H NMR spectrum of 4.68 in CDCl3. 
 
Figure 4.21. 100 MHz 13C NMR spectrum of 4.68 in CDCl3. 
11 10 9 8 7 6 5 4 3 2 1 0 ppm
220 200 180 160 140 120 100 80 60 40 20 0 ppm
HO
H
OH
OH
4.68
 150 
 
Figure 4.22. 600 MHz 1H NMR spectrum of 4.96 in CDCl3. 
 
 Figure 4.23. 150 MHz 13C NMR spectrum of 4.96 in CDCl3.  
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Figure 4.24. 400 MHz 1H NMR spectrum of 4.52 in CDCl3. 
 
Figure 4.25. 100 MHz 13C NMR spectrum of 4.52 in CDCl3. 
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Figure 4.26. 400 MHz 1H NMR spectrum of 4.53 in CDCl3. 
 
Figure 4.27. 100 MHz 13C NMR spectrum of 4.53 in CDCl3. 
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Figure 4.28. 600 MHz 1H NMR spectrum of 4.54 in CDCl3. 
 
Figure 4.29. 150 MHz 13C NMR spectrum of 4.54 in CDCl3. 
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Figure 4.30. 600 MHz 1H NMR spectrum of 4.55 in CDCl3. 
 
Figure 4.31. 150 MHz 13C NMR spectrum of 4.55 in CDCl3. 
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Figure 4.32. 400 MHz 1H NMR spectrum of 4.56 in CDCl3. 
 
Figure 4.33. 100 MHz 13C NMR spectrum of 4.56 in CDCl3. 
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Figure 4.34. 600 MHz 1H NMR spectrum of 4.57 in CDCl3. 
 
Figure 4.35. 150 MHz 13C NMR spectrum of 4.57 in CDCl3. 
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Figure 4.36. 400 MHz 1H NMR spectrum of 4.58 in CDCl3. 
 
Figure 4.37. 100 MHz 13C NMR spectrum of 4.58 in CDCl3. 
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Figure 4.38. 400 MHz 1H NMR spectrum of 4.59 in CDCl3. 
 
Figure 4.39. 100 MHz 13C NMR spectrum of 4.59 in CDCl3. 
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Figure 4.40. 400 MHz 1H NMR spectrum of 4.65 in CDCl3. 
 
Figure 4.41. 100 MHz 13C NMR spectrum of 4.65 in CDCl3. 
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Figure 4.42. 400 MHz 1H NMR spectrum of 4.66 in CDCl3. 
 
Figure 4.43. 100 MHz 13C NMR spectrum of 4.66 in CDCl3. 
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Figure 4.44. 400 MHz 1H NMR spectrum of 4.66 and 4.67 in CDCl3. 
 
Figure 4.45. 100 MHz 13C NMR spectrum of 4.66 and 4.67 in CDCl3. 
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Figure 4.46. 400 MHz 1H NMR spectrum of 4.97 in CDCl3. 
 
Figure 4.47. 100 MHz 13C NMR spectrum of 4.97 in CDCl3. 
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Figure 4.48. 400 MHz 1H NMR spectrum of 4.98 in CDCl3. 
 
Figure 4.49. 100 MHz 13C NMR spectrum of 4.98 in CDCl3. 
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Figure 4.50. 600 MHz 1H NMR spectrum of 4.70 in CDCl3. 
 
Figure 4.51. 150 MHz 13C NMR spectrum of 4.70 in CDCl3. 
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Figure 4.52. 600 MHz 1H NMR spectrum of 4.71 in CDCl3. 
 
Figure 4.53. 150 MHz 13C NMR spectrum of 4.71 in CDCl3. 
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Figure 4.54. 600 MHz 1H NMR spectrum of 4.82 in CDCl3.
 
Figure 4.55. 150 MHz 13C NMR spectrum of 4.82 in CDCl3. 
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Figure 4.56. 400 MHz 1H NMR spectrum of 4.75a in CDCl3.
 
Figure 4.57. 100 MHz 13C NMR spectrum of 4.75a in CDCl3. 
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Figure 4.58. 400 MHz 1H NMR spectrum of 4.75b in CDCl3. 
 
Figure 4.59. 100 MHz 13C NMR spectrum of 4.75b in CDCl3. 
11 10 9 8 7 6 5 4 3 2 1 0 ppm
220 200 180 160 140 120 100 80 60 40 20 0 ppm
OO
PMP H
H OH
H
4.75a
 169 
 
Figure 4.60. 600 MHz 1H NMR spectrum of 4.76 in CDCl3.
 
Figure 4.61. 150 MHz 13C NMR spectrum of 4.76 in CDCl3. 
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Figure 4.62. 400 MHz 1H NMR spectrum of 4.80 in CDCl3. 
 
Figure 4.63. 100 MHz 13C NMR spectrum of 4.80 in CDCl3. 
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Figure 4.64. 600 MHz 1H NMR spectrum of 4.77 in CDCl3.
 
Figure 4.65. 150 MHz 13C NMR spectrum of 4.77 in CDCl3. 
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Figure 4.66. 600 MHz 1H NMR spectrum of epi-4.77 in CDCl3.
 
Figure 4.67. 150 MHz 13C NMR spectrum of epi-4.77 in CDCl3. 
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Figure 4.68. 600 MHz 1H NMR spectrum of 4.81 in CDCl3.
 
Figure 4.69. 150 MHz 13C NMR spectrum of 4.81 in CDCl3. 
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Figure 4.70. 600 MHz 1H NMR spectrum of 4.79 in CDCl3.
 
Figure 4.71. 150 MHz 13C NMR spectrum of 4.79 in CDCl3. 
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Figure 4.72. 600 MHz 1H NMR spectrum of 4.78 in CDCl3.
 
Figure 4.73. 150 MHz 13C NMR spectrum of 4.78 in CDCl3. 
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Figure 4.74. 600 MHz 1H NMR spectrum of 4.87 in CDCl3. 
 
Figure 4.75. 150 MHz 13C NMR spectrum of 4.87 in CDCl3. 
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Figure 4.76. 600 MHz 1H NMR spectrum of 4.89 in CDCl3. 
 
Figure 4.77. 150 MHz 13C NMR spectrum of 4.89 in CDCl3. 
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Figure 4.78. 600 MHz 1H NMR spectrum of 4.92 in CDCl3. 
 
Figure 4.79. 150 MHz 13C NMR spectrum of 4.92 in CDCl3. 
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CHAPTER 5  
 
FUTURE WORK TOWARD UPENAMIDE TOTAL SYNTHESIS 
 
Accessing Cyclic Imine via an Alternative Condensation and Cyclization 
With advanced intermediate 5.3 in hand, we can access our desired cyclic imine 
via the cyclization of an imine bearing a nitrogen radical on to the terminal alkene and 
subsequent ring expansion (Scheme 5.1). 
 
 
Scheme 5.1. Retrosynthetic Approach to Cyclic Imine 5.1. 
 
Imines bearing radically labile groups (5.5) can be easily prepared via 
condensation of the corresponding amine and aldehyde 5.4 (Scheme 5.2). The predicted 
primary radical resulting from the 5-exo cyclization (5.6) would then undergo further 
cyclization to form the 3,5-ring system and a rearrangement to give the 6-endo 
cyclization product 5.1.89 
 
                                                
89 a) Portela-Cubillo, F.; Scott, J. S.; Walton, J. C. Chem. Commun. 2007, 4041-4043. b) Gagosz, F.; Zard, 
S. Z. Synlett 1999, 12, 1978-1980. c) Lin, X.; Stien, D.; Weinreb, S. M. Org. Lett. 1999, 1, 637-639. 
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Scheme 5.2. Accessing Cyclic Imine 5.1 Via Radical Cyclization. 
 
N-Bromosuccinimide could also be used to access 6-endo cyclization product 
5.11 via cyclic bromonium intermediate 5.9 (Scheme 5.3).90 The resulting hydroxy 
substitution at the γ-position to the imine could be deoxygenated via Barton-McCombie 
or Markó-Lam deoxygenation procedures. 
 
 
Scheme 5.3. Accessing Cyclic Imine 5.11 Via Alkene Activation with Bromine. 
 
The desired 6-endo cyclization product, 5.1, could also be accessed via a gold 
catalysis route developed by Nevado and coworkers (Scheme 5.4).91 Treatment of N-
tosyl-4-pentenyl amine (5.12) with cationic [(Ph3P)AuSbF6], Selectfluor, and sodium 
hydrogen carbonate in acetonitrile and water gave amino alcohols 5.13 and 5.14 in a ratio 
of 1:9, respectively, favoring the 6-endo product. They propose that the preference for the 
                                                
90 a) De Kimpe, N.; Boelens, M.; Contreras, J. Tetrahedron Lett. 1996, 37, 3171-3174. b) Stevens, C. V.; 
Peristeropoulou, M.; De Kimpe, N. Tetrahedron, 2001, 57, 7865-7870. c) Schley, D.; Liebscher, J. Eur. J. 
Org. Chem. 2007, 2945-2957. 
91 de Haro, T.; Nevado, C. Angew. Chem. Int. Ed. 2011, 50, 906-910. 
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6-endo product (5.14) over the 5-exo product (5.13) is due to the ability of the stabilized 
gold coordinated intermediate 5.16 to undergo intramolecular reductive elimination to 
give 5.17, which then gives the 6-membered product (5.14) upon nucleophilic 
displacement.  
 
 
Scheme 5.4. Gold Catalyzed Cyclization to the 6-Endo Product 5.14. 
 
To apply this methodology to our synthesis, we would access the N-tosyl amine 
via reductive amination and utilize the Nevado method to access the 6-membered amino 
alcohol. From there, dehydration, deprotection, and alkene isomerization would give the 
cyclic imine (Scheme 5.5). 
 
 
Scheme 5.5. Proposed Gold Cyclization to Access 6-Endo Product 5.1. 
 
Alternatively, we envision accessing first the A ring, followed by installation of 
the spirocyclic B ring (Scheme 5.6). Dihydrooxazinone A ring 5.21 can be accessed via 
formal [4+2] from imine 5.2. The hemiaminal nitrogen could then be cyclized on to the 
alkene to give the B ring product 5.20. 
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Scheme 5.6. Retrosynthetic Approach to the ABC Tricycle 5.15. 
 
Starting from aldehyde 5.4, imine 5.2 could be accessed via condensation with an 
amine (Scheme 5.7). Formal [4+2] cyclization of imine 5.2 with acyl ketene 5.17 (see 
Chapter 4) will give dihydrooxazinone 5.16. Gold cyclization would then provide 
spirocyclic ABC tricycle 5.15.91,92 Yield of the 6-endo cyclization product can be 
optimized by the screening of amine R groups to favor gold intermediate ring expansion. 
 
 
Scheme 5.7. Accessing the ABC Spirocycle 5.20. 
 
With these routes to the spirocyclic B ring we will be able to access 
dihydrooxazinone 5.23 via dehydration and deprotection from 5.20 or formal [4+2] 
cycloaddition from 5.1 and 5.22 (Scheme 5.8). From there, we will access our two 
synthetic diastereomers of upenamide (5.25) according to our previously outlined 
retrosynthetic analysis (Scheme 5.9). 
                                                
92 Chi, Y.-J.; Yu, H.-T. Computational and Theoretical Chem. 2013, 52-57. 
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Scheme 5.8. Retrosynthetic Approach to Dihydrooxazinone 5.23. 
 
 
Scheme 5.9. Retrosynthetic Approach to the Completion of Upenamide (5.25). 
 
Upon accessing the two synthetic diastereomers of upenamide we will be able to 
establish the overall structure of natural (-)-upenamide (Figure 5.1). 
 
 
Figure 5.1. Establishing the Structure of Natural (-)-Upenamide. 
 
Our strategy for structural elucidation is to access the two synthetic diastereomers 
via racemic spirocyclic ABC tricycle, but it is also in our interest to develop an 
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enantiopure route to the tricycle so as to access large amounts of the correct structure of 
natural (-)-upenamide (5.18) for biological evaluation. 
 
Toward an Enantiopure Bromomaleic Anhydride Diels-Alder Product 
We have made preliminary efforts toward an unprecedented enantioselective 
Diels-Alder with bromomaleic anhydride (Figure 5.2). With this selective Diels-Alder 
established, we would have a method for accessing large quantities of the correct 
structure of upenamide (5.25) in an enantioselective manner.  
We propose two methods by which we may impart selectivity for one Diels-Alder 
enantiomer over the other (Figure 5.2). Selectivity could be imparted using a Corey-
Bakshi-Shibata (CBS) catalyst (5.29)93 via coordination of the boron to the oxygen of 
bromomaleic anhydride (5.26). A hydrogen-bonding interaction between the α-hydrogen 
and the CBS ether would then sterically control the approach of the diene. Another 
approach would be to employ BOX ligand catalysts coordinated to a bromophilic metal 
center.94 The central metal atom would situate itself between the anhydride oxygen and 
the bromine and the ligand would sterically inhibit the approach of the diene from one 
face. 
 
                                                
93 a) Ryu, D. H.; Zhou, G.; Corey, E. J. J. Am. Chem. Soc. 2004, 126, 4800-4802. b) Corey, E. J. Angew. 
Chem. Int. Ed. 2009, 48, 2100-2117. 
94 a) Evans, D. A.; Barnes, D. A.; Johnson, J. S.; Lectka, T.; von Matt, P.; Miller, S. J.; Murry, J. A.; 
Norcross, R. D.; Shaughnessy, E. A.; Campos, K. R. J. Am. Chem. Soc. 1999, 121, 7582-7594. b) 
McManus, H. A.; Guiry, P. J. Chem. Rev. 2004, 104, 4151-4202. c) Hargaden, G. C.; Guiry, P. J. Chem. 
Rev. 2009, 109, 2505-2550. 
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Figure 5.2. Enantioselective Diels-Alder Approach. 
 
Our initial attempts at assessing enantiomeric excess proved difficult, as the solid 
product was not amenable to chiral column assays. Therefore, a method for forming 
diastereomers of the Diels-Alder adduct was developed to circumvent the solubility 
problems encountered. Derivatizing the anhydride with Ender’s (S)-(−)-1-amino-2-
(methoxymethyl)pyrrolidine95 (SAMP) would provide a method by which we could infer 
enantioselectivity by evaluating the diastereomeric ratio of (+)-5.28 and (-)-5.28 by NMR 
(Scheme 5.10). Unfortunately, treatment of our racemic Diels-Alder adduct 5.28 with 
SAMP led to elimination of bromine followed by aromatization to give 5.29 instead of 
giving diastereomers 5.30a and 5.30b.  
 
 
Scheme 5.10. Attempts at Accessing SAMP Diastereomers 5.30a and 5.30b. 
 
                                                
95 Lebrun, S.; Couture, A.; Deniau, E.; Grandclaudon, P. Tetrahedron: Asymm. 2003, 14, 2625-2632. 
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Consequently, we moved forward with a model system using cyclopentadiene 
(5.31) and bromomaleic anhydride (5.26) (Scheme 5.11). We were able to obtain the 
SAMP diastereomers 5.33a and 5.33b of this catalyzed Diels-Alder adduct and assess the 
enantiomeric excess by NMR analysis. 
 
 
Scheme 5.11. Diels-Alder Model System. 
 
Preliminary efforts at enantioselection were not successful (Table 5.1). Several 
metal centers were screened with the BOX ligands (5.34) at varying temperatures with 
only moderate results (entries 1-3). Moving forward, several Lewis acid activators of the 
CBS catalyst (5.29) were screened at several temperatures with comparable success 
(Table 5.1, entries 4-14). We discovered that both TBS dienyl ether (5.27) and 
cyclopentadiene were acid sensitive. Prolonged treatment with catalyst conditions led to 
diene decomposition and lower yields of the Diels-Alder cycloadduct, due to production 
of the bromine elimination side product (5.29). We were interested to see if we could get 
enantioselection using a TADDOL catalyst (5.35),96 by taking advantage of H-bonding 
interactions to impart selectivity and eliminate any side reactions due to the acidity of the 
catalyst. However, this was unsuccessful and provided no enantioselection (Table 5.1, 
entries 15-18). We next investigated BOX ligands developed by the Ishihara group97 
(5.36, 5.37, and 5.38). Ishihara and coworkers add heteroatom-containing side chains to 
                                                
96 Thadani, A. N.; Stankovic, A. R.; Rawal, V. H. Proc. Natl. Acad. Sci. 2004, 101, 5846-5850. 
97 Sakakura, A.; Kondo, R.; Matsumura, Y.; Akakura, M.; Ishihara, K. J. Am. Chem. Soc. 2009, 131, 
17762-17764. 
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BOX ligands to effectively reduce the Lewis acidity of metal by donating their lone-pair 
electrons to the metal center. These catalysts provided only a modest yield (Table 5.1, 
entries 19-21). 
 
Table 5.1. Conditions Screened to Optimize the Diels-Alder. 
 
 
Moving forward, we propose using a maleic anhydride substituted with either a 
nitro group (5.40) or a xanthate group (5.39) to better coordinate to the metal center of 
the BOX ligands, but still provide a radically-labile handle appropriate for Keck 
allylation.  
 
entry ligand Lewis	acid catalyst	load	(mol	%) temperature %	yield dr
b %	eec
1 5.35 CuCl2,	AgSbF6 20 −20	°C 81 1:1 0
2 5.35 FeCl2,	I2 20 −20	°C 96 1:1.5 20
3 5.35 Cu(OTf)2 20 −20	°C 98 1:1.3 13
4 CBS NH(Tf)2 20 0	°C 33 1:1.2 9
5 CBS NH(Tf)2 20 −10	°C 99 1:1.5 20
6 CBS NH(Tf)2 20 −20	°C 96 1:1.6 23
7 CBS NH(Tf)2 20 −40	°C 91 1:1.6 23
8 CBS NH(Tf)2 20 −40	°C	d 98 1:1.3 13
9 CBS NH(Tf)2 20 −40	°C	d 41 1:1.3 13
10 CBS AlBr3 20 −40	°C	d 98 1:1.2 9
11 CBS TfOH 20 −40	°C	d 10e - -
12 CBS BF3OEt2 20 −40	°C	d 37 1:1.2 9
13 CBS TiCl4 20 −40	°C	d 83 1:1.1 6
14 CBS NH(Tf)2 20 −40	°C	d 98 1:1.1 6
15 TADDOL - 20 0	°C 40 1:1 0
16 TADDOL - 20 −10	°C 30 1:1 0
17 TADDOL - 20 −20	°C 48 1:1 0
18 TADDOL - 20 −40	°C 32 1:1 0
19 5.36 Cu(OTf)2 10 −20	°C	d 98 1:1.2 9
20 5.37 Cu(OTf)2 10 −20	°C	d 65 1:1.3 13
21 5.38 Cu(OTf)2 10 −20	°C	d 92 1:1.4 21
a	all	reactions	were	run	on	a	0.10	mmol	scale	at	0.1	M	in	dichloromethane	and	
under	the	conditions	listed.	b	dr	of	the	SAMP	derivative.	c	calculated	based	on	dr	
values.	d	the	Lewis	acid	was	added	dropwise	over	the	course	of	the	reaction.																											
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Scheme 5.12. Future Catalysis Direction. 
 
Alternatively, we envision using the Diels-Alder developed by Dr. Luo starting 
with bromofuranone 5.43 (Scheme 5.13). In this case enantioselection can be imparted by 
adding a chiral auxiliary to the free alcohol of 5.34. 
 
 
Scheme 5.13. An Alternative Approach to an Enantioselective Diels-Alder. 
 
With this chemistry developed, we will have a scalable and enantiomerically pure 
method to access the proposed structure of upenamide. 
 
Experimental Methods 
General procedure: All reactions were performed in flame-dried or oven dried round-
bottomed flasks under an atmosphere of argon unless otherwise noted. Stainless steel 
syringes or cannula were used to transfer air- and moisture-sensitive liquids. Reaction 
temperatures were controlled using a thermocouple thermometer and analog hotplate 
stirrer. Reactions were conducted at room temperature (approximately 22 °C) unless 
otherwise noted. Flash column chromatography was conducted as described Still et. al. 
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using silica gel 230-400 mesh.64 Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV light (254 nm) 
and ceric ammonium molybdate, potassium permanganate, or anisaldehyde stains. Yields 
were reported as spectroscopically pure compounds.  
Materials. Reagents and solvents used were of commercial grade and purified prior to 
use when necessary. Tetrahydrofuran, toluene, and dichloromethane were obtained from 
either an MBraun MB-SPS solvent system, where they were dried using activated 
alumina columns, or freshly distilled (tetrahydrofuran and ether were both distilled from 
sodium metal with benzophenone indicator), and when necessary solvents were further 
dried over activated 4 Å molecular sieves under an atmosphere of argon. Triethylamine 
was distilled from calcium hydride and stored over sodium hydroxide. The molarity of 
commercial n-butyllithium solutions was determined by titration using 2,2,2′-
Trimethylpropionanilide65 as an indicator (average of three determinations). 
Instrumentation. Nuclear magnetic resonance (NMR) spectra were acquired on Bruker 
DRX-400 (400 MHz), DRX-500 (500 MHz), or (600 MHz) spectrometers and are 
reported relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16; MeOD: 3.31). 
Data for 1H NMR spectra are reported as follows: chemical shift d (ppm), multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septet, m = multiplet, br = 
broad singlet, app = apparent). Infrared (IR) spectra were obtained as thin films on NaCl 
plates using a Thermo Electron IR100 series spectrophotometer and are reported in 
wavenumbers (cm-1). High-resolution mass spectra were obtained from the Department 
of Chemistry and Biochemistry, University of Notre Dame using a microTOF QII mass 
spectrometer. Optical rotations were measured on a Perkin-Elmer 341 digital polarimeter 
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at ambient temperature (zeroed with pure, solvent-grade chloroform). X-ray crystal 
structures were obtained from the X-ray Diffraction Laboratory in the Department of 
Chemistry at Texas A & M University using a Bruker single-crystal APEXii CCD 
Diffractometer. 
 
5.29. Dissolved racemic anhydride 5.28 (100 mg, 0.277 mmol) in DCM 
(350 µL) and added SAMP (37 µL, 0.277 mmol) dropwise and let 
reaction stir 1 h. Then sodium acetate (3 mg) and acetic acid (40 µL, 
0.416 mmol) were added and reaction was refluxed for 5 h. The reaction was then cooled 
to 0 °C and quenched with 5% aqueous sodium bicarbonate (3 mL) and let stir at 0 °C for 
30 min. Then mixture was extracted with DCM, and the combined organic layers were 
dried (MgSO4), concentrated, and the residue was purified by flash chromatography 
(SiO2, 30% ethyl acetate, hexanes) to yield phthalimide 5.29 (34 mg, 48%) as a light 
yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.02 (dd, 2H, J = 5.56, 3.08), 7.91 (dd, 2H, J = 
5.62, 3.02), 7.82 (dd, 2H, J = 5.46, 3.06), 7.71 (dd, 2H, J = 5.48, 3.08), 3.86 (quint, 1H, J 
= 6.99), 3.59 (q, 1H, J = 8.16), 3.39 (d, 2H, J = 5.80), 3.37-3.31 (m, 1H), 3.18 (s, 3H),  
2.16-1.89 (m, 4H), 1.73-1.63 (2H). 13C NMR (150 MHz, CDCl3) δ 167.6, 162.9, 136.2, 
134.2, 131.4, 130.5, 125.8, 123.3, 76.2, 61.3, 59.2, 52.7, 29.8, 27.1, 22.5. 
 
(±)-5.32. Cyclopentadiene (5.31) (232 µL, 2.83 mmol) was added 
to bromomaleic anhydride (5.26) (131 µL, 1.413) in toluene (3.5 
mL) and the reaction was heated to 120 °C in a sealed tube for 1 h. Reaction was 
concentrated and the residue was purified by recrystallization in hexanes to yield adduct 
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(±)-5.32 (379 mg, 100%) as a white solid. M.P. 100-106 °C; IR (neat) νmax = 2975, 1866, 
1787. 1H NMR (400 MHz, CDCl3) δ 6.40 (dd, 1H, J = 5.70, 2.78), 6.34 (dd, 1H, J = 5.52, 
3.08), 3.75 (d, 1H, 4.60), 3.57-3.53 (m, 2H), 2.27 (d, 1H, J = 9.56), 2.12 (dt, 1H, J = 9.56, 
1.54). 13C NMR (100 MHz, CDCl3) δ 168.2, 168.0, 137.6, 135.5, 58.0, 57.9, 55.1, 52.1, 
47.3. HRMS (ESI) calc’d for C9H7BrO3 [M+H]+: 242.9579, found 242.9677. 
 
5.33a and 5.33b. 98  Dissolved racemic 
cyclopentadiene adduct (±)-5.32 (100 mg, 0.411 
mmol) in DCM (550 µL) and added (S)-1-amino-2-
methoxymethylpyrrolidine (55 µL, 0.411 mmol) dropwise and let reaction stir one h. 
Then sodium acetate (3 mg) and acetic anhydride (58 µL, 0.617 mmol) were added and 
reaction was refluxed for 5 h. The reaction was then cooled to 0 °C and quenched with 
5% aqueous sodium bicarbonate (3 mL) and let stir at 0 °C for 30 min. Then mixture was 
extracted with DCM  (3 x 4 mL), and the combined organic layers were dried (MgSO4), 
concentrated, and the residue was purified by flash chromatography (SiO2, 30% ethyl 
acetate, hexanes) to yield a 1:1 mixture of pyrrolidines diastereomers 5.33a and 5.33b 
(83.2 mg, 57%) as a light yellow oil. IR (neat) νmax = 2924, 2876, 1785, 1721, 1453. 1H 
NMR (400 MHz, CDCl3) δ 6.22-6.18 (m, 1H), 6.19-6.17 (m, 1H), 3.69-3.361 (m, 1H), 
3.50-3.48 (m, 1H), 3.47-3.43 (m, 1H), 3.40 (dd, 1H, J = 4.56, 1.80), 3.29 (s, 1.5H), 3.28 
(s, 1.5H), 3.30-3.28 (m, 1H), 3.28-3.25 (m, 2H), 3.13 (ddd, 1H, J = 8.06, 8.06, 4.30), 2.20 
(d, 1H, J = 9.3), 2.05 (dp, 1H), 2.02 (dd, 1H, J = 9.33, 1.35), 1.96 (dp, 1H), 1.87 (dt, 1H), 
1.61 (dt, 1H). 13C NMR (100 MHz, CDCl3) δ 173.5, 172.6, 136.7, 134.7, 76.0, 61.0, 59.2, 
                                                
98 Lebrun, S.; Couture, A.; Deniau, E.; Grandclaudon, P. Tetrahedron: Asymm. 2003, 14, 2625-2632. 
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57.6, 55.2, 54.2, 51.8, 51.1, 46.2, 27.3, 22.8. HRMS (ESI) calc’d for C15H19BrN2O3 
[M+H]+: 355.0579, found 355.0668.  
 
General Procedure for the CBS Catalyzed Enantioselective Diels-Alder Reaction 
Using TF2NH, AlBr3, BF3•OEt2, TiCl4, or TfOH. (S)-(−)-o-Tolyl-CBS-oxazaborolidine 
(0.5 M in toluene, 0.055 mmol) was cooled to 0 °C and TF2NH (13 mg, 0.046 mmol), 
AlBr3 (12 mg, 0.046mmol), BF3•OEt2 (6 µL, 0.046 mmol), TiCl4 (5 µL, 0.046 mmol), or 
TfOH (4 µL, 0.046 mmol) in DCM (315 µL) was added dropwise and mixture was 
stirred 10 min at 0 °C. Bromomaleic anhydride (20.4 µL, 0.22 mmol) was added to CBS 
catalyst mixture and was let stir 10 min before cooling to reaction temperature. 
Cyclopentadiene was added portion-wise over a 10 h period (36 µL, 0.44 mmol every 2 
h). After which time reaction was let stir additional 8 h. The reaction was then quenched 
with water (2 mL) and purified directly by flash chromatography (SiO2, 10% hexanes, 
ethyl acetate) to give adduct 5.32. Enantiomeric excess was calculated via formation of 
the (S)-1-amino-2-methoxymethylpyrrolidine diastereomers 5.33a and 5.33b (see above 
procedure). Spectral data matched those reported above for the racemic synthesis. 
 
General Procedure for the TADDOL Catalyzed Enantioselective Diels-Alder 
Reaction. TADDOL (75.0 mg, 0.113 mmol), and bromomaleic anhydride (52.0 µL, 
0.565 mmol) were added to toluene (800 µL) and was let stir 10 min before cooling to 
reaction temperature. Cyclopentadiene was added portion-wise over a 10 h period (92.7 
µL, 1.13 mmol every 2 h). After which time reaction was let stir additional 8 h. The 
reaction was then concentrated and the residue was purified by flash chromatography 
 193 
(SiO2, 5% hexanes, ethyl acetate) to give adduct 5.32. Enantiomeric excess was 
calculated via formation of the (S)-1-amino-2-methoxymethylpyrrolidine diastereomers 
5.33a and 5.33b (see above procedure). Spectral data matched those reported above for 
the racemic synthesis. 
 
General Procedure for the BOX Catalyzed Enantioselective Diels-Alder Reaction 
Using Cu(OTf)2, AgSbF6, or FeCl2, I2. Cu(OTf)2 (19.3 mg, 0.0535 mmol), AgSbF6 
(18.4 mg, 0.0535 mmol), or FeCl2 (6.78 mg, 0.0535 mmol) and I2 (6.78 mg, 0.0268 
mmol) and ligand (0.531 mmol) were combined and anhydrous DCM (5 mL) was added. 
The solution was stirred for 1 h. This formed a homogeneous, blue or green solution of 
the ligand complex. Bromomaleic anhydride (49.7 µL, 0.535 mmol) was added to BOX 
catalyst mixture and was let stir 10 min before cooling to reaction temperature. 
Cyclopentadiene was added portion-wise over a 10 h period (88 µL, 1.07 mmol every 2 
h). After which time reaction was let stir additional 8 h. The reaction was then quenched 
with water (2 mL) and purified directly by flash chromatography (SiO2, 10% hexanes, 
ethyl acetate) to give adduct 5.32. Enantiomeric excess was calculated via formation of 
the (S)-1-amino-2-methoxymethylpyrrolidine diastereomers 5.33a and 5.33b (see above 
procedure). Spectral data matched those reported above for the racemic synthesis. 
 
5.46. L-threoninol (1.00 g, 9.51 mmol), dimethylmalonitrile (358 
mg, 3.804 mmol), and cadmium diacetate dihydrate (51 mg, 0.190 
mmol) were refluxed 16 h in chlorobenzene (13 mL). Reaction was concentrated and the 
N N
OO
MeMe
OHHO
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residue was purified by flash chromatography (SiO2, 9% methanol, DCM). The resulting 
solid residue was then recrystallized in diethyl ether, petroleum ether to yield hydroxyl 
BOX catalyst 5.46 (421 mg, 41%) as a white solid. Spectral data matched reported 
values.99 
 
5.36.100 Sodium hydride (60%, 37 mg, 0.925 mmol) was added to 
free hydroxyl BOX catalyst 5.46 (100 mg, 0.370 mmol) in THF (2 
mL), once bubbling stopped (approximately 2 min) dimethyl sulfate (80 µL, 0.836 mmol) 
was added dropwise and the reaction was let stir 1 h. Then diethyl ether (5 mL) and 25% 
aqueous ammonium hydroxide (3 mL) were added and let stir 10 min. The organics were 
then washed with 10% aqueous sodium hydroxide (4 mL), water (4 mL), brine (4 mL), 
and then dried (MgSO4) and concentrated. The residue was purified by flash 
chromatography (SiO2, 5:5:1 hexanes, ethyl acetate, methanol) to yield O-methyl BOX 
catalyst 5.36 (77.3 mg, 70%) as a light yellow oil. Spectral data matched reported 
values.101 
 
5.37. 102  Triethylamine (227 µL, 1.63 mmol) and then mesyl 
chloride (64 µL, 0.814 mmol) were added to free hydroxyl BOX 
catalyst 5.46 (100 mg, 0.370 mmol) in DCM (2.5 mL) at 0 °C. After 20 min the reaction 
was let warm to RT and stirred an additional 3 h.  Then the reaction was quenched with 
                                                
99 Sakakura, A.; Kondo, R.; Matsumura, Y.; Akakura, M.; Ishihara, K. J. Am. Chem. Soc. 2009, 131, 
17762-17764. 
100 Frölander, A.; Lutsenko, S.; Privalov, T.; Moberg, C. J. Org. Chem. 2005, 70, 9882-9891. 
101 Lutsenko, S.; Jacobsson, U.; Moberg, C. Syn. Comm. 2003, 33, 661-666. 
102 Aggarwal, V. K.; Coogan, M. P.; Stenson, R. A.; Jones, R. V. H. Fieldhouse, R.; Blacker, J. Eur. J. Org. 
Chem. 2002, 319-326. 
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saturated aqueous sodium bicarbonate (4 mL) and the organic layer was washed with 
brine (4 mL). The organics were then dried (MgSO4) and concentrated. The residue was 
purified by flash chromatography (SiO2, 5:5:1 hexanes, ethyl acetate, methanol) to yield 
O-mesyl BOX catalyst 5.37 (83.2 mg, 53%) as a white solid. Spectral data matched 
reported values.99 
 
5.38.102 Sodium hydride (60%, 3 mg, 0.0563 mmol) was added 
to methanesulfonamide (5 mg, 0.0563 mmol) in DMF (250 µL) 
at 0 °C and let stir 10 min. O-mesyl BOX catalyst 5.37 (20 mg, 0.0469 mmol) in DMF 
(250 µL) was added dropwise to the reaction mixture at 0 °C. After 20 min the reaction 
was heated to reflux and stirred an additional 16 h.  Then the reaction was concentrated 
and the residue was purified by flash chromatography (SiO2, 10:10:1 hexanes, ethyl 
acetate, methanol) to yield N-mesyl BOX catalyst 5.38 (25.2 mg, 81%) as a light yellow 
solid. Spectral data matched reported values.99 
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Figure 5.3. 600 MHz 1H NMR spectrum of 5.29 in CDCl3. 
 
Figure 5.4. 150 MHz 13C NMR spectrum of 5.29 in CDCl3. 
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Figure 5.5. 400 MHz 1H NMR spectrum of (±)-5.32 in CDCl3. 
 
Figure 5.6. 100 MHz 13C NMR spectrum of (±)-5.32 in CDCl3. 
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Figure 5.7. 600 MHz 1H NMR spectrum of 5.33a and 5.33b in CDCl3. 
 
Figure 5.8. 150 MHz 13C NMR spectrum of 5.33a and 5.33b in CDCl3. 
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Figure 5.9. 600 MHz 1H NMR spectrum of 5.46 in CDCl3.
 
Figure 5.10. 150 MHz 13C NMR spectrum of 5.46 in CDCl3. 
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Figure 5.11. 400 MHz 1H NMR spectrum of 5.36 in CDCl3. 
 
Figure 5.12. 100 MHz 13C NMR spectrum of 5.36 in CDCl3. 
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Figure 5.13. 600 MHz 1H NMR spectrum of 5.37 in CDCl3. 
 
Figure 5.14. 150 MHz 13C NMR spectrum of 5.37 in CDCl3. 
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Figure 5.15. 400 MHz 1H NMR spectrum of 5.38 in CDCl3. 
 
  
10 9 8 7 6 5 4 3 2 1 ppm
N N
OO
MeMe
NHMsMsHN 5.38
 203 
CHAPTER 6  
 
THE DISCOVERY OF SMALL MOLECULES CAPABLE OF ALTERING THE 
HUMAN CIRCADIAN RHYTHM 
 
The discovery of new targets for the treatment of diseases requires the 
understanding of the relationship between small molecules, the phenotypic change they 
cause, and a genetic variation implicated in the disease. As we search for new drug 
candidates and probe poorly understood biological systems the use of small molecules 
becomes significant as they can provide quick access to these new biological targets.103 
This chapter will include a discussion of an ongoing collaborative project with the lab of 
Dr. Carl H. Johnson to elucidate the biological mechanism of the circadian rhythm and 
provide insight into possible treatments for circadian-related disease. 
 
Background and Significance of the Biological Clock 
In mammals, the circadian rhythm is observed as any natural process that occurs 
with an approximate 24-hour cycle. They are endogenous and self-sustained but they are 
influenced by external environmental cues such as light/dark cycles. The circadian clock 
registers these cues and translates them into biological signals in order to maintain the 
synchrony of metabolic processes at the tissue level affecting the sleep/wake cycle, 
                                                
103 Workman, P.; Collins, I. Chemistry & Biology. 2010, 17, 561-577. 
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metabolism, body temperature, hormone secretion, and immune function, among other 
important processes. 104 
Chronic circadian misalignment and circadian sleep disorders are increasingly 
common problems. Circadian dyssynchrony occurs when a person’s professional or 
social life and their sleep/wake patterns are out of sync with the environment cues that 
signal metabolic processes. Chronic misalignment of the circadian rhythm, often due to 
shift work, can result in chronic disruption of the temporal organization of their metabolic 
processes and chronic dyssynchrony can result in adverse cardiometabolic effects, 
gastrointestinal disorders, and the increased risk of developing some types of cancer.105 
On the other hand, transient misalignment, most commonly experienced due to jetlag, is 
associated with fatigue, irregular sleep patterns, insomnia, disorientation, and 
irritability.106  
The circadian clock that drives the circadian rhythm is an internal timekeeping 
mechanism that regulates the body’s natural processes independent of the cell cycle by 
synchronizing hormone secretion and protein translation resulting in the regulation of 
various processes including the regulation of body temperature, heart rate, metabolism, 
sensory function, and reproduction.107 The circadian clock in mammals is organized in a 
hierarchical manner. Peripheral clocks are located in the organs and regulate local 
rhythmic outputs. The master clock, located in the suprachiasmatic nucleus (SCN) of the 
                                                
104 Mohawk, J. A.; Green C. B.; Takahashi J. S. Ann. Rev. Neurosci. 2012, 35, 445-462. 
105 a) Boivin D. B.; Tremblay G. M.; James F. O. Sleep Med. 2008, 8, 578-589. b) Foster R. G.; Wulff K. 
Nat. Rev. Neurosci. 2005, 6, 407-414. c) Scheer F. A.; Hilton M. F.; Mantzoros C. S.; Shea S. A. Proc. 
Natl. Acad. Sci. 2009, 106, 4453-4458. d) Buxton O. M.; Cain S. W.; O'Connor S. P.; Porter J. H.; Duffy J. 
F.; Wang W.; Czeisler C. A.; Shea S. A. Sci. Transl. Med. 2012, 4, 129-143. e) Hanlon E. C.; Van Cauter 
E. Proc. Natl. Acad. Sci. 2011, 108, 15609-15616. 
106 Sack R. L. N. Engl. J. Med. 2010, 362, 440-447. 
107 Dunlap, J. C.; Loros, J. J.; DeCoursey, P. J. Chronobiology: Biological Timekeeping 2004, (Sunderland, 
M. A.: Sinauer Associates). 
 205 
hypothalamus in the brain, coordinates the peripheral clocks resulting in the overall 
coordinated function of the body. The master clock is a self-sustained, endogenous 
oscillator and it is responsible for the processing of temporal information from the 
environment and adjusting the pace of the clock and then communicating that 
information throughout the body to maintain synchrony at all levels.108 
The molecular mechanism that drives the circadian clock at the cellular level 
consists of transcriptional/translational feedback loops that result in the regulation of 
biological rhythms of specific clock proteins in a manner that coincides with external 
cues.109 In the core feedback loop (Figure 6.1) two proteins, BMAL (brain and muscle 
ARNT-like protein) and CLOCK (circadian locomotor output cycles kaput), 
heterodimerize and translocate into the nucleus where they initiate the transcription of 
target genes Period and Cryptochrome. PER (period) and CRY (Cryptochrome) proteins 
heterodimerize inhibiting the transcriptional activity of the CLOCK:BMAL complex. In 
addition, the PER:CRY protein complex is targeted for degradation via phosphorylation 
thereby decreasing the inhibition of CLOCK:BMAL and restarting the cycle. Without the 
activator complex, CLOCK:BMAL, acting on the promoters of the per and cry genes, the 
levels of PER and CRY proteins decline causing disruption in the 24-hour circadian 
cycle.  
 
                                                
108 a) Yamazaki, S.; R. Numano, M.; Abe, A.; Hida, R.; Takahashi, M.; Ueda, G. D.; Block, Y.; Sakaki, M.; 
Menaker, M.; Tei, H. Science 2000, 288, 682-685. b) Yoo, S. H.; Yamazaki. S.; Lowrey, P. L.; Shimomura, 
K.; Ko, C. H.; Buhr, E. D.; Siepka, S. M.; Hong, H. K.; Oh, W. J.; Yoo, O. J.; Menaker, M.; Takahashi, J. 
S. Proc. Natl. Acad. Sci. 2004, 101, 5339-5346. c) Mohawk, J. A.; Green, C. B.; Takahashi, J. S. Ann. Rev. 
Neurosci. 2012, 35, 445-462. 
109 a) Balsalobre A.; Damiola F.; Schibler U. Cell 1998, 93, 929-937. b) Izumo, M.; Johnson, C. H.; 
Yamazaki, S. Proc. Natl. Acad. Sci. 2003, 100, 16089-16094. c) Dunlap, J. C. Cell 1999, 96, 271-290; d) 
Reppert, S. M.; Weaver, D. R. Nature 2002, 418, 935-941. e) Ukai, H.; Ueda, H. R. Ann. Rev. Physiol. 
2010, 72, 579-603. 
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Figure 6.1. Diagram of the Circadian Clock Mechanism. 
 
In addition to the direct regulation of the transcription/translation feedback loop, 
there are accessory feedback loops that can inhibit or facilitate the core feedback loop 
(Figure 6.1). An accessory feedback loop regulates the expression of Bmal gene. The 
BMAL:CLOCK heterodimer also initiates the transcription of REV-ERBα and Rorα 
genes. REV-ERBα protein quickly accumulates and translocate into the nucleus, where it 
represses Bmal1 transcription. Later, REV-ERBα repressor activity declines as a 
consequence of the PER:CRY protein complex repressor activity on CLOCK:BMAL1 
heterodimer. RORA, which accumulates more slowly in the cytoplasm, translocates into 
the nucleus to activate Bmal transcription, restarting the circadian feedback loop.110 
Posttranslational modifications of circadian clock proteins are also an important 
factor in the robustness of the circadian cycle. Modifications, phosphorylation, 
ubquitination, and acetylation contribute to protein stability and protein degradation, 
ultimately altering the circadian cycle by inhibiting the negative feedback loop of the 
                                                
110 Dickmeis, T. J Endocrinology 2008, 200, 3-22. 
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PER:CRY protein heterodimer (Figure 6.1).111 Targeting these interactions in a selective 
manner using small molecules may be an efficient way to positively affect the circadian 
clock to improve health outcomes for people with chronic or temporal disruption of 
circadian synchrony. Additionally, as the role of the circadian clock in physiology is not 
well established, the discovery of small molecule modifiers that alter circadian function 
will also provide a better understanding of circadian-associated diseases.112 
 
Identification of Small Molecules Capable of Altering the Circadian Rhythm 
Utilizing a High-Throughput Screening Platform 
To better understand the human circadian cycle research in this field has led to the 
development of cell-based high-throughput screening systems that have allowed for the 
efficient screening of chemical libraries and the identification several drugs-like 
molecules capable of altering period length, phase or amplitude of the molecular clock 
were made.113  
                                                
111 a) Eide, E. J.; Woolf, M. F.; Kang, H.; Woolf, P.; Hurst, W.; Camacho, F.; Vielhaber, E. L.; Giovanni, 
A.; Virshup, D. M. Mol. Cell. Biol. 2005, 25, 2795-2807. b) Etchegaray, J. P.; Lee, C.; Wade, P. A.; 
Reppert, S. M. Nature 2003, 421, 177-182. c) Brown, S. A.; Kowalska, E; Dallmann, R. Dev. Cell 2012, 
22, 477-487. d) Eide, E. J.; Vielhaber, E. L.; Hinz, W. A.; Virshup, D. M. J. Biol. Chem. 2002, 277, 17248-
17254l. e) Doi, M.; Hirayama, J.; Sassone-Corsi, P. Cell 2006, 125, 497-508. 
112 Liu, A. C.; Lewis, W. G.; Kay, S. A. Nat. Chem. Bio. 2007, 3, 630-639. 
113 a) Antoch, M. P.; Chernov, M. V. Mutat. Res. 2009, 679, 17-23. b) Isojima, Y.; Nakajima, M.; Ukai, H.; 
Fujishima, H.; Yamada, R. G.; Masumoto, K. H.; Kiuchi, R.; Ishida, M.; Ukai-Tadenuma, M.; Minami, Y.; 
Kito, R.; Nakao, K.; Kishimoto, W.; Yoo, S. H.; Shimomura, K.; Takao, T.; Takano, A.; Kojima, T.; Nagai, 
K.; Sakaki, Y.; Takahashi, J. S.; Ueda, H. R. Proc. Natl. Acad. Sci. 2009, 106, 15744-15749. c) Hirota, T.; 
Lee, J. W.; St. John, P. C.; Sawa, M.; Iwaisako, K.; Noguchi, T.; Pongsawakul, P. Y.; Sonntag, T.; Welsh, 
D. K.; Brenner, D. A.; Doyle III, F. J.; Schultz, P. G.; Kay, S. A. Science 2012, 337, 1094-1097. d) Lee, J. 
W.; Hirota, T.; Peters, E. C.; Garcia, M.; Gonzalez, R.; Cho, C. Y.; Wu, X.; Schultz, P. G.; Kay, S. A. 
Angew. Chem. Int. Ed. 2011, 50, 10608-10611. e) Hirota, T.; Lee, J. W.; Lewis, W. G.; Zhang, E. E.; 
Breton, G.; Liu, X.; Garcia, M.; Peters, E. C.; Etchegaray, J. P.; Traver, D.; Schultz, P. G.; Kay, S. A. PLoS 
Biol. 2010, 8, e1000559. f) Hirota, T.; Lewis, W. G.; Liu, A. C.; Lee, J. W.; Schultz, P. G.; Kay, S. A. 
Proc. Natl. Acad. Sci. 2008, 105, 20746-20751. g) Chen, Z.; Yoo, S. H.; Park, Y. S.; Kim, K. H.; Wei, S.; 
Buhr, E.; Ye, Z. Y.; Pan, H. L.; Takahashi, J. S. Proc. Natl. Acad. Sci. 2012, 109, 101-106. h) 
Vougogiannopoulou, K; Ferandin, Y.; Bettayeb, K.; Myrianthopoulos, V.; Lozach, O.; Fan, Y.; Johnson, C. 
H.; Magiatis, P.; Skaltsounis, A. L.; Mikros, E.; Meijer, L. J. Med. Chem. 2008, 51, 6421-6431. 
 208 
Utilizing these previously developed methods for cell-based high-throughput 
screening (HTS) 114 in search of new small molecules that manipulate the circadian 
rhythm in mammalian cells Vanderbilt’s HTS library of approximately 70,000 drug-like 
compounds was screened using Rat1 cells stably transfected with the Per2-dLuc 
bioluminescence reporter and several small molecule leads were identified. One of those 
lead compounds containing a novel phenazine scaffold 6.2 was found to produce a 
stronger long-period phenotype as compared to the other small molecule lead compounds 
(Figure 6.2). 
 
 
Figure 6.2. Top Hits for Small Molecules Producing a Period-Lengthening Phenotype. 
 
A library of small molecules was constructed around this phenazine scaffold 
according to Scheme 6.1. Buchwald-Hartwig coupling115 of nitro ester 6.9 and aniline 
followed by saponification gave biarylamine acid 6.11. Reductive cyclization with 
sodium borohydride and freshly prepared sodium methoxide in methanol upon irradiation 
                                                
114 Look, D. C.; Stoll, L. L.; Romig, S. A.; Humlicek, A.; Britigan, B. E.; Denning, G. M. J. Immunol. 
2005, 175, 4017–4023. 
115 Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. J. Org. Chem. 2000, 65, 1158-1174. 
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with microwaves gave carboxyphenazine 6.12.116  With carboxyphenazine 6.12 in hand 
we were able to access a variety of substituted aryl an alkyl amides (6.13). 
 
 
Scheme 6.1. Synthesis of a Small Molecule Library of Substituted Phenazine Amides. 
 
A subsequent structure-activity relationship (SAR) study  identified original 
phenazine 6.2 as the best lead in producing a strong period-lengthening phenotype (for 
the full results of the SAR study see Appendix I). Phenazine 6.2 (10 µM) was found to 
produce a period lengthening effect (7.2 h) in a dose-dependent manner with a minimal 
effect on the amplitude of the signal (Figure 6.3).  
                                                
116 Tietze, M.; Iglesias, A.; Merisor, E.; Conrad, J.; Klaiber, I.; Beifuss, U. Org. Lett. 2005, 7, 1549-1552. 
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Figure 6.3. Dose-Dependent Period-Lengthening Effect of Phenazine 6.2. 
 
Determining the Mechanism of Period-Lengthening 
There are a variety of known phenazine natural products, however, bacteria are 
the only known producers of phenazine secondary metabolites. Bacteria use phenazines 
to generate reactive oxygen species (ROS) in other organisms and tissues to gain an 
advantage in host invasion and in competing for space with other bacteria and fungi.117 
This functional trait of these phenazine secondary metabolites is attributed to the ability 
of phenazine compounds to redox cycle (Scheme 6.2). 
 
 
Scheme 6.2. The Redox Cycle of Phenazines. 
                                                
117 Pierson III, L. S.; Pierson, E. A. Appl. Microbiol. Biotechnol. 2010, 86, 1659-1670. 
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If phenazine 6.2 is affecting a period-lengthening effect due to its ability to 
decrease cellular oxygen levels this would result in a stabilization effect by reducing 
oxidative stress in the cell. To test this theory we designed redox inactive compounds as 
negative controls (Figure 6.4). By synthesizing compounds with one or both nitrogens 
removed (6.14, 6.15, 6.16) it will inhibit compounds from participating in redox cycling 
and effectively produce ROS.  
 
 
Figure 6.4. Redox Inactive Negative Controls. 
 
The synthesis of acridine 6.14 followed a similar synthesis to the phenazine 
synthesis, beginning with a Buchwald-Hartwig coupling115 of arylamine 6.17 and 
arylchloride 6.18 to give biarylamine 6.19 (Scheme 6.3). Reduction of the ester and 
subsequent oxidation gave aldehyde 6.21. Acid-promoted cyclization with trifluoroacetic 
acid gave cyanoacridine 6.22.118 Hydrolysis of the cyano group and subsequent coupling 
of the resultant carboxylic acid with aniline gave acridine 6.14. 
                                                
118 Rosevear, J.; Wilshire, J. F. K. Australian J. Org. Chem. 1981, 34, 839-853. 
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Scheme 6.3. The Synthesis of Acridine 6.14. 
 
The synthesis of iso-acridine 6.15 followed the same scheme as acridine 6.14, 
beginning with the Buchwald-Hartwig coupling115 of arylamine 6.24 and arylchloride 
6.25 to give biarylamine 6.27 (Scheme 6.4). Reduction of the ester and subsequent 
oxidation gave aldehyde 6.28. Acid-catalyzed cyclization gave iso-cyanoacridine 6.29,116 
which upon hydrolysis and subsequent amide coupling, provided iso-acridine 6.15. 
 
 
Scheme 6.4. The Synthesis of iso-Acridine 6.15. 
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Finally the synthesis of the fully redox inactive 6.16 began with commercially 
available anthracene acid 6.30. Amide coupling with aniline gave anthracene 6.16 
(Scheme 6.5). 
 
 
Scheme 6.5. The Synthesis of Anthracene 6.16. 
 
With these redox inactive compounds acridine 6.14, iso-acridine 6.15, and 
anthracene 6.16 in hand, we first screened for any effects on the circadian rhythm and 
were indeed found to be inactive (Figure 6.5).  
 
 
Figure 6.5. Circadian Rhythm Activity of Redox Incapable Compounds Acridine 6.14,  
iso-Acridine 6.15, and Anthracene 6.16 Compared to Phenazine 6.2 and DMSO. 
 
Next, the activity of phenazine 6.2 and its inactive analogs acridine 6.14, iso-
acridine 6.15, and anthracene 6.16 were assessed in two assays measuring fluorescent 
markers of cellular levels of superoxides and peroxides. However, we were disappointed 
to find that phenazine 6.2 had little to no activity directly affecting levels of cellular ROS 
(Figure 6.6). 
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Figure 6.6. Effect of Phenazine 6.2, iso-Acridine 6.15, and Anthracene 6.16 on  
Cellular Peroxide and Superoxide Levels. 
 
Moving forward, we envisioned other routes by which phenazine 6.2 may be 
effecting cellular redox cycles. Oxidation and reduction cycles of peroxiredoxin are a 
universal marker for circadian rhythms and they play an important role in removing ROS 
and other species capable of causing cell damage.119 So we next evaluated the ability of 
phenazine 6.2 to affect cellular levels of ROS via a possible interaction with 
peroxiredoxin. However, we found phenazine 6.2 and its inactive analog, anthracene 
6.16, had no effect on cellular peroxiredoxin levels (Figure 6.7). 
                                                
119 Edgar, R. S.; Green, E. W.; Zhao, Y.; van Ooijen, G.; Olmedo, M.; Qin, X.; Xu, Y.; Pan, M.; Valekunja, 
U. K.; Feeney, K. A.; Maywood, E. S.; Hastings, M. H.; Baliga, N. S.; Merrow, M.; Millar, A. J.; Johnson, 
C. H.; Kyriacou, C. P.; O'Neill, J. S.; Reddy A. B. Nature 2012, 485, 459-464. 
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Figure 6.7. Effect of Phenazine 6.2 and Anthracene 6.16 on  
Cellular Levels of Peroxiredoxin. 
 
With these two negative results we went back to the literature to explore how 
other phenazine natural products interact with their hosts and their environments. It is 
known that some phenazine natural products are implicated in maintaining intracellular 
redox balance by acting as electron acceptors.120 For example, in bacteria, production of a 
phenazine compound, pyocyanin (PYO), results in a high NADH/NAD+ ratio in the cell 
as PYO serves as an alternative electron acceptor reoxidizing NADH to maintain redox 
homeostasis.121 This led us to investigate the possibility that phenazine 6.2 may be 
effecting the circadian rhythm by altering cellular levels of NAD+.  
To this end we employed multiphoton and fluorescence microscopy techniques to 
detect the ratio of cellular NADH to FAD (Figure 6.8). In this case we used FK866 as a 
control because we observed autofluorescent interference from our negative control 
compounds acridine 6.14, iso-acridine 6.15, and anthracene 6.16. We chose to use FK866 
                                                
120 Price-Whelan, A.; Dietrich, L. E.; Newman, D. K. Nat. Chem. Bio. 2006, 2, 71-78. 
121 a) de Graef, M. R.; Alexeeva, S.; Snoep J. L.; Teixeira de Mattos, M. J. J Bacteriol 1999, 181, 2351-
2357. b) Price-Whelan, A.; Dietrich, L. E.; Newman, D. K. Nat. Chem. Bio. 2006, 2, 71-78. 
phenazine	6.2	 anthracene	6.16	
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as a control as it is a commercially available known specific inhibitor of nicotinamide 
phosphoribosyl-transferase (NAMPT) that lowers cellular NAD+ levels over a prolonged 
length of time.122 We were delighted to find that phenazine 6.2 was able to effect a 
change in the cellular ratio of NADH to FAD comparable to the change effected by 
FK866. 
 
 
Figure 6.8. Fluorescent Measurement of Cellular Levels of NADH and FAD Upon Treatment  
with DMSO, Phenazine 6.2, and FK866. 
 
In cells CLOCK-BMAL1 can regulate it’s own activity by directing NAD+ 
biosynthesis via the NAMPT pathway (Figure 6.9).123  Increasing cellular NAD+ levels 
increases the activity of SIRT1 and PARP-1. An increased level of SIRT1 results in the 
deacetylation of BMAL1 and PER proteins124 and Tasselli and Chua propose that SIRT1 
translates cellular changes in NAD+ into circadian regulation and metabolic 
                                                
122 Hasmann, M.; Schemainda, I. Cancer Res. 2003, 63, 7436-7442.  
123 a) Ramsey, K. M.; Yoshino, J.; Brace, C. S.; Abrassart, D.; Kobayashi, Y.; Biliana Marcheva, B.; Hong, 
H.-K.; Chong, J. L.;  Buhr, E. D.; Lee, C.; Joseph S. Takahashi, J. S.; Imai, S.-i.; Bass, J. Science 2009, 
324, 651-654. b) Nakahata, Y.; Sahar, S.; Astarita, G.; Kaluzova, M.; Sassone-Corsi, P. Science 2009, 324, 
654-657. c) Peek, C. B.; Affinati, A. H.; Ramsey, K. M.; Kuo, H.-Y.; Yu, W.; Sena, L. A.; Ilkayeva, O.; 
Marcheva, B.; Kobayashi, Y.;  Omura, C.; Levine, D. C.; David J. Bacsik, D. J.; Gius, D.; Newgard, C. B.; 
Goetzman, E.; Chandel, N. S.; Denu, J. M.; Mrksich, M.; Bass, J. Science 2013, 342, 1243417. 
124 a) Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F. 
W.; Schibler, U. Cell, 2008, 134, 317-328. b) Nakahata, Y.; Kaluzova, M.; Grimaldi, B.; Sahar, S.; 
Hirayama, J.; Chen, D.; Guarente, L. P.; Sassone-Corsi, P. Cell 2008, 134, 329-340. 
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homeostasis.125 PARP-1 is implicated in a negative feedback loop where CLOCK protein 
is poly(ADP-ribosyl)ated, thus inhibiting translation of per and cry genes and effectively 
decreasing NAMPT biosynthesis.126 If phenazine 6.2 is affecting a change in cellular 
levels of NAD+ it could produce the observed period-lengthening phenotype by 
decreasing cellular levels of SIRT1 resulting in a stabilization of the PER:CRY 
heterodimer increasing the length of the core loop oscillation.   
 
 
Figure 6.9. Diagram of the Cellular Mechanism of the Effect of NAMPT Synthesis  
on the Circadian Rhythm Core Feedback Loop. 
 
This possible regulation of cellular NAD+ levels by phenazine 6.2 would help 
elucidate a newly discovered interaction between NAD+/NADH and circadian clock. This 
will also have implications in human health and metabolism as the interplay between 
PARP-1, SIRT1, NAD+ levels is not well established. The mechanism by which the 
cellular PARP-1, SIRT1, NAD+ levels are regulated is also unexplored and improving 
this understanding of how circadian rhythms and metabolic cycles are linked could aid in 
metabolism-related diseases.127 To this end, current studies are underway to measure the 
                                                
125 Tasselli, L.; Chua, K. F. Nat. Struc. Molec. Biol. 2015, 22, 275-277. 
126 Asher, G.; Reinke, H.; Altmeyer, M.; Gutierrez-Arcelus, M.; Hottiger, M. O.; Schibler, U. Cell 2010, 
142, 943-953. 
127 Kumar, V.; Takahashi, J. S. Cell, 2010, 142, 841-843. 
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change in cellular levels of NAD+ over a 3 day period to determine if there is a change in 
oscillation of NAD+ upon treatment with phenazine 6.2 and if this change in oscillation 
overlays with the change in period oscillation initially observed with phenazine 6.2. 
 
Experimental Methods 
The Vanderbilt High-Throughput Screening Facility and System Integration. The 
high-throughput screening was done at the Vanderbilt Molecular Recognition and 
Screening Facility. The robotic automated system, including the Echo550 drug dispenser, 
the Hamamatsu Functional Drug Screening System (FDSS) used for the luminescent 
measurement, and F3 robotic arm used for plate handling in this protocol, were integrated 
with Polara scheduling software, which provided a platform for integrating and 
controlling systems and their automation. The Hamamatsu FDSS kinetic imaging plate 
reader is a CCD-based detector system that serially reads allowing the acquisition of 384 
data points simultaneously.  
High-Throughput Screening of the Vanderbilt Library of Small Molecules. A clonal 
line of Rat1 fibroblast cells stably expressing the Per2-dLuc gene was used to perform 
the screening.128 Cells were grown at 37 °C in a 5% CO2 concentration in DMEM culture 
medium with phenol red (Gibco 11965-092) and supplemented with 5% FBS (Atlanta 
Biologicals S11195), 50 units/mL penicillin, and 50 µg/mL streptomycin. Cells were 
grown for three days in tissue culture flasks. The cell culture was synchronized one h 
prior to harvesting the cells by adding 1 µL of 100 mM dexamethasone in ethanol per 1 
mL of culture media. 4 h after synchronization, the cells were harvested and resuspended 
                                                
128 Izumo, M.; Sato, T. R.; Straume, M.; Johnson, C. H. PLOS Computational Biology 2006, 2, 1248-1261. 
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at a concentration of 1x106 cells/mL in fresh DMEM culture medium without phenol red 
and supplemented with 5% FBS, 50 units/mL penicillin, 50 µg/mL streptomycin, and 1 
µL of 100 mM luciferin (Promega E1601) per 1 mL of culture medium. Cells were then 
plated onto 384-well, black plates with clear bottoms (BD 353221) using a Thermo 
Electron multidrop 384 combi-automated liquid handler, 40 µL per well (40.000 cells per 
well) to columns 1-23, and column 24 was a blank column used to monitor background 
signal. DMSO (100%) and Roscovitine (10 mM in DMSO) controls were dispensed as 40 
nL per well, followed by 40 nL per well of each compound (each as 10 mM solution in 
DMSO). The plates were then placed in the cell culture incubator and were robotically 
removed and transferred to the Hamamatsu FDSS for a 2 min measurement of 
luminescence every hour. The hourly FDSS assay of bioluminescence intensity was 
performed over a 3 d period. 
Cell-based Circadian Assay. Stripwell plates were seeded with either Per2-dLuc 
transformed Rat1 cells, or, Human Bmal1-dLuc U2OS cells one day prior to the 
experiment. Before recording, the cells were treated with 100 nM dexamethasone in 
ethanol (final ethanol concentration of 0.001%) for 2 h. At the end of each treatment, the 
medium was washed twice with DPBS and replaced with the assay medium DMEM 
without phenol red (Gibco 13000–021) and supplemented with 10% FBS (Gibco 16000–
044), 10 mM HEPES pH 7.2, 50 units/mL penicillin, 50 µg/mL streptomycin, 0.1 mM 
luciferin (Promega), and either DMSO or compound (as 10 mM solution in DMSO). 
Each well was separated and sealed with autoclaved coverslips sealed with a bead of 
silicon grease. 
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Recording of Bioluminescence. All assays were done in a LumiCycle, a 32-channel 
automated luminometer, placed within a 36.5 °C incubator in a temperature-controlled 
room. All samples were measured every 10 min with an integration time of 75 sec for a 
period of at least 5 d. 
General procedure. All reactions were performed in flame-dried or oven dried round-
bottomed flasks under an atmosphere of argon unless otherwise noted. Stainless steel 
syringes or cannula were used to transfer air- and moisture-sensitive liquids. Reaction 
temperatures were controlled using a thermocouple thermometer and analog hotplate 
stirrer. Reactions were conducted at room temperature (approximately 22 °C) unless 
otherwise noted. Flash column chromatography was conducted as described Still et. al. 
using silica gel 230-400 mesh.64 Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV light (254 nm) 
and ceric ammonium molybdate, potassium permanganate, or anisaldehyde stains. Yields 
were reported as spectroscopically pure compounds.  
Materials. Reagents and solvents used were of commercial grade and purified prior to 
use when necessary. Tetrahydrofuran, toluene, and dichloromethane were obtained from 
either an MBraun MB-SPS solvent system, where they were dried using activated 
alumina columns, or freshly distilled (tetrahydrofuran and ether were both distilled from 
sodium metal with benzophenone indicator), and when necessary solvents were further 
dried over activated 4 Å molecular sieves under an atmosphere of argon. Triethylamine 
was distilled from calcium hydride and stored over sodium hydroxide. The molarity of 
commercial n-butyllithium solutions was determined by titration using 2,2,2′-
Trimethylpropionanilide65 as an indicator (average of three determinations). 
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Instrumentation. Nuclear magnetic resonance (NMR) spectra were acquired on Bruker 
DRX-400 (400 MHz), DRX-500 (500 MHz), or (600 MHz) spectrometers and are 
reported relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16; MeOD: 3.31). 
Data for 1H NMR spectra are reported as follows: chemical shift d (ppm), multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septet, m = multiplet, br = 
broad singlet, app = apparent). Infrared (IR) spectra were obtained as thin films on NaCl 
plates using a Thermo Electron IR100 series spectrophotometer and are reported in 
wavenumbers (cm-1). High-resolution mass spectra were obtained from the Department 
of Chemistry and Biochemistry, University of Notre Dame using a microTOF QII mass 
spectrometer. Optical rotations were measured on a Perkin-Elmer 341 digital polarimeter 
at ambient temperature (zeroed with pure, solvent-grade chloroform). X-ray crystal 
structures were obtained from the X-ray Diffraction Laboratory in the Department of 
Chemistry at Texas A & M University using a Bruker single-crystal APEXii CCD 
Diffractometer. Liquid chromatographic and mass spectra (LC/MS) data were obtained 
on an Agilent Technologies 6130 Quadrupole instrument. 
 
6.10.115 To a solution of methyl 4-bromo-3-nitrobenzoate (4.36 g, 
16.7 mmol), aniline (4.6 mL, 50.3 mmol), rac-BINAP (1.00 g, 
1.26 mmol), and cesium carbonate (10.9 g, 33.5 mmol) in toluene 
(80 mL) in a sealed tube was quickly added tris(dibenzylideneacetone)-dipalladium (462 
mg, 0.545 mmol) and the reaction was resealed and stirred at 110 °C for 18 h. The 
reaction mixture was then cooled to room temperature, filtered through Celite, and 
concentrated. The residue was purified by flash chromatography (SiO2, 10% ethyl 
Br
O2N OMe
O
H2N
Pd2dba3, rac-BINAP
Cs2CO3, toluene N
H
O2N OMe
O
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acetate, hexanes) to yield secondary amine 6.10 (4.52 g, 98%) as a white solid. 1H NMR 
(400 MHz, CDCl3) δ 9.80 (s, 1H), 8.92 (d, 1H, J = 2.04), 7.97 (dd, 1H, J = 9.04, 1.88), 
7.47 (t, 2H, J = 7.82), 7.32 (t, 1H, J = 7.28), 7.30 (d, 2H, J = 7.40), 7.17 (d, 1H, J = 9.04), 
3.91 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 165.5, 146.2, 137.7, 136.0, 130.1, 129.4, 
126.9, 125.3, 119.3, 115.7, 52.3. LCMS calc’d for C14H12N2O4 [M+H]+: 273.1, measured 
273.3. 
 
6.11. 1 M aqueous sodium hydroxide (33.1 mL, 33.1 mmol) was 
added to a solution of secondary amine 6.10 (4.52 g, 16.5 mmol) in 
methanol (200 mL) and the reaction was let stir 18 h. The resulting 
solid was filtered to give pure carboxylic acid 6.11 (2.08 g, 49%) as a while solid. 1H 
NMR (400 MHz, MeOD) δ 8.82 (d, 1H, J = 1.96), 7.97 (dd, 1H, J = 8.92, 2.04), 7.45 (t, 
2H, J = 8.56), 7.26 (t, 1H, J = 7.38), 7.15 (d, 1H, J = 8.92). 13C NMR (100 MHz, MeOD) 
δ 169.6, 145.2, 140.76, 137.8, 132.9, 131.0, 128.8, 126.7, 125.6, 116.5. LCMS calc’d for 
C13H10N2O4 [M+H]+: 259.1, measured 259.0. 
 
6.12 (VU0517711).116 Carboxylic acid 6.11 (1.20 g, 9.65 mmol) 
and sodium borohydride (703 mg, 18.6 mmol) were added to a 5 M 
solution of sodium methoxide in methanol (30 mL) and the solution was refluxed for 18 
h. The reaction was then cooled to RT and the solution was then poured over ice water. 
The suspension was then acidified to a pH of 2 with a 6 M aqueous solution of HCl and 
then extracted with diethyl ether (4 x 80 mL). The combined organics were dried 
(MgSO4) and concentrated and the residue was purified by flash chromatography (SiO2, 
N
H
O2N OMe
O
N
H
O2N OH
O
NaOH, H2O
MeOH
N
N
OH
O
NaBH4, NaOMe
MeOH, 
N
H
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60% ethyl acetate, hexanes) to yield carboxyphenazine 6.12 (1.45 g, 67%) as a yellow 
solid. 1H NMR (600 MHz, MeOD) δ 8.93 (s, 1H), 8.47 (d, 1H, J = 10.56), 8.31 (t, 1H, J = 
8.92), 8.00 (t, 1H, J = 9.02), 7.49 (d, 1H, J = 7.64), 7.38 (d, 1H, J = 8.36), 7.19 (d, 1H, J = 
9.12). 13C NMR (150 MHz, MeOD) δ 169.2, 161.4, 157.7, 145.8, 145.5, 145.3, 143.8, 
133.3, 132.7, 131.0, 130.6, 130.4. LCMS calc’d for C13H8N2O2 [M+H]+: 225.1, measured 
225.3. 
 
General Procedure for the Phenazine Carboxylic Acid Coupling. To a solution of 
carboxyphenazine 6.12 (50.0 mg, 0.223 mmol) in NMP (1.5 mL) was added the 
corresponding amine or aniline (0.268 mmol), Hünig’s base (117 µL, 0.669 mmol), and 
HATU (102 mg, 0.268 mmol). The reaction was heated via microwave irradiation at 100 
°C for 45 min. The resulting solution was purified directly by reverse phase 
chromatography. 
 
6.2 (VU0010661). Purified by C18 chromatography (gradient: 
39% to 70% acetonitrile, water) to yield phenazine amide 6.2 
(9.5 mg, 14%) as a brown solid. 1H NMR (600 MHz, CDCl3) δ 8.68 (s, 1H), 8.34 (s, 2H), 
8.26 (t, 2H, J = 9.48), 8.21 (s, 1H), 7.89 (m, 2H), 7.73 (d, 2H, J = 7.86), 7.42 (t, 2H, J = 
7.89), 7.21 (t, 1H, J = 7.41). 13C NMR (150 MHz, CDCl3) δ 164.7, 144.5, 144.4, 144.3, 
137.8, 136.7, 131.7, 131.3, 130.8, 129.9, 129.4, 128.8, 128.3, 125.2, 120.4. LCMS calc’d 
for C19H13N3O [M+H]+: 300.1, measured 300.0. 
 
N
N N
H
O
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6.32 (VU0470023). Purified by C18 chromatography 
(gradient: 39% to 70% acetonitrile, water) to yield phenazine 
amide 6.32 (3.6 mg, 5%) as a brown solid. 1H NMR (600 
MHz, CDCl3) δ 8.88 (s, 1H), 8.74 (s, 1H), 8.61 (d, 1H, J = 9.12), 8.42 (d, 1H, J = 9.00), 
8.38 (d, 1H, J = 8.82), 8.30 (m, 2H), 7.92 (m, 2H), 7.15 (dt, 1H, J = 7.82, 1.56), 7.07 (dt, 
1H, J = 7.74, 1.12), 6.98 (dd, 1H, J = 8.13, 1.11), 3.99 (s, 3H). 13C NMR (150 MHz, 
CDCl3) δ 164.0, 148.2, 144.3, 142.6, 131.5, 131.1, 130.5, 129.8, 128.1, 127.5, 124.3, 
121.2, 119.9, 109.9, 55.8. LCMS calc’d for C20H15N3O2 [M+H]+: 331.1, measured 331.0. 
 
6.33 (VU0517764). Purified by C18 chromatography 
(gradient: 39% to 71% acetonitrile, water) to yield 
phenazine amide 6.33 (16.8 mg, 23%) as a brown solid. 1H NMR (600 MHz, CDCl3) δ 
8.67 (s, 1H), 8.49 (s, 1H), 8.30 (s, 2H), 8.23 (m, 2H), 7.87 (m, 2H), 7.50 (s, 1H), 7.29 (t, 
1H, J = 8.08), 7.21 (d, 1H, J = 8.00), 6.74 (dd, 1H, J = 8.12, 1.88), 3.85 (s, 3H). 13C NMR 
(150 MHz, CDCl3) δ 164.8, 160.4, 144.4, 144.3, 144.2, 142.5, 139.1, 136.6, 131.7, 131.2, 
130.7, 130.0, 129.9, 128.8, 128.3, 112.5, 111.0, 106.1, 55.5. LCMS calc’d for 
C20H15N3O2 [M+H]+: 331.1, measured 331.0. 
 
6.34 (VU0517755). Purified by C18 chromatography 
(gradient: 38% to 68% acetonitrile, water) to yield 
phenazine amide 6.34 (9.4 mg, 13%) as a brown solid. 1H NMR (600 MHz, CDCl3) δ 
8.66 (s, 1H), 8.32 (m, 2H), 8.24 (m, 3H), 7.88 (m, 2H), 7.63 (d, 2H, J = 8.40), 6.94 (d, 
2H, J = 8.34), 3.83 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 164.6, 157.1, 144.4, 144.3, 
N
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144.2, 142.6, 136.8, 131.6, 131.2, 130.9, 130.7, 129.9, 128.9, 128.3, 122.2, 114.5, 144.4, 
55.7. LCMS calc’d for C20H15N3O2 [M+H]+: 331.1, measured 331.0. 
 
6.35 (VU0517669). Purified by C18 chromatography 
(gradient: 34% to 65% acetonitrile, water) to yield 
phenazine amide 6.35 (20.1 mg, 25%) as an orange solid. 1H NMR (600 MHz, CDCl3) δ 
7.76 (s, 1H), 7.48 (d, 1H, J = 2.34), 7.36 (d, 1H, J = 1.38), 7.28 (dd, 1H, J = 7.50, 0.90), 
7.18 (m, 2H), 6.98-6.92 (m, 2H), 6.91 (dd, 2H, J = 7.56, 0.70), 6.84 (d, 1H, J = 8.64), 
3.89 (s, 3H), 3.87 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 165.4, 149.1, 145.8, 143.1, 
139.2, 133.9, 131.8, 130.1, 129.8, 129.4, 129.2, 126.9, 121.0, 119.9, 117.8, 177.3, 115.67, 
112.0, 111.3, 105.1, 56.1, 55.9. LCMS calc’d for C21H17N3O3 [M+H]+: 360.1, measured 
360.4. 
 
6.36 (VU0517756). Purified by C18 chromatography 
(gradient: 34% to 64% acetonitrile, water) to yield phenazine 
amide 6.36 (4.3 mg, 6%) as an orange solid. 1H NMR (600 
MHz, CDCl3) δ 8.74 (m, 1H), 8.45 (dd, 1H, J = 8.4, 1.32), 7.76 (dd, 1H, J = 6.42, 1.80), 
7.69 (d, 1H, J = 1.98), 7.44 (m, 1H), 7.37 (t, 2H, J = 6.99), 7.12 (d, 1H, J = 9.40), 7.09 (t, 
1H, J = 7.39). 13C NMR (150 MHz, CDCl3) δ 162.6, 151.8, 141.1, 140.2, 135.9, 135.3, 
129.8, 129.6, 125.0, 123.2, 120.9, 120.1, 119.5, 118.7, 116.2, 115.5. LCMS calc’d for 
C19H11Cl2N3O [M+H]+: 369.0, measured 369.2. 
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6.37 (VU0517757). Purified by C18 chromatography 
(gradient: 39% to 70% acetonitrile, water) to yield phenazine 
amide 6.37 (9.1 mg, 11%) as an orange solid. 1H NMR (600 MHz, CDCl3) δ 8.71 (s, 1H), 
8.39, (s, 1H), 8.35 (d, 1H, J = 9.06), 8.29 (t, 2H, J = 5.13), 7.93 (m, 3H), 7.67 (d, 1H, J = 
7.45), 7.61 (d, 1H, J = 7.98), 7.29 (t, 1H, J = 6.66). 13C NMR (150 MHz, CDCl3) δ 131.7, 
131.2, 130.8, 130.5, 129.8, 128.4, 128.3, 127.9, 123.1, 118.5. LCMS calc’d for 
C19H12BrN3O [M+H]+: 379.0, measured 379.2. 
 
6.38 (VU0517762). Purified by C18 chromatography 
(gradient: 34% to 64% acetonitrile, water) to yield 
phenazine amide 6.38 (4.3 mg, 13%) as an orange solid. 1H NMR (600 MHz, CDCl3) δ 
9.82 (s, 1H), 8.74 (d, 1H, J = 2.16), 7.97 (d, 1H, J = 1.98), 7.95 (d, 1H, J = 2.04), 7.85 (d, 
1H, J = 2.13), 7.84 (d, 1H, J = 2.14), 7.51 (d, 1H, J = 7.92), 7.47 (t, 2H, J = 7.92), 7.43 (d, 
1H, J = 7.32), 7.32 (t, 1H, 7.50). 13C NMR (150 MHz, CDCl3) δ 145.7, 138.2, 137.4, 
134.6, 131.7, 130.0, 129.7, 126.9, 125.4, 125.1, 123.2, 122.8, 121.2, 116.9, 116.5. LCMS 
calc’d for C20H12F3N3O [M+H]+: 368.1, measured 368.3.  
 
6.39 (VU0470007). Purified by C18 chromatography 
(gradient: 58% to 87% acetonitrile, water) to yield 
phenazine amide 6.39 (7.5 mg, 10%) as a brown solid. 1H 
NMR (600 MHz, CDCl3) δ8.68 (s, 1H), 8.36 (m, 2H), 8.27 (t, 2H, J = 9.00), 8.11 (s, 1H), 
7.91 (m, 2H), 7.64 (d, 2H, J = 8.52), 7.44 (d, 2H, J = 8.64), 1.35 (s, 9H). 13C NMR (150 
MHz, CDCl3) δ 164.8, 148.3, 144.5, 144.4, 144.3, 142.6, 136.8, 135.2, 131.7, 131.3, 
N
N N
H
O
Br
N
N N
H
O
CF3
N
N
N
H
O
 227 
130.8, 130.0, 129.9, 128.9, 128.2, 126.3, 120.2, 31.5. LCMS calc’d for C23H21N3O 
[M+H]+: 356.2, measured 356.1. 
 
6.40 (VU0517754). Purified by C18 chromatography 
(gradient: 57% to 85% acetonitrile, water) to yield 
phenazine amide xx (5.3 mg, 6%) as a brown solid. 1H 
NMR (600 MHz, CDCl3) δ 8.66 (s, 1H), 8.33 (s, 2H), 8.25 (t, 2H, J = 8.85), 8.14 (s, 1H), 
8.25 (m, 2H), 7.61 (d, 2H, J = 8.58), 6.94 (d, 2H, J = 8.70), 3.98 (t, 2H, J = 6.48), 1.78 
(quint, 2H, J = 7.02), 1.51 (sext, 2H, J = 7.45), 0.99 (t, 3H, J = 7.38). 13C NMR (150 
MHz, CDCl3) δ 164.6, 156.7, 144.4, 144.3, 144.2, 142.6, 136.8, 131.6, 131.2, 130.7, 
130.7, 129.9, 128.9, 128.2, 122.2, 115.3, 115.1, 68.2, 31.5, 19.4, 14.0. LCMS calc’d for 
C23H21N3O2 [M+H]+: 372.2, measured 372.0. 
 
6.41 (VU0517670). Purified by C18 chromatography 
(gradient: 50% to 80% acetonitrile, water) to yield 
phenazine amide 6.41 (14.8 mg, 19%) as a yellow solid. 1H NMR (600 MHz, CDCl3) δ 
8.76 (s, 1H), 8.44 (s, 1H), 8.39 (m, 2H), 8.32 (s, 1H), 8.29 (m, 2H), 7.92 (m, 2H), 7.88 (t, 
2H, J = 8.79), 7.83 (d, 1H, J = 8.16), 7.65 (d, 1H, J = 8.40), 7.51 (t, 1H, J = 7.14), 7.46 (t, 
1H, J = 7.26). 13C NMR (150 MHz, CDCl3) δ 164.8, 144.5, 144.4, 144.3, 142.6, 136.7, 
135.2, 134.0, 131.8, 131.4, 131.1, 130.9, 130.0, 129.3, 128.8, 128.6, 128.4, 128.0, 127.8, 
126.9, 125.6, 120.0, 117.4. LCMS calc’d for C23H15N3O [M+H]+: 350.1, measured 350.0.  
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6.42 (VU0470008). Purified by C18 chromatography 
(gradient: 26% to 56% acetonitrile, water) to yield phenazine 
amide 6.42 (6.0 mg, 10%) as a brown solid. 1H NMR (600 MHz, CDCl3) δ 8.55 (d, 1H, J 
= 1.56), 8.32 (d, 1H, J = 8.94), 8.27 (m, 3H), 7.89 (m, 2H), 6.39 (s, 1H), 3.57 (q, 2H, J = 
1.56), 1.68 (quint, 2H, J = 7.41), 1.49 (sext, 2H, J = 7.50), 1.00 (t, 3H, J = 7.38). 13C 
NMR (150 MHz, CDCl3) δ 166.6, 144.3, 144.2, 142.7, 136.7, 131.5, 131.2, 130.5, 130.0, 
129.9, 129.1, 128.0, 40.3, 31.8, 20.3, 13.9. LCMS calc’d for C17H17N3O [M+H]+: 280.1, 
measured 280.0. 
 
 6.19.115 To a solution of ethyl anthranilate (515 mL, 3.48 mmol), p-
chlorobenzonitrile (400 mg, 2.90 mmol), rac-BINAP (180 mg, 0.29 
mmol), and cesium carbonate (2.83 g, 8.70 mmol) in toluene (29 mL) in a sealed tube 
was quickly added palladium diacetate (32 mg, 0.145 mmol) and the reaction was sealed 
and stirred at 110 °C for 36 h. The reaction mixture was then cooled to RT, filtered 
through Celite, and concentrated. The residue was purified by flash chromatography 
(SiO2, 5% ethyl acetate, hexanes) to yield secondary amine 6.19 (311 mg, 40%) as a pale 
yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 8.03 (d, 1H, J = 6.60), 7.56 (d, 
2H, J = 8.70), 7.45 (t, 1H, J = 8.16), 7.43 (d, 1H, J = 8.28), 7.25 (d, 2H, J = 8.63), 6.93 (t, 
1H, J = 8.16), 4.37 (q, 2H, J = 7.14), 1.41 (t, 3H, J = 7.14). 13C NMR (100 MHz, CDCl3) 
δ 168.4, 145.8, 144.7, 134.1, 133.8, 132.0, 120.1, 119.6, 118.9, 116.2, 115.2, 104.2, 61.3, 
29.9, 14.4. LCMS calc’d for C16H14N2O2 [M+H]+: 267.1, measured 267.1. 
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6.20. To a solution of secondary amine 6.19 (100 mg, 0.441 mmol) in 
THF (700 µL) cooled to 0 °C was added lithium borohydride (19 mg, 
0.882 mmol) and reaction was stirred 16 h at RT. The reaction 
mixture was quenched at 0 °C with water (100 µL) and extracted with ether (3 x 1 mL). 
The combined organics were dried (MgSO4), concentrated, and the resulting residue was 
purified by flash chromatography (SiO2, 10% ethyl acetate, hexanes) to yield alcohol 
6.20 (90 mg, 91%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.47 (d, 2H, J = 
8.70), 7.41 (d, 1H, J = 7.98), 7.31 (t, 1H, J = 7.71), 7.28 (d, 1H, J = 7.44), 7.24 (s, 1H), 
7.05 (t, 1H, J = 7.41), 7.00 (d, 2H, J = 8.70), 4.70 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 
147.8, 140.4, 133.9, 131.1, 129.9, 129.4, 123.3, 120.3, 120.0, 115.7, 101.6, 64.4. LCMS 
calc’d for C14H12N2O [M+H]+: 225.1, measured 225.2. 
 
6.21. To a solution of alcohol 6.20 (90 mg, 0.401 mmol) in DCM (4 
mL) and DMSO (4 mL) was added IBX (124 mg, 0.441 mmol) and 
the solution was stirred 2 h. The reaction mixture was then diluted with water and 
extracted with ether. The combined organics were dried (MgSO4), concentrated, and the 
resulting residue was purified by flash chromatography (SiO2, 5% ethyl acetate, hexanes) 
to yield aldehyde 6.21 (60 mg, 67%) as a bright yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 10.21 (s, 1H), 9.93 (s, 1H), 7.66 (d, 1H, J = 6.30), 7.61 (d, 2H, J = 8.64), 7.48 
(t, 1H, J = 7.08), 7.44 (d, 1H, J = 8.28), 7.33 (d, 2H, J = 8.64), 7.02 (t, 1H, J = 7.83). 13C 
NMR (100 MHz, CDCl3) δ 194.8, 144.9, 144.7, 137.0, 135.8, 133.9, 133.8, 121.1, 120.4, 
119.8, 119.3, 114.3, 105.7. LCMS calc’d for C14H10N2O [M+H]+: 223.1, measured 223.3. 
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6.22. 118 A solution of aldehyde 6.21 (60 mg, 0.270 mmol) in TFA 
(900 mL) was heated via microwave irradiation at 60 °C for 1 h. The 
reaction mixture was quenched very slowly by the dropwise addition of 15% aqueous 
sodium hydroxide (5 mL, at which point pH measured > 7) at 0 °C and then extracted 
with ether (3 x 10 mL). The combined organics were dried (MgSO4), concentrated, and 
the resulting residue was purified by flash chromatography (SiO2, 15% ethyl acetate, 
hexanes) to yield 5-cyanoacridine 6.22 (47 mg, 85%) as a bright yellow solid. 1H NMR 
(400 MHz, CDCl3) δ 8.87 (s, 1H), 8.46 (d, 1h, J = 1.68), 8.32 (d, 1H, J = 8.32), 8.27 (d, 
1H, J = 8.84), 8.06 (d, 1H, J = 8.48), 7.90 (dt, 1H, J = 7.74, 1.36), 7.85 (dd, 1H, J = 9.04, 
1.80), 7.64 (t, 1H, 7.56). 13C NMR (100 MHz, CDCl3) δ 150.7, 148.8, 137.6, 135.8, 
133.9, 132.4, 131.9, 131.2, 129.7, 128.7, 127.2, 125.3, 118.8, 114.3, 109.6. LCMS calc’d 
for C14H8N2 [M+H]+: 205.1, measured 205.2. 
 
6.23. To a solution of 5-cyanoacridine 6.22 (47 mg, 0.230 mmol) in 
ethanol (630 mL) was added 3 M sodium hydroxide (320 mL) and 
the reaction was stirred 16 h. The reaction mixture was then neutralized with 1 M HCl (2 
mL) and extracted with ether (3 x 4 mL). The combined organics were dried (MgSO4), 
concentrated, and the resulting residue was purified by flash chromatography (SiO2, 50% 
ethyl acetate, hexanes) to yield 5-carboxyacridine 6.23 (35 mg, 68%) as a yellow solid. 
1H NMR (400 MHz, MeOD) δ 9.96 (s, 1H), 9.15 (s, 1H), 8.70 (d, 1H, J = 9.12), 8.50 (d, 
1H, J = 8.52), 8.34 (m, 3H), 7.95 (t, 1H, J = 7.30). 13C NMR (100 MHz, MeOD) δ 167.5, 
150.8, 143.8, 143.5, 139.2, 136.9, 134.1, 131.4, 131.3, 129.5, 128.2, 126.9, 122.5, 122.1. 
LCMS calc’d for C14H9NO2 [M+H]+: 224.1, measured 224.1. 
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6.14 (VU0517673). To a solution of 5-carboxyacridine 6.23 
(35 mg, 0.143 mmol) in NMP (1 mL) was added aniline (16 
mL, 0.172 mmol), Hünig’s base (117 µL, 0.669 mmol), and HATU (130 mg, 0.172 
mmol). The reaction was heated via microwave irradiation at 100 °C for 45 min. The 
combined organics were dried (MgSO4), concentrated, and the resulting residue was 
purified by flash chromatography (SiO2, 50% ethyl acetate, hexanes) to yield acridine 
amide 6.14 (12 mg, 28%) as a dark yellow solid. 1H NMR (600 MHz, CDCl3) δ 8.91 (s, 
1H), 8.61 (d, 1H, J = 1.80), 8.34 (d, 1H, J = 9.06), 8.27 (d, 1H, J = 8.64), 8.20 (dd, 1H, J 
= 9.06, 1.92),  8.06 (s, 1H), 8.05 (d, 1H, J = 8.22), 7.86 (dt, 1H, J = 7.71, 1.26), 7.72 (d, 
2H, J = 7.80), 7.61 (t, 1H, J = 7.47), 7.49 (d, 1H, J = 7.92), 7.42 (t, 2H, J = 7.92), 7.32 (t, 
1H, J = 7.83), 7.21 (t, 1H, J = 7.44). 13C NMR (150 MHz, CDCl3) δ 165.2, 150.3, 149.6, 
138.0, 137.9, 132.1, 131.7, 130.5, 129.7, 129.4, 129.2, 128.8, 128.6, 127.7, 127.2, 126.6, 
125.7, 125.0, 124.5, 120.5, 120.0. LCMS calc’d for C20H14N2O [M+H]+: 299.1, measured 
299.2. 
 
6.26.115 To a solution of methyl anthranilate (1.7 mL, 13.1 mmol), m-
chlorobenzonitrile (1.5 g, 10.9 mmol), rac-BINAP (679 mg, 1.09 
mmol), and cesium carbonate (10.6 g, 32.7 mmol) in toluene (110 mL) in a sealed tube 
was quickly added palladium diacetate (125 mg, 0.545 mmol) and the reaction was 
resealed and stirred at 110 °C for 36 h. The reaction mixture was then cooled to RT, 
filtered through Celite, and concentrated. The residue was purified directly by flash 
chromatography (SiO2, 2% ethyl acetate, hexanes) to yield secondary amine 6.26 (2.7 g, 
98%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.59 (s, 1H), 8.00 (dd, 1H, J 
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= 8.04, 1.56), 7.53 (s, 1H), 7.43-7.37 (m, 3H), 7.30 (t, 2H, J = 7.48), 6.88 (t, 1H, J = 
6.86), 3.84 (s, 3H). 13C NMR (100 MHz, CDCl3) δ168.9, 146.1, 142.3, 134.4, 132.0, 
130.4, 126.3, 125.6, 123.8, 119.1, 118.8, 114.8, 113.6, 113.5, 52.2. LCMS calc’d for 
C15H12N2O2 [M+H]+: 253.1, measured 253.2. 
 
6.27. To a solution of secondary amine 6.26 (220 mg, 0.872 mmol) in 
THF (0.9 mL) cooled to 0 °C was added lithium borohydride (132 
mg, 3.49 mmol) and reaction was let stir 16 h at RT. The reaction mixture was then 
quenched at 0 °C with water (2 mL) and extracted with ether (3 x 5 mL). The combined 
organics were dried (MgSO4), concentrated, and the resulting residue was purified by 
flash chromatography (SiO2, 10% ethyl acetate, hexanes) to yield alcohol 6.27 (190 mg, 
97%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, 1H, J = 7.98), 7.34-
7.29 (m, 3H), 7.28-7.20 (m, 2H), 7.14 (d, 1H, J = 8.64), 7.02 (bs, 1H), 7.00 (t, 1H, J = 
7.40), 4.72 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 144.5, 141.6, 130.4, 130.1, 130.0, 
129.6, 123.8, 122.5, 121.6, 119.6, 119.3, 118.7, 113.4, 64.7. LCMS calc’d for C14H12N2O 
[M+H]+: 225.1, measured 225.2. 
 
6.28. To a solution of alcohol 6.27 (190 mg, 0.847 mmol) in DCM (9 
mL) and DMSO (9 mL) was added IBX (480 mg, 1.70 mmol) and the 
mixture was stirred 2 h. The reaction mixture was then diluted with brine (15 mL) and 
extracted with ether (3 x 20 mL). The combined organics were dried (MgSO4), 
concentrated, and the resulting residue was purified by flash chromatography (SiO2, 5% 
ethyl acetate, hexanes) to yield aldehyde 6.28 (151 mg, 80%) as a bright yellow solid. 1H 
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NMR (400 MHz, CDCl3) δ 10.09 (s, 1H), 9.92 (s, 1H), 7.63 (dd, 1H, J = 7.74, 1.62), 7.59 
(s, 1H), 7.49-7.43 (m, 3H), 7.38 (td, 1H, J = 7.14, 1.47), 7.27 (d, 1H, J = 8.80), 6.96 (t, 
1H, J = 7.05). 13C NMR (100 MHz, CDCl3) δ 194.7, 146.2, 141.2, 137.0, 135.9, 130.6, 
127.3, 126.7, 124.9, 120.4, 119.0, 118.6, 113.6, 113.2. LCMS calc’d for C14H10N2O 
[M+H]+: 223.1, measured 223.0. 
 
6.29.118 A solution of aldehyde 6.28 (590 mg, 2.889 mmol) in TFA 
(14.4 mL) was heated via microwave irradiation at 60 °C for 1 h. The 
reaction mixture was quenched with 15% aqueous sodium hydroxide (75 mL, at which 
point pH measured > 7) at 0 °C and then extracted with ether (3 x 100 mL). The 
combined organics were dried (MgSO4), concentrated, and the resulting residue was 
purified by flash chromatography (SiO2, 15% ethyl acetate, hexanes) to yield 4-
cyanoacridine 6.29 (275 mg, 47%) as a bright yellow solid. 1H NMR (600 MHz, CDCl3) 
δ 9.73 (s, 1H), 9.01 (d, 1H, J = 8.94), 8.73 (d, 1H, J = 8.88), 8.38 (d, 1H, 8.52), 8.29 (dd, 
1H, J = 6.84, 1.26), 8.27 (d, 1H, J = 7.56), 8.21 (d, 1H, 7.98), 8.05 (dd, 1H, J 7.98, 1.02), 
7.98 (dd, 1H, J = 7.77, 1.71), 7.97 (d, 1H, J = 6.28), 7.44 (dt, 1H, J = 7.56, 1.10), 7.20 (dt, 
1H, J = 7.65, 1.56). 13C NMR (150 MHz, CDCl3) δ 169.5, 161.0, 160.7, 142.8, 142.6, 
141.9, 140.8, 138.0, 134.7, 134.5, 133.5, 133.1, 132.0, 129.7, 129.1, 128.1, 127.7, 127.3, 
124.5, 122.5. LCMS calc’d for C14H8N2 [M+H]+: 205.1, measured 205.2. 
 
6.30. To 4-cyanoacridine 6.29 (275 mg, 1.348 mmol) in ethanol (2 
mL) was added 3 M aqueous sodium hydroxide (1.4 mL) and the 
reaction was stirred 16 h. The reaction mixture was concentrated and taken up in ether (5 
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mL), and washed with 1 M HCl (3 x 5 mL). The organics were then dried (MgSO4), 
concentrated, and the resulting residue was purified by flash chromatography (SiO2, 50% 
ethyl acetate, hexanes) to yield 4-carboxyacridine 6.30 (180 mg, 59%) as a yellow solid. 
1H NMR (600 MHz, CDCl3) δ 9.54 (s, 1H), 9.17 (s, 1H), 8.50 (d, 1H, J = 8.88), 8.28 (d, 
1H, 8.28), 8.13 (d, 1H, J = 8.46), 8.04 (dd, 1H, J = 7.71, 1.32), 7.83 (d, 1H, J = 8.82), 
7.82 (d, 1H, J = 8.88), 7.68 (dt, 1H, J = 7.53, 0.78). 13C NMR (150 MHz, CDCl3) δ 150.0, 
147.5, 135.3, 133.9, 133.2, 131.7, 129.5, 128.7, 128.5, 127.4, 127.3, 125.0, 117.0, 110.7. 
LCMS calc’d for C14H9NO2 [M+H]+: 224.1, measured 224.1. 
 
6.15 (VU0659164). To 4-carboxyacridine 6.30 (180 mg, 0.806 
mmol) in NMP (5.3 mL) was added aniline (88 mL, 0.968 
mmol), Hünig’s base (421 µL, 2.418 mmol), and HATU (368 mg, 0.968 mmol). The 
reaction was heated via microwave irradiation at 100 °C for 45 min. The resulting 
solution was purified directly by flash chromatography (SiO2, 50% ethyl acetate, 
hexanes) to yield acridine amide 6.15 (12 mg, 28%) as a dark yellow solid. 1H NMR (600 
MHz, CDCl3) δ 8.81 (s, 1H), 8.65 (s, 1H), 8.24 (s, 1H), 8.23 (d, 1H, J = 8.64), 8.07 (m, 
3H), 7.83 (dt, 1H, J = 7.13, 1.32), 7.73 (d, 2H, J = 7.64), 7.60 (t, 1H, J = 7.52), 7.42 (t, 
2H, J = 7.94), 7.19 (t, 1H, J = 7.44). 13C NMR (150 MHz, CDCl3) δ 165.3, 149.9, 148.1, 
138.1, 136.7, 136.1, 131.1, 129.7, 129.4, 128.4, 127.8, 127.7, 127.5, 126.9, 124.9, 124.2, 
120.2. LCMS calc’d for C20H14N2O [M+H]+: 299.1, measured 299.2. 
 
6.16 (VU0517761). To a solution of commercial anthracene 2-
carboxylic acid (100 mg, 0.450 mmol) in NMP (3.0 mL) was 
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added aniline (50.0 mL, 0.540 mmol), Hünig’s base (235 µL, 1.35 mmol), and HATU 
(205 mg, 0.540 mmol). The reaction was heated via microwave irradiation at 100 °C for 
45 min. The resulting solution was purified directly by C18 chromatography (gradient: 
40% to 75% acetonitrile, water) to yield anthracene amide 6.16 (128 mg, 96%) as a white 
solid. 1H NMR (600 MHz, DMSO) δ 10.51 (s, 1H), 8.79 (s, 1H), 8.78 (s, 1H), 8.69 (s, 
1H), 8.23 (d, 1H, J = 8.88), 8.20 (d, 1H, J = 7.32), 8.16 (d, 1H, J = 7.44), 8.00 (dd, 1H, J 
= 8.79, 1.50), 7.87 (d, 2H, 7.56), 7.60 (m, 2H), 7.41 (t, 2H, J = 7.92), 7.15 (t, 1H, J = 
7.35). 13C NMR (150 MHz, DMSO) δ 165.6, 139.3, 132.3, 131.8, 131.67, 131.63, 130.0, 
128.7, 128.4, 128.3, 128.1, 128.0, 126.5, 126.1, 126.0, 123.8, 123.7, 120.3. LCMS calc’d 
for C21H15NO [M+H]+: 298.1, measured 298.0. 
 
Superoxide and Peroxide Detection. Detection was done by the Vanderbilt Free 
Radicals in Medicine Core (FRIMCORE). Fluorescence intensities were acquired using a 
BioTek H1 96-well plate reader.129 Black glass-bottom plates (BD Biosciences) were 
seeded with Rat1 Per2-dLuc cells one day prior to the experiment. Before recording, the 
cells were treated with 100 nM dexamethasone (final ethanol concentration of 0.001%) 
for 2 h. At the end of each treatment, the medium was washed twice with DPBS and 
replaced with assay medium (50 mM Krebs-HEPES buffer).  
Peroxiredoxin Detection. SDS-PAGE was done using 26-lane, pre-cast 4-12% gradient 
gels with 1X MES buffer using the recommended antioxidant in the recommended Novex 
midi tanks. Using the iBlot system with nitrocellulose membrane stacks and staining with 
coomassie blue. Quantification of total protein loading was done using western blotting 
                                                
129 Nazarewicz, R. R.; Bikineyeva, A.; Dikalov, S. I. J. Biomol. Screen 2012, 18, 498-503. 
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and a LiCor fluorescence scanner. Membrane was blocked at room temperature for 1 h on 
a rocking table with 15 mL of freshly diluted 1X Blocking Buffer (2.5 g BSA + 2.5 g 
skimmed milk powder, up to 50 ml 1x TBST [200 ml 1M Tris-HCl (pH 7.4), 400 ml 5M 
NaCl, and 20 ml Tween-20, dilute to 10x ] diluted to 10x and dissolved on rotating wheel 
at RT for 1 h, centrifuged for 5 min at 4000 rpm to remove particulate and filtered 
through a 0.45 µm syringe filter). The primary antibody, rabbit polyclonal anti prdx-SO2/3 
(abcam ab16830), is diluted by 1 in 10,000 in 15 mL freshly diluted 1X Blocking buffer. 
Blocking buffer is removed and replaced with primary antibody dilution and incubated at 
RT on a shaking table for 1 h. The solution was then washed 3 x 5 min in TBST and 
diluted with anti-rabbit HRP-conjugate secondary 1/10,000 in 1X Blocking buffer. 
Washed again for 4 x 5 min in TBST, the excess buffer was removed and gels were 
developed using Millipore’s Immobilon ECL reagent.  
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Figure 6.10. 400 MHz 1H NMR spectrum of 6.10 in CDCl3. 
 
 
 
 
Figure 6.11. 400 MHz 1H NMR spectrum of 6.11 in CD3OD. 
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Figure 6.12. 600 MHz 1H NMR spectrum of 6.12 in CD3OD. 
 
Figure 6.13. 150 MHz 13C NMR spectrum of 6.12 in CD3OD. 
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Figure 6.14. 600 MHz 1H NMR spectrum of 6.2 in CDCl3. 
 
Figure 6.15. 150 MHz 13C NMR spectrum of 6.2 in CDCl3. 
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Figure 6.16. 600 MHz 1H NMR spectrum of 6.32 in CDCl3. 
 
Figure 6.17. 150 MHz 13C NMR spectrum of 6.32 in CDCl3. 
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Figure 6.18. 600 MHz 1H NMR spectrum of 6.33 in CDCl3. 
 
Figure 6.19. 150 MHz 13C NMR spectrum of 6.33 in CDCl3. 
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Figure 6.20. 600 MHz 1H NMR spectrum of 6.34 in CDCl3. 
 
Figure 6.21. 150 MHz 13C NMR spectrum of 6.34 in CDCl3. 
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Figure 6.22. 600 MHz 1H NMR spectrum of 6.35 in CDCl3. 
 
Figure 6.23. 150 MHz 13C NMR spectrum of 6.35 in CDCl3. 
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Figure 6.24. 600 MHz 1H NMR spectrum of 6.36 in CDCl3. 
 
Figure 6.25. 150 MHz 13C NMR spectrum of 6.36 in CDCl3. 
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Figure 6.26. 600 MHz 1H NMR spectrum of 6.37 in CDCl3. 
 
Figure 6.27. 150 MHz 13C NMR spectrum of 6.37 in CDCl3. 
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Figure 6.28. 600 MHz 1H NMR spectrum of 6.38 in CDCl3. 
 
Figure 6.29. 150 MHz 13C NMR spectrum of 6.38 in CDCl3. 
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Figure 6.30. 600 MHz 1H NMR spectrum of 6.39 in CDCl3. 
 
Figure 6.31. 150 MHz 13C NMR spectrum of 6.39 in CDCl3. 
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Figure 6.32. 600 MHz 1H NMR spectrum of 6.40 in CDCl3. 
 
Figure 6.33. 150 MHz 13C NMR spectrum of 6.40 in CDCl3. 
11 10 9 8 7 6 5 4 3 2 1 0 ppm
220 200 180 160 140 120 100 80 60 40 20 ppm
N
N N
H
O O
6.40
 249 
 
Figure 6.34. 600 MHz 1H NMR spectrum of 6.41 in CDCl3. 
 
Figure 6.35. 150 MHz 13C NMR spectrum of 6.41 in CDCl3. 
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Figure 6.36. 600 MHz 1H NMR spectrum of 6.42 in CDCl3. 
 
Figure 6.37. 150 MHz 13C NMR spectrum of 6.42 in CDCl3. 
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Figure 6.38. 600 MHz 1H NMR spectrum of 6.19 in CDCl3. 
 
Figure 6.39. 150 MHz 13C NMR spectrum of 6.19 in CDCl3. 
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Figure 6.40. 600 MHz 1H NMR spectrum of 6.20 in CDCl3. 
 
Figure 6.41. 150 MHz 13C NMR spectrum of 6.20 in CDCl3. 
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Figure 6.42. 600 MHz 1H NMR spectrum of 6.21 in CDCl3. 
 
Figure 6.43. 150 MHz 13C NMR spectrum of 6.21 in CDCl3. 
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Figure 6.44. 400 MHz 1H NMR spectrum of 6.22 in CDCl3. 
 
Figure 6.45. 100 MHz 13C NMR spectrum of 6.22 in CDCl3. 
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Figure 6.46. 400 MHz 1H NMR spectrum of 6.23 in CD3OD. 
 
Figure 6.47. 100 MHz 13C NMR spectrum of 6.23 in CD3OD. 
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Figure 6.48. 600 MHz 1H NMR spectrum of 6.14 in CDCl3. 
 
Figure 6.49. 150 MHz 13C NMR spectrum of 6.14 in CDCl3. 
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Figure 6.50. 400 MHz 1H NMR spectrum of 6.26 in CDCl3. 
 
Figure 6.51. 100 MHz 13C NMR spectrum of 6.26 in CDCl3. 
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Figure 6.52. 600 MHz 1H NMR spectrum of 6.27 in CDCl3. 
 
Figure 6.53. 150 MHz 13C NMR spectrum of 6.27 in CDCl3. 
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Figure 6.54. 600 MHz 1H NMR spectrum of 6.28 in CDCl3. 
 
Figure 6.55. 150 MHz 13C NMR spectrum of 6.28 in CDCl3. 
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Figure 6.56. 600 MHz 1H NMR spectrum of 6.29 in CDCl3. 
 
Figure 6.57. 150 MHz 13C NMR spectrum of 6.29 in CDCl3. 
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Figure 6.58. 600 MHz 1H NMR spectrum of 6.30 in CDCl3. 
 
Figure 6.59. 150 MHz 13C NMR spectrum of 6.30 in CDCl3. 
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Figure 6.60. 400 MHz 1H NMR spectrum of 6.15 in CDCl3. 
 
Figure 6.61. 100 MHz 13C NMR spectrum of 6.15 in CDCl3. 
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Figure 6.62. 600 MHz 1H NMR spectrum of 6.16 in C2D6SO. 
 
Figure 6.63. 150 MHz 13C NMR spectrum of 6.16 in C2D6SO. 
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APPENDIX I 
 
STRUCTURE ACTIVITY RELATIONSHIP STUDY DATA 
 
 
Figure A.1. Graphical Representation of SAR Study to Determine the Structure Eliciting the 
Strongest Period-Lengthening Effect. 
 
 265 
 
Figure A.2. Period Lengthening Effect of Compounds Screened  
for SAR Compared to DMSO. 
 
 
10	µM	treatment 10	µM	DMSO Std	Dev
6.2 22.05 22.83 0.38
6.12 22.20 21.86 0.54
6.32 30.39 21.67 0.47
6.33 24.99 22.83 0.36
6.34 24.77 22.83 0.16
6.35 28.82 21.67 0.23
6.36 23.08 22.83 0.34
6.37 22.98 22.83 0.68
6.38 22.83 22.83 0.62
6.39 22.79 22.70 0.34
6.40 23.12 22.70 0.25
6.41 23.42 23.77 0.53
6.42 23.16 23.77 0.24
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